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Abstract  
 
Non-alcoholic fatty liver disease is defined by the accumulation of intrahepatic triglycerides 
stored in metabolically active lipid droplets (LDs). Hundreds to thousands of proteins associate 
on the surface of LDs to regulate the storage and utilisation of the neutral lipids stored inside. 
Further, proteins from non-canonical processes such as oxidative stress and proteasomal 
degradation also reside on LDs and contribute to the diverse and dynamic functions of these 
cytosolic organelles. Hepatocytes are important regulators of glucose, lipid and cholesterol flux 
and thus accumulation of protein-rich LDs in the liver can disrupt molecular signalling and 
metabolism that is often linked with whole-body insulin resistance. Resident LD-associated 
proteins that participate in lipolysis have been of particular interest in elucidating the 
pathogenesis of insulin resistance in fatty liver disease; however, single target gain- and loss- 
of function studies of these regulators have provided largely contradictory results. 
Additionally, there is emerging evidence for the diverse regulation of these proteins, such as 
translocation, post-translational activation and molecular interactions, that govern their 
function at the LD more than absolute expression. High throughput proteomic and 
phosphoproteomic research have revealed large changes in the composition and post-
translational modifications of LD proteins following a high-fat diet challenge, most of which 
have not been pathologically described. Moreover, little attention has been paid to the influence 
of normal and dysregulated insulin action on the proteome, phosphoproteome and ubiquitome 
within fatty liver.  
 
Therefore, the overall aim of this project was to quantify high-fat diet and insulin-sensitive 
changes in the abundance, ubiquitination and phosphorylation of cellular and LD-associated 
proteins and to identify novel regulation of candidates in the pathogenesis of non-alcoholic 
fatty liver disease and insulin resistance.  
 
Using a quantitative proteomics approach, this work provided comprehensive profiles on 
proteins and post-translational modifications of whole livers and LDs from chow or fat-fed rats 
with or without acute insulin stimulation. The study is the first to show that the ubiquitome is 
sensitive to insulin and diet and is differentially regulated in steatotic and insulin resistant 
livers. Further, LD-associated proteins are responsive to insulin signalling and demonstrate 
dramatic changes in abundance and phosphorylation with hepatic insulin resistance. In 
particular, phosphorylation and/or ubiquitination of several known lipolytic regulators, such as 
 xix 
ATGL and Plin2 differed more than their total protein expression levels at the LD, suggesting 
previously unknown multi-layered regulation in hepatocytes. Finally, characterisation of the 
LD-associated protein, UBXD8, revealed a novel role in selectively promoting PPARa-
mediated FA oxidation by regulating various components of the hepatic lipolysome.     
 
Collectively, the results described in this thesis demonstrates that post-translational 
modifications, subcellular localization and protein-protein interactions are underestimated 
regulators of key lipolytic processes in the liver. Understanding their dysregulation is important 
in elucidating the pathogenesis of insulin resistance within fatty liver disease.  
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1.1. Introduction 
Non-alcoholic fatty liver disease (NAFLD) is a metabolic condition largely fuelled by the 
alarming epidemic of obesity. Although the prevalence of NAFLD has not been well 
established, systematic reviews predict that about 20-30% of individuals in Western countries 
have NAFLD, with an increasing number of affected of patients observed in Eastern countries 
(Younossi et al. 2016). Historically, the condition is referred to as a spectrum that includes 
hepatic steatosis, steatohepatitis (NASH), fibrosis, cirrhosis, hepatocellular carcinoma (HCC) 
and liver failure (Fig 1.1); however, clinical studies have shown that simple steatosis practically 
never develops into NASH (Bedogni et al. 2014). Therefore, ‘NAFL(D)’ is used in this thesis 
as a broader term for fatty liver, as suggested by the American Gastroenterological Association 
(Chalasani et al. 2012) and is defined as intrahepatic triglyceride content greater than 5% 
(Kleiner et al. 2005). The accumulation of lipids in insulin-sensitive organs, such as the liver, 
is often associated with perturbed lipid and glucose homeostasis, which is characteristic of 
insulin resistance and is almost universally presented in patients with NAFL (Marchesini et al. 
1999). Over 76% of type 2 diabetics, defined as long-term insulin resistance, have been 
reported to have NAFL(D), whereas diabetes was identified in over 23% of NAFL(D) cases, 
indicating a strong link between the two conditions. A necessary feature of their coexistence is 
an imbalance of uptake, synthesis, oxidation and export of fatty acids.  
 
 
Figure 1.1 Pathogenesis of NAFLD.  
The majority of NAFL(D) patients develop steatosis, or TAG accumulation in the liver, without progressing further. A small 
subset may develop non-alcoholic steatohepatitis (NASH), which may develop into cirrhosis and hepatocellular carcinoma. 
Figure adapted from (Cohen et al. 2011). 
 
In the liver, esterified lipids are primarily stored in dynamic organelles called lipid droplets 
(LDs). The LD is composed of a neutral lipid core surrounded by a monolayer of phospholipids 
and associated proteins involved in energy homeostasis, particularly lipid flux, protein 
trafficking and  signal transduction (Vanni 2017).  It is likely that hormonal and transcriptional 
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regulation of proteins in close proximity to stored accessible lipids in LDs underlie the 
metabolic pathology that leads to NAFL(D), and therefore dysfunctions in this organelle make 
it a promising direction for research. This Introductory Chapter presents an overview of the 
pathogenesis of NAFL and discusses available theories linking excess triglycerides with 
impaired insulin action, followed by an in depth analysis of LD physiology and its role in health 
and disease. 
 
1.2. Non-Alcoholic Fatty Liver 
 General Characteristics of NAFL(D) 
A liver is classified as steatotic when there is more than 5% of triglycerides accumulated within 
hepatocytes in the absence of any other secondary causes such as medications or alcohol 
(Bedogni et al. 2014). While liver biopsies are the gold-standard for the diagnosis of NAFL, 
liver ultrasonography is often employed as a less invasive method that can be used in the 
general population outside of specialist liver centres. When ultrasonography is used, the 
minimum detection for accurate diagnosis starts from an intrahepatic triglyceride content of 
10% (Adams et al. 2005, Machado and Cortez-Pinto 2013). The majority of fatty liver patients 
present with macrovesicular steatosis, defined as lipid accumulation in few medium to large 
lipid droplets that displace nuclei to the periphery, as opposed to numerous smaller droplets 
(Tandra et al. 2011). Treatment options for fatty liver include weight loss, exercise, bariatric 
surgery and pharmacological therapy aimed at treating comorbidities of NAFL, such as insulin 
resistance and dyslipidaemia (Tolman and Dalpiaz 2007). Patients with fatty liver have 
increased mortality due to cardiovascular disease despite relatively passive histological 
progression (Chalasani et al. 2012). For the <4% of individuals with fatty liver that do progress 
to cirrhotic and fibrotic stages of liver injury, liver-related mortality is more common (Boutari 
et al. 2018, Mahady and Adams 2018). Due to the variability in stage classification, assessment 
and treatment, prognosis is unclear. There is currently no known or approved cure for NAFL 
or NASH-related outcomes. 
 
1.2.2 Prevalence of NAFL(D) 
NAFL(D) is the most common cause of chronic liver disease in the world (Marchesini et al. 
2008), with over 66 million individuals affected with NAFL in the United States alone (Estes 
et al. 2018). The global prevalence of NAFL(D) is estimated to be 24%, similar to the 
prevalence in North America, with higher estimates in the Middle East (32%), South America 
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(30%) and Asia (27%), and lower estimates in Europe (24%) and Africa (14%) (Younossi et 
al. 2016). In Australia, there are a limited number of epidemiological studies on NAFL(D) in 
the general population and even fewer with accurate tools. However, a recent meta-analysis 
estimated a prevalence of 25% in Caucasians and over 40% in ethnic groups (Mahady and 
Adams 2018). Hispanics are especially susceptible to increased hepatic fat content, which is 
evidenced by a high frequency of the PNPLA3-148M allele that is strongly associated with 
NAFL(D) (Romeo et al. 2008). Further, the prevalence of NAFL(D) steadily increases with 
age, with 22% in individuals in their 30’s and up to 34% in individuals in their 70’s (Younossi 
et al. 2018), similar to the pattern of age-related prevalence for obesity (Ng et al. 2014). 
Additionally, men with NAFL(D) tend to be in their youth or middle-age, whereas women 
display higher prevalence in the development of fatty liver post-menopause, likely when the 
protective effects of oestrogen decrease (Fan et al. 2005, Eguchi et al. 2012, Hamaguchi et al. 
2012, Ballestri et al. 2017, Summart et al. 2017). It is important to note that studies that measure 
liver enzyme levels to diagnose NAFL markedly underestimate its prevalence compared to 
tools such as sonography or biopsy and it is likely that prevalence in all categories are, in 
reality, significantly higher than reported (Khodadoostan et al. 2016).   
   
1.2.3 Pathophysiology of NAFL(D) 
NAFL is primarily characterized by excess accumulation of triglycerides within the liver. 
Although considerable quantities of fatty acids are handled by the liver, less than 5% are stored 
in the form of triglycerides under normal physiological conditions (Dowman et al. 2010). Free 
fatty acids, which are esterified with glycerol to form triglycerides, can arise from dietary 
sources, adipose tissue lipolysis and via de novo lipogenesis using substrates such as pyruvate, 
acetate and amino acids (Ipsen et al. 2018). In contrast, hepatic fatty acid levels are balanced 
by beta oxidation, fatty acid re-esterification for storage into lipid droplets or exported with 
cholesterol into circulation as very-low density lipoproteins (Fig 1.2). Therefore, an 
accumulation of triglycerides can be attributed to an increase in delivery and synthesis or a 
decrease in oxidation and export.  
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1.2.3.1 Mechanisms of TAG Accumulation 
1.2.3.1.1 Hepatic Fatty Acid Uptake 
Over 90-95% of lipids derived from dietary sources are composed of triglycerides, while the 
remaining 5%-10% consists of phospholipids, free fatty acids, sterols and fat soluble vitamins 
(Iqbal and Hussain 2009). In the small intestine, these meal-derived lipids are broken down 
 
Figure 1.2 Summary of lipid metabolism in the liver.  
Accumulation of TAG in the liver can occur from either an increased influx or decreased efflux of FFA. Lipids derived from 
adipose tissue lipolysis and dietary sources can be taken up by the liver to be converted into TAG for storage in LDs. TAG 
can then be repackaged and secreted as VLDL or oxidized in  mitochondria to generate energy or ketone bodies. Figure adapted 
from (Cohen et al. 2011). 
 
into fatty acids and monoglycerides for absorption into enterocytes where they are re-
synthesized as TAG and secreted into circulation in small lipoprotein transport particles called 
chylomicrons (Rui 2014). Chylomicron-TAGs are then subjected to hydrolysis by lipoprotein 
lipases (LPLs) at priority tissues such as adipose and muscle to release non-esterified FAs 
(NEFAs) for storage and oxidation, respectively (Lambert and Parks 2012). Remaining TAG 
in chylomicron remnants, as well as released FAs that were not taken up by adipose or muscle 
tissues, are then transported to hepatocytes for LPL-mediated lipolysis and fatty acid uptake. 
Interestingly, morbidly obese patients with hepatic steatosis have increased protein levels and 
activity of hepatic LPL before bariatric surgery compared to control patients (Pardina et al. 
2009). Similarly, liver-specific LPL overexpression increased intrahepatic TAG content and 
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liver-specific insulin resistance due to increased delivery of FAs (Kim et al. 2001), 
demonstrating the importance of LPLs in regulating hepatic lipid homeostasis.  
 
During fasting, the major contributor of NEFAs to the liver are those released from intracellular 
lipolysis of TAG pools in adipose tissue (Frayn 2002). In the postprandial state, hormonal 
regulation by insulin inhibits adipose-derived FA contribution to hepatocytes in healthy 
individuals (Chakrabarti et al. 2013). Stable isotope labelling of NEFAs in NAFL(D) patients 
prior to liver biopsy revealed over 50% of hepatic TAG arose from systemic adipose-derived 
NEFAs (Donnelly et al. 2005). Although there was no control group in the study, there is strong 
evidence from other studies demonstrating the lack of insulin suppression of adipose tissue 
lipolysis in patients with hepatic steatosis and related insulin resistance (Thorne et al. 2010, 
Schweiger et al. 2017).  
 
FAs primarily enter hepatocytes via CD36/fatty acid translocases (FATs), fatty acid transport 
protein 2 (FATP2), FATP4 and FATP5. FATP5 is exclusively expressed in the liver and loss 
of function in mice decreased hepatic long-chain FA uptake and lower intracellular TAG and 
FFA levels (Doege et al. 2006). Further, liver specific deletion of CD36 protected mice fed a 
60% high-fat diet from developing hepatic steatosis (Wilson et al. 2016). Likewise in humans, 
the histological grade of steatosis in 227 NAFLD patients correlated with progressive increases 
in soluble CD36 levels in serum (Garcia-Monzon et al. 2014), demonstrating a positive 
relationship between fatty acid uptake and hepatic steatosis.  
 
1.2.3.1.2 Intracellular Fatty Acid Activation and Transport 
Once taken up, FAs must be activated by long chain acyl-CoA synthetases (ACSLs) in order 
to form acyl-CoAs and enter almost any downstream metabolic pathway, including TAG 
synthesis and beta oxidation.  Coenzyme A, or CoA, is a highly conserved polar molecule with 
an adenosine 3’,5’-disphosphate moiety that increases the affinity of CoA to enzymes, thereby 
acting as a necessary substrate for numerous FA enzymatic reactions, including elongases, 
desaturases, dehydrogenases, thioesterases, and many more (Davaapil et al. 2014). It has been 
hypothesized that different ACSL isoforms target FAs of specific chain-length groups and 
channel newly formed FA-CoAs into distinct tissue-specific downstream pathways. For 
instance, ACSL 1 and 5 are highly expressed in the liver and target 12 to 20 carbon FAs to 
channel into synthesis of phospholipids and cholesterol, or incorporation of exogenous FAs 
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into TAG, respectively (Mashek et al. 2007). Furthermore, ACSL isoforms also exhibit 
organelle specificity, whereby ACSL1 is detected in the mitochondria, ACSL3 and 4  have 
been identified in lipase-activated LDs,  and ACSL5 and 6  are enriched in cholesterol-rich 
regions of the plasma membrane (Soupene and Kuypers 2008). While these enzymes are 
important for the downstream synthesis of complex lipids from fatty acids (Bu and Mashek 
2010), their role in hepatic steatosis and metabolic disease remains largely unsettled (Ellis et 
al. 2010, Yan et al. 2015).  
 
To increase the solubility of hydrophobic molecules such as long-chain FA and FA-CoAs in 
aqueous environments, fatty acid binding proteins (FABPs) and acyl carrier binding proteins 
(ACBPs) facilitate their transport in the cytosol (Wang et al. 2015).  Although they do not have 
any catalytic activity themselves, the importance of binding proteins in FA utilisation is 
reflected in the impairment of FA uptake and oxidation pathways in liver-specific FABP null 
mice (Newberry et al. 2003), consistent with decreased FABP protein levels found in steatotic 
rodent models (Guzman et al. 2013). This is likely due to the role that FABPs play in FA-
mediated ligand activation of peroxisome proliferator-activated receptor alpha (PPARa) 
transcription factors and their downstream effects on lipid metabolism (Tan et al. 2002). 
Additionally, FABPs and ACBPs both promote the increase in intracellular LCFA-CoA pool 
size by binding to the end-products of ACSLs and preventing its feedback inhibition (Huang 
et al. 2005). This collectively functions as a cytoprotectant from lipotoxic free FAs (Gajda et 
al. 2013).   
 
1.2.3.1.3 Hepatic de novo Lipogenesis 
The most striking result of Donnelly’s stable isotope study in NAFL(D) patients (2005) was 
the increase in intrahepatic triglyceride content that originated from de novo lipogenesis 
(DNL), with almost 30% from DNL in individuals with NAFL(D) compared to less than 5% 
in healthy individuals (Parks 2002). Lipogenesis is primarily driven by dietary carbohydrates, 
whereby the main glycolytic product, pyruvate, is broken down in the mitochondria by 
pyruvate dehydrogenase complex to provide acetyl-CoA as the carbon source for DNL, thereby 
linking glycolysis to lipogenesis (Rui 2014). Although there are other lipogenic tissues, such 
as adipose and mammary glands, the major site for DNL in response to acute or prolonged 
carbohydrate feeding in humans is the liver (Diraison et al. 2003).  
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The rate-limiting step of DNL is the conversion of acetyl-CoA to malonyl-CoA, which is 
catalysed by acetyl-CoA carboxylases (ACC). ACC1 is found in tissues where synthesis is 
important, such as adipose and mammary tissue, whereas ACC2 is enriched in oxidative tissues 
such as skeletal muscle and heart, while the liver is highly enriched for both of these isoforms. 
Despite distinct enrichment, ACC1 and 2 are largely compensatory and  thus evidence of their 
role in NAFL pathogenesis has been controversial. For example, antisense oligonucleotide 
(ASO)-mediated double KD of ACC1 and 2 in mice led to decreased hepatic fat and increased 
insulin sensitivity as expected (Savage et al. 2006). However, liver-specific ACC double KO 
in mice in another study unexpectedly revealed increased hepatic fat accumulation, decreased 
fatty acid oxidation and increased protein acetylation, likely due to activation of compensatory 
fat storage pathways (Chow et al. 2014).   
 
Following carboxylation, malonyl-CoA is converted to palmitate, a 16-carbon saturated fatty 
acid, by fatty acid synthase (FAS). Palmitate can be elongated by acyl-CoA elongase (Elovl) 
to form long-chain FAs or desaturated by stearoyl-CoA desaturases (SCD) to form mono- and 
polyunsaturated FAs (Drag et al. 2017). Interestingly, several studies have demonstrated a 
decrease in n-3 and n-6 polyunsaturated FAs (PUFAs) in NAFL patients (Arendt et al. 2015), 
and that supplementation of long PUFAs derived from essential FAs can reduce hepatic 
steatosis after 12 months (Capanni et al. 2006). Likewise, ELOVL5 deletion contributed to the 
pathogenesis of NAFL in mice (Moon et al. 2009), while hepatic SCD1 activity in humans 
showed the inverse effect (Kotronen et al. 2009). Collectively, these studies suggest that more 
FA desaturation may be required when not provided by dietary sources.    
 
1.2.3.1.4 Lipid Esterification into Triglycerides 
When FAs are not immediately required for cellular processes, they are esterified to glycerol 
and stored as TAG in LDs. In hepatocytes, glycerol is derived as glycerol-3-phosphate (G3P) 
from three main processes: 1) glycolysis, forming G3P from a critical branchpoint of glucose 
breakdown by glycerophosphate dehydrogenase; 2) partial reverse glycolysis or 
glyceroneogenesis, from the conversion of lactate and pyruvate and; 3) uptake of circulating 
glycerol from other tissues and conversion to G3P by glycerokinase (Festuccia et al. 2003). 
FA-CoAs are added to G3P sequentially (Fig 1.3), each step catalysed by a specific enzyme. 
G3P acyltransferases (GPATs) and acylglycerol-3-phosphate acyltransferases (AGPATs) 
reside primarily in the ER and mitochondria but can also be found on newly synthesized  LDs 
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(Wilfling et al. 2013, Wilfling et al. 2014). They generate lysophosphatidic acid (LPA) and 
phosphatidic acid (PA), respectively, by acylation of G3P (Takeuchi and Reue 2009). Although 
these enzymes are important for TAG synthesis, their role in the pathogenesis of hepatic 
steatosis is unclear. When investigating TAG synthesis in hepatocytes isolated from GPAT1, 
2, 3 or 4 KO mice, GPAT1 was the only isoform that diverge de novo synthesized FAs away 
from oxidation and incorporated into TAG in the liver (Wendel et al. 2013). Consequently, the 
role of GPAT1 in aggravating NAFL has since been suggested, however ob/ob mice lacking 
GPAT1 were not protected from steatosis when fed a high-fat diet long-term (Yazdi et al. 
2008), indicating a different culprit in the pathway. 
 
Diacylglycerols (DAGs) act as an important branchpoint of glycerophospholipid formation and 
precursor for TAG synthesis, and are one of the most studied lipid intermediates due to their 
involvement in various metabolic reactions as signalling molecules. Diacylglycerols (DAGs) 
can then be formed via the dephosphorylation of PA by lipin, otherwise known as PA 
phosphatase-1, or via the esterification of monoacylgerols (MAGs) by MAG O-acyltransferase 
1 (MGAT1). Although DAGs are thought to play a pivotal role in lipotoxicity and IR (discussed 
in detail in 1.3.3.1), their position as intermediates in lipid synthesis and breakdown pathways 
makes it difficult to distinctly associate their pool size with impaired lipid metabolism. 
 
 
Figure 1.3 Triglyceride Synthesis Pathway 
Triglyceride (TAG) synthesis encompasses numerous enzymes in a multi-step pathway. Glycerol-3-phosphate (G-3-P) 
acyltransferase (GPAT) adds a FA-CoA to G-3-P to form lysophosphatidic acid (LPA), followed by phosphatidic acid (PA) 
by 1-acylglycerol-3-phosphate O-acyltransferase (AGPAT), and diacylglycerol (DAG) by lipin. DAG can also be made from 
the addition of an FA-CoA to monoacylglycerol (MAG). DAG is then converted to TAG by DAG acyltransferases (DGAT).      
 
The final pivotal step of TAG synthesis is catalysed by DAG acyltransferases (DGATs) that 
add the final FA-CoA to generate TAG for safe storage in lipid droplets or for very-low density 
lipoproteins (VLDL) synthesis (Yen et al. 2008). Although the two isoforms, DGAT 1 and 2, 
are generally compensatory, DGAT2 is more potent and is associated with more TAG 
accumulation when overexpressed than DGAT1 (Zammit 2013). Furthermore, DGAT2 is 
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proposed to be primarily involved in glycerolipid synthesis whereas DGAT1 may play a more 
important role in re-esterification of hydrolysed TAG, suggesting that DGAT2 is a critical 
regulator of DNL rates in the development of hepatic steatosis (Monetti et al. 2007, Yen et al. 
2008). The source-dependent use of FAs by the two DGAT isoforms can be linked to their 
differential proximity to key proteins., Specifically, DGAT2 has been found to interact with 
enzymes that catalyse the de novo synthesis or transport of FAs and MAGs, such as SCD1, 
MGAT2 and FATP1 (Wurie et al. 2012, Xu et al. 2012, Jin et al. 2014). Interestingly, high fat-
fed mice with decreased DGAT2 expression, and not DGAT1, was associated with reduced 
hepatic TAG levels (Choi et al. 2007), similar to studies done in humans with two or more 
copies of a minor DGAT2 mutation (Kantartzis et al. 2009). 
 
1.2.3.2 Mechanisms of TAG Disposal 
1.2.3.2.1 Triglyceride Secretion as VLDL 
Triglycerides in the liver can be delivered to adipose or muscle tissue by secretion as very low-
density lipoproteins (VLDL), defined as triglyceride-rich, cholesterol-poor transport particles 
similar in composition to lipid droplets (Mahley et al. 1984). Lipoproteins are characterized by 
the attachment of core structural apolipoproteins (Apo) that are distinct to each lipoprotein 
category, with ApoB-100 identifying hepatic VLDL particles (Feingold and Grunfeld 2000). 
The formation of nascent VLDL begins with the translocation of ApoB-100 on ribosomes at 
the ER and subsequent lipidation of the protein by microsomal triglyceride transfer protein 
(MTP) (Choi and Ginsberg 2011). VLDLs undergo further maturation in the Golgi apparatus 
by receiving a bulk of lipids from cytosolic lipid droplets before eventually moving to the 
plasma membrane for secretion into the blood. Once in circulation, VLDLs become 
progressively more dense as triglycerides get released as FAs into tissues. As the proportion of 
lipoprotein cholesterol content increases, particles are gradually defined as low-density (LDL), 
intermediate-density (IDL) and high-density (HDL) lipoproteins. Individuals with familial 
hypobetalipoproteinaemia, characterized by a mutation in the ApoB gene, have decreased 
VLDL-TAG secretion and increased intrahepatic TAG levels (Schonfeld et al. 2003). In 
contrast, NAFL patients actually report a heightened rate of VLDL-TAG secretion, despite 
increased intracellular TAG stores (Adiels et al. 2006). Interestingly, individuals with normal 
intrahepatic TAG levels exhibit progressive increases in VLDL-TAG secretion with greater 
FA delivery to the liver (Fabbrini et al. 2008). In contrast, NAFL patients are able to upregulate 
VLDL-TAG synthesis and secretion only up to a certain ceiling, thereafter capping the export 
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of lipids and resulting in increased intracellular storage and extracellular export of TAG 
(Fabbrini et al. 2008). Therefore, TAG disposal is an important mechanism that the liver 
utilizes in order to offset increased FA availability in hepatic steatosis.  
 
1.2.3.2.2 Intrahepatic Lipolysis 
During times of energy deprivation, TAG stores can be hydrolysed to release FAs for 
signalling, stimulate b oxidation, and ketone body generation (Hodson and Frayn 2011). 
Neutral lipases on the surface of lipid droplets work in a stepwise manner to catalyse the 
degradation of TAG. The successive hydrolysis of TAG to DAG and monoacylglycerols 
(MAG) is catalysed by adipose triglyceride lipase (ATGL), followed by hormone-sensitive 
lipase (HSL) and finally monoacylglyceride lipase (MAGL), respectively. Overexpression of 
ATGL and HSL in ob/ob mice ameliorates hepatic steatosis by increasing TAG breakdown 
leading to the upregulation of b oxidation (Reid et al. 2008). In the liver, the rate-limiting 
lipolytic enzyme ATGL is regulated by two proteins: the ATGL coactivator, comparative gene 
identification-58 (CGI-58) and the inhibitor G0/G1 switch gene 2 (G0S2). Humans with CGI-
58 autosomal recessive disease and ASO-mediated knockdown of CGI-58 in mice decreased 
lipolysis and increased hepatic steatosis (Yamaguchi and Osumi 2009, Cantley et al. 2013). 
Similarly, liver overexpression of G0S2 in mice resulted in excess TAG in the liver, suggesting 
that ATGL-mediated availability of FFAs, regulated by activators and inhibitors, is important 
for in the pathogenesis of hepatic steatosis (Wang et al. 2013, Zhang et al. 2014). Finally, after 
FAs are released from hydrolysis by cytoplasmic lipases, LDs localize and fuse with 
mitochondria to enable efficient oxidative metabolism and avoid lipotoxicity (Jagerstrom et al. 
2009, Rambold et al. 2015), as discussed in section 1.2.3.2.3. 
 
1.2.3.2.3 Hepatic b-oxidation 
The liver has one of the highest metabolic rates of any organ in the human body, nearly 20 
times more than the resting rate of skeletal muscle and 50 times greater than that of adipose 
tissue (Klein and Jeejeebhoy 2002). Long-chain FAs from adipose tissue lipolysis or 
degradation of LD TAG stores in the liver are converted to acyl-CoAs before being sequentially 
broken down in the mitochondria (Fabbrini et al. 2010). Carnitine palmitoyltransferase-1 
(CPT1) and 2 (CPT2) are present on the outer and inner mitochondrial membranes, 
respectively, and facilitate the transport of FA-CoAs into the mitochondria by converting them 
into acylcarnitines (Nassir and Ibdah 2014). Through a series of dehydrogenation, hydration 
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and cleavage reactions, two-carbon units of acetyl-CoA are progressively removed from FA-
CoA each cycle to generate the coenzymes NADH and FADH2. The acetyl-CoA can then be 
subsequently used to generate ketone bodies or be completely oxidized by entering the 
tricarboxylic acid cycle (TCA) (Hodson and Frayn 2011). The TCA cycle generates additional 
NADH and FADH2 that are substrates for the electron transport chain to generate usable 
chemical energy in the form of ATP. The electron transport chain contains five complexes that 
play critical roles in oxygen consumption and energy generation. A current therapeutic target 
for the treatment of NAFL is the stimulation of peroxisome proliferator-activated receptors 
(PPARs), which are ligand-activated transcriptions factors, via agonists (Seo et al. 2008). 
Specifically, PPARa and g modulate oxidative genes such as CPT1 and 2 to enhance fatty acid 
oxidation and improve steatosis. Furthermore, overexpression of the rate-limiting oxidative 
gene CPT1a in mice significantly attenuated hepatic steatosis by 35% and was associated with 
a 70% increase in beta-oxidation and 60% decrease in TAG secretion (Stefanovic-Racic et al. 
2008). Interestingly, 2H and 13C NMR analysis in African Americans and Hispanics with 
NAFLD showed higher rates of lipolysis associated with a 2-fold increase in mitochondrial 
oxidative metabolism and production of reactive oxygen species, especially in the progression 
of NASH (Sunny et al. 2011). It is possible that FA oxidation represents two sides of a coin in 
distinguishing simple steatosis from patients that progress to NASH in the pathogenesis of 
NAFLD.   
 
1.2.3.3 Co-morbidities 
1.2.3.3.1 Obesity 
Obesity is a multifaceted and generally preventable metabolic disease, affecting over 650 
million individuals and almost 25% of the worldwide population in 2016; nearly triple the 
prevalence since 1975 (World Health Organization 2018). Although not the most precise 
measurement of body fat proportion, obesity is commonly defined as having a body mass index 
(BMI) greater than or equal to 30 kg/m2 height (Ofei 2005). Individuals with obesity have been 
long associated with a disproportionately higher risk of developing comorbid conditions, 
including fatty liver disease. In a meta-analysis of 21 cohort studies with over 380,000 
participants, obese individuals had a 3.5-fold greater risk of developing NAFL compared to 
control patients and demonstrated a clear dose-dependent relationship between NAFL risk and 
BMI (Li et al. 2016). In morbidly obese Australian patients, the prevalence of NAFL increases 
to a staggering 83-96% of the cohort when diagnosed by liver biopsy (Dixon et al. 2001, Ooi 
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et al. 2018). This not only demonstrates a strong association between obesity and NAFL, but 
also suggests the influence of diagnostic tools in determining the true prevalence of NAFL. 
However, it is not uncommon for lean individuals to develop NAFL, with roughly 7-19% of 
lean individuals diagnosed with the disease worldwide, compared to roughly 29-76% in obese 
individuals (Kumar and Mohan 2017). While there are a few distinct characteristics of lean 
NAFL individuals compared to their obese counterparts, such as a preponderance to the female 
sex, younger age and lower risk for NAFLD progression, they still demonstrate higher BMI, 
blood pressure and prevalence of metabolic syndrome compared to healthy individuals (Kumar 
and Mohan 2017). Research in Asian populations with lean and obese NAFL patients indicates 
a unifying feature between the two groups linked to localisation of adiposity (Mohan et al. 
2009, Kumar and Mohan 2017). In particular, centralised or abdominal obesity from fat 
accumulation in the visceral compartment, commonly measured by waist circumference, is a 
better predictor of NAFL and IR than generalized adiposity or obesity, thereby providing a 
likely distinction between “metabolically obese” versus “physically obese” cases (Chitturi et 
al. 2011, Mirza 2011, Ha et al. 2015). Although race and genetics likely play a role in 
determining variability in fat distribution, it is clear that there is a strong relationship between 
obesity, specifically central obesity, and NAFL development.   
 
1.2.3.3.2 Cardiovascular Disease 
There is an increased prevalence for the development of cardiovascular diseases (CVD), 
including atherosclerosis and coronary heart disease, in patients with NAFL. Hepatic steatosis 
has been diagnosed in various cardiovascular conditions, including 20% of cerebrovascular 
disease (Targher et al. 2007), 43% of ischaemic stroke patients (Moshayedi et al. 2014), 51% 
of mild coronary stenosis patients and 100% of patients with three affected coronary arteries 
(Choi et al. 2013). Additionally, a longitudinal study on roughly 1000 Finnish participants 
found that the presence of severe hepatic steatosis was a predictor for the occurrence of a 
cardiovascular event within a 19-year follow-up period, whereby 29% of NAFL patients 
experienced coronary or a stroke compared to 14% of non-NAFL patients (Pisto et al. 2014). 
In particular, individuals with NAFLD are reported to have increased carotid intima-media 
thickness, coronary artery calcification, arterial stiffness and impaired flow-mediated 
vasodilation (Oni et al. 2013), all of which are reported to be predictive of future CVD and 
stroke events (Darabian et al. 2013). The association of CVD and hepatic lipid accumulation 
can be explained by reports of hypertriglyceridemia, increased VLDL secretion and localized 
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lipolysis of lipoproteins in conjunction with heightened release of thrombotic factors such as 
fibrinogen and inflammatory factors such as IL-6 and TNF-alpha (Linton et al. 2000). The 
inflammatory response is thought to occur due to a build-up of apoB-containing lipoproteins 
in the walls of arteries, promoting atherogenic and atherothrombotic consequences. Not only 
has epidemiological research shown that NAFL can precede and exacerbate CVD events, but 
longitudinal cohort studies have proven CVD to be the most common cause of death among 
NAFL patients, especially those within the 45-54 age range (Adams et al. 2005, Dunn et al. 
2008). Early patient education on the importance of recognizing symptoms of co-pathologies 
of NAFL can improve cardiovascular mortality and patient outcomes.    
 
1.2.3.3.3 Insulin Resistance 
Lean and obese patients with NAFLD almost universally exhibit hepatic IR, which 
substantially increases the risk of developing subsequent type 2 diabetes mellitus by 2 to 5-fold 
(Armstrong et al. 2014). Conversely, the estimated prevalence of NAFLD in diabetic patients 
is reportedly between 60-87% depending on the country, compared to 20-30% in the general 
population (Targher et al. 2007, Prashanth et al. 2009, Chalasani et al. 2012, Doycheva et al. 
2013). IR is defined as a whole organism or target organ’s attenuated response to insulin, 
resulting in increased insulin production and secretion by the pancreas in order to maintain 
blood glucose levels in the healthy range (Shanik et al. 2008). When beta cells can no longer 
produce enough insulin to overcome the demand, blood glucose levels remain elevated and 
T2DM ensues.  
 
Insulin has multiple direct and indirect effects on the gluconeogenic and lipogenic pathways of 
the liver that contribute to insulin resistance (Brown and Goldstein 2008). In the postprandial 
state, insulin directly acts on forkhead box protein 1 (FoxO1) to inhibit the transcription of 
gluconeogenic genes such as PEPCK and G6Pase to reduce hepatic glucose output. Insulin also 
simultaneously stimulates glycogen synthase to promote glycogen synthesis (Matsumoto et al. 
2006). When hepatic glycogen stores reach maximum capacity, insulin acts on SREBP-1c to 
enhance transcription of lipogenic genes such as ACC and FAS for conversion of glucose into 
FAs and TAG via DNL (Foretz et al. 1999). Further, hepatic gluconeogenesis is indirectly 
inhibited by suppressing adipose tissue lipolysis and the subsequent release of NEFAs for 
hepatic uptake (Bergman 2000). In ob/ob mice which are insulin resistant, the FoxO1 pathway 
regulating gluconeogenesis is impaired, while the SREBP-1c pathway in charge of lipid 
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synthesis remains insulin sensitive, thereby causing high levels of hepatic gluconeogenesis and 
lipogenesis (Shimomura et al. 2000). Excess DNL-derived TAG is secreted in VLDL to other 
tissues, such as adipose and muscle, further exacerbating systemic whole-body insulin 
resistance. A time-course comparison of muscle, adipose and liver insulin resistance supported 
the notion that lipid accumulation initiates insulin resistance at the liver after just 1 week of 
high fat-feeding, followed by peripheral tissues after three weeks (Turner et al. 2013). Although 
selective hepatic insulin resistance can lead to elevated TAG levels in the liver and increase 
risk for NAFL, it is likely that central obesity and TAG accumulation in the liver initiates and 
provokes hepatic insulin resistance, which will be discussed in greater detail in the following 
section.  
 
1.2.3.3.4 Complexities to Uncouple NAFLD, IR and Obesity 
The coexistence of elevated lipid levels, basal or fasting insulin levels and IR make it 
particularly difficult to determine unidirectional causality. Although the concept of obesity-
induced IR causing hyperinsulinemia is well accepted, there is also evidence supporting the 
causal role of hyperinsulinemia in the pathogenesis of IR and obesity (Fig 1.4) (Shanik et al. 
2008). Increased pancreatic secretion of insulin causes desensitization of the target cell to 
insulin (Gavin et al. 1974). Mice transfected with extra copies of the insulin gene displayed 
two to four times higher plasma insulin levels compared to controls in the basal state, which 
were associated with reduced binding of the insulin receptor, increased postprandial glucose, 
and elevated TAG levels (Marbani and Roth 1996). Desensitization of the insulin receptor to 
insulin, due to complete inactivation of Foxa2 (Wolfrum et al. 2004), is therefore thought to 
cause IR, which has been directly associated with hepatic lipid accumulation and NAFL. 
Indeed, hyperinsulinemia in obese Zucker rat hepatocytes increased CD36 mRNA, 
translocation of CD36 protein to the plasma membrane and subsequent hepatic FA uptake, all 
of which preceded obesity and NAFL (Buque et al. 2012, Steneberg et al. 2015).  
 
Admittedly, the relationship between IR and NAFL is cyclical due to the nature of their 
pathogenesis and is therefore difficult to determine causality. While IR can be induced by 
elevated visceral FA levels, it can also provoke or exacerbate lipid accumulation, thereby 
acting as a cause and consequence simultaneously. Furthermore, hyperinsulinemia acts as both 
a compensatory mechanism of impaired insulin signalling (IR), as well as a driver of insulin 
desensitization and lipid synthesis. In reality, the direction of causality is not as important as 
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the factors that affect the known features of metabolic disease, particularly hormonal regulation 
of energy metabolism. The effect of insulin on LD homeostasis, the availability of  lipid 
intermediates such as DAGs and ceramides, and the regulation of ubiquitination in metabolism 
are all key pieces of a larger and more complex puzzle. 
 
 
Figure 1.4 Relationships between IR and Hepatic TAG Accumulation 
Obesity is associated with increased energy input that is primarily stored as lipids in adipose tissue. When adipose reaches its 
capacity, lipid accumulation occurs in ectopic tissues such as liver and muscle in the form of TAG. Fatty liver is intimately 
linked with insulin resistance in the liver and whole body insulin resistance. Insulin resistance is associated with a lack of 
suppression of adipose tissue lipolysis and hepatic glucose production while selectively activating DNL, thereby exacerbating 
lipid accumulation and blood glucose levels. Impaired insulin action and elevated blood glucose levels signal for more 
secretion of insulin from beta cells, which causes further desensitization of the body to insulin. 
 
1.3. Linking Lipids with IR Signalling 
Obesity has long been correlated with insulin resistance. More than 50 years ago, Randle and 
colleagues (Randle et al. 1963) postulated that lipids and carbohydrate metabolic pathways 
were related in the form of a cycle and that this relationship played a role in impairing insulin 
sensitivity in muscle and adipose tissues. However, studies have shown that steatotic liver can 
also become insulin resistant in the form of dysregulated hepatic glucose production. There are 
four distinct, yet interrelated, hypotheses for the mechanisms that contribute to its 
pathogenesis. Elevated lipid levels in peripheral tissues can lead to increased FFA flux into the 
liver and affect gluconeogenic and lipogenic pathways. Moreover, increased degradation of 
key metabolic proteins due to obesity may impair intracellular signalling. Additionally, active 
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lipid accumulation in the form of DAGs and ceramides can act as signals to trigger novel 
kinases and subsequent perturbations. Finally, faulty LD dynamics may lead to increased 
hepatic FA availability and impede cellular homeostasis. The following sections describe these 
hypotheses in detail.        
1.3.1 Hepatic Glucose Output 
The liver is one of the three main insulin-sensitive tissues in the body and is integral in 
facilitating the insulin-mediated suppression of gluconeogenesis, a process that is impaired in 
IR. Elevated postprandial levels of insulin bind to insulin receptors in hepatocytes to activate 
Akt and induce the downstream phosphorylation of FOXO1 (Matsumoto et al. 2007). FOXO1 
is a transcription factor that promotes the transcription of key gluconeogenic genes such as 
PEPCK and G6Pase (Wang et al. 2014). Phosphorylated FOXO1 is then translocated from the 
nucleus to the cytosol, causing subsequent suppression on gluconeogenesis. Meanwhile, 
PEPCK is the rate-limiting enzyme that converts oxaloacetate to phosphoenolpyruvate, while 
G6Pase catalyses the last step in the generation of glucose from glucose-6-phosphate.  
 
Although insulin-mediated suppression of gluconeogenesis is well accepted, the mechanism 
controlling hepatic glucose output remains to be defined. It was previously believed that insulin 
had a linear and direct effect on gluconeogenesis and output from the liver; however, insulin 
secreted from pancreatic beta cells can circulate either directly or indirectly in relation to the 
liver (Bradley et al. 1993, Lewis et al. 1996). When insulin is secreted into the portal vein, it 
reaches the liver immediately due to the lack of endothelial barrier in hepatic capillaries and 
acts on suppressing gluconeogenesis (Cherrington 1999). In contrast, insulin that is targeted 
for peripheral tissues such as adipose or muscle work on decreasing gluconeogenic precursors 
available to the liver, thereby acting indirectly (Sindelar et al. 1997). Interestingly, the rate of 
suppression of glucose output in the liver and the rate of increased glucose disposal in 
peripheral tissues is similar, suggesting an indirect extrahepatic effect. This explanation, named 
the Single Gateway Hypothesis, postulates that insulin may travel to adipose tissue and inhibit 
lipolysis, thereby decreasing plasma FFA levels and subsequently reducing hepatic 
gluconeogenesis (Bergman et al. 1993, Rebrin et al. 1995). Thus, the single gateway for insulin 
in this context is the endothelium of extrahepatic tissues. However, the validity of this 
hypothesis has been questioned several times with the characterisation of liver-specific insulin 
receptor KO (LIRKO) mice, whereby loss of the insulin receptor in the liver causes 
hyperinsulinemia and severe IR (Michael et al. 2000). Elevated plasma insulin levels in LIRKO 
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mice provides further evidence for the direct binding of insulin to its hepatic receptor and the 
subsequent receptor-mediated degradation of insulin at the liver, responsible for almost 75-
80% of total insulin clearance (Duckworth et al. 1998). It is likely that both direct and indirect 
effects are critical for normal insulin action and downstream metabolic homeostasis in the liver.  
 
1.3.2. Ubiquitin-Proteasomal Degradation 
The ubiquitin-proteasome system is a tightly coordinated process required to preserve cellular 
homeostasis, and its dysregulation can lead to inappropriate degradation of specific proteins 
implicated in the pathogenesis of IR. Ubiquitination involves three steps regulated by distinct 
classes of enzymes to attach a ubiquitin molecule to the target protein for degradation (Fig 1.5) 
(Hershko and Ciechanover 1998). Ubiquitin is first activated by ubiquitin-activating enzyme 
(E1), then transferred to the cysteine site of  ubiquitin-conjugating enzyme (E2), which 
catalyses the transfer of ubiquitin to ubiquitin ligase (E3), through which it is finally linked to 
lysine residues of the protein target (Stewart et al. 2016). Additional ubiquitin molecules are 
added to one of the seven lysine residues on the primary ubiquitin, eventually forming a chain 
of numerous ubiquitin chains to signal the proteasome for degradation which can occur in a 
variety of ways (Schrader et al. 2009). One mechanism of signalling degradation occurs via the 
recognition of the polyubiquitinated substrate by 19S regulatory proteins and transfer to 20S 
proteasomal regulatory particles for cleavage into short peptides (Finley 2009). Alternatively, 
ubiquitinated substrates can be transported to the proteasome by adaptor proteins that can bind 
to both ubiquitin chains and the proteasome (Elsasser et al. 2004). Although most proteins 
require at least monoubiquitylation, there are substrates that have an intrinsic high affinity for 
the proteasome and do not require ubiquitination for proteasomal degradation. Ubiquitinated 
substrates can be deubiquitinated by ubiquitin C-terminal hydrolases (UCH) and ubiquitin-
specific proteases (USP) and are involved in disassembling polyubiquitin chains and regulating 
signal transduction of a variety of pathways (Wilkinson 2000).     
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Figure 1.5 Ubiquitin-proteasome system. 
Proteins are degraded by the 26S proteasome via recognition of a multi-ubiquitin chain attached to substrate proteins. Ubiquitin 
molecules are added to substrates by the successive action of E1-3 enzymes. Ubiquitin molecules can be removed from 
substrate proteins by deubiquitinating enzymes (DUBs).   
 
Expression levels of several proteins involved in the ubiquitin-proteasome system are altered 
in patients with obesity, NAFL and IR. In particular, overall total intracellular protein 
proteolysis is increased in metabolic disease (Balasubramanyam et al. 2005, Ishii et al. 2015). 
The downregulation of deubiquitinating enzymes USP 4, 10 and 18 protein levels in hepatic 
steatosis and IR suggest inappropriate degradation of key proteins that regulate lipid 
accumulation and insulin action (An et al. 2017, Luo et al. 2018, Zhao et al. 2018). 
Furthermore, E3 ubiquitin ligases such as MG53, Nedd4 and Trim32 specifically target IRS1/2, 
reduce its tyrosine phosphorylation and downstream AKT/FOXO1 signalling (Yang et al. 
2016). Increased proteasomal activity is likely associated with obesity and subsequent chronic 
low-grade inflammation (Wunderlich et al. 2013, Pereira and Alvarez-Leite 2014). Suppressors 
of cytokine signalling (SOCS) 1 and 3 proteins are E3 ubiquitin ligases that upregulate with 
severe lipid accumulation and, like other E3 enzymes, affect downstream insulin signalling 
(Rui et al. 2002). Interestingly, insulin action is associated with inhibition of degradation, and 
this is impaired in IR, thereby exacerbating abnormal proteasomal activity on other protein 
targets (Russell-Jones and Umpleby 1996). These targets include key lipogenic regulators such 
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as PPARa and SREBP and likely contribute to the pathogenesis of selective IR in the liver and 
further steatosis (Hirano et al. 2001, Blanquart et al. 2002). 
 
1.3.3. Bioactive Lipid Signalling 
The unifying pathological feature of both lean and obese NAFL is the increase in FFA flux 
into the liver. FAs can be converted to an array of distinct lipid species that not only serve as 
building blocks for cell membranes or sources of energy, but act as pathophysiological 
mediators of intracellular processes. Bioactive lipids influence cell signalling functions and can 
be divided into four main families depending on their biochemical structure and function: 
classical eicosanoids such as prostaglandins, specialized pro-resolving mediators such as 
docosahexaenoic acids (DHA) and eicosapentaenoic acids (EPA), glycerolipids or 
sphingolipids such as ceramides and DAGs, and cannabinoid-receptor specific eicosanoids 
called endocannabinoids (Chiurchiu et al. 2018). Currently, ceramides and DAGs are 
considered two putative regulators of lipid-induced hepatic IR.   
 
1.3.3.1. Diacylglycerols 
Intrahepatic DAG content is a strong predictor of whole-body and liver-specific IR in obese 
and NAFLD patients, even more so than BMI, ER stress, cytokine concentrations and long-
chain FA-CoA content (Kumashiro et al. 2011). Indeed, pharmacological treatment to reduce 
total intrahepatic DAG levels in rodent models significantly attenuated IR, regardless of 
distinct species pools (Perry et al. 2013, Tao et al. 2014, Perry et al. 2015). DAGs are versatile 
lipids that can be generated from a myriad of metabolic reactions, each resulting in distinct 
isomers of DAG depending on the enzymes and precursors involved. For instance, TAGs have 
three possible sites for lipase action which can result in three different isomers of DAG: sn-
1,2, sn-2,3 or the less common rac-1,3, which has unknown stereochemistry (Eichmann and 
Lass 2015). In contrast, precursors such as phospholipids and PAs which utilize 
phospholipase/transferases or phosphatases, respectively, can only result in sn-1,2 DAG 
isoforms. Although DAGs can exist in three different stereo/regioisoforms and originate from 
FAs of a variety of lengths and saturation states, research indicates that the majority of DAG 
species correlate positively with hepatic IR (Wang et al. 2014, Luukkonen et al. 2016). When 
the cytosolic content of over 13 distinct DAG species were measured in insulin sensitive and 
insulin resistant livers of obesity-induced NAFL patients, all species except C20:4-C20:5 and 
C18:0 were increased in the insulin resistant samples (Ter Horst et al. 2017).  
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DAGs are proposed to impair insulin signalling through the activation of novel or atypical 
protein kinase C (PKC) isoforms. DAG-mediated activation of PKCs can directly 
phosphorylate serine residues and IRS-1 and the insulin receptor and consequently inhibit 
downstream PI3-kinase/Akt pathway (Schmitz-Peiffer and Biden 2008). Furthermore, PKCs 
act upstream by activating other kinases such as Jun NH2-termnal kinase (JNK), p42/44 
mitogen-activated protein kinase (MAPK), and inhibitor of nuclear factor kB kinase (IKK)-b 
to specifically modulate insulin signalling (Khoshnan et al. 2000, Aguirre et al. 2002). 
Although PKCs as therapeutic targets seem promising, KO and KD studies show contrasting 
results. Inhibition of certain PKC isoforms have improved insulin sensitivity in mostly short-
term HFD studies (Samuel et al. 2004, Samuel et al. 2007, Schmitz-Peiffer et al. 2007) but not 
long-term models, likely due to alternative compensatory isoforms (Gao et al. 2007, Schmitz-
Peiffer and Biden 2008).            
 
1.3.3.2. Ceramides  
Apart from DAGs, liver ceramide levels have also been reported to be elevated in NAFLD 
patients (Yetukuri et al. 2007) and promote IR through a similar mechanism to DAGs. 
Ceramides can be produced from the re-acylation of sphingosine or from the condensation of 
palmitate and serine, both of which use ceramide synthase (CERS) to catalyse the final step 
(Levy and Futerman 2010). The generation of ceramides of different chain lengths is facilitated 
by 6 distinct CERS isoforms, some more associated with the development of obesity and IR 
than others (Kanety et al. 1996, Chavez et al. 2003, Stratford et al. 2004). Inhibition of its 
endogenous synthesis in obese rodents reverses IR (Holland et al. 2007) via restored Akt 
phosphorylation (Holland and Summers 2008). In particular, the C14-C16 fatty acyl chains 
generated by CERS6 specifically has been shown to block PKC-mediated Akt translocation 
for downstream insulin signalling (Reali et al. 2017), although it is unknown whether its 
inhibition rescues insulin action. More research into liver-specific isoforms of CERS and IR in 
rodents and humans need to done to understand its role in NAFL.     
     
1.3.4. Leaky Lipid Droplets 
From a reductionist point of view, steatosis occurs from an imbalance in synthesis and 
breakdown of TAG; however, the difficulty in elucidating the aetiology of NAFL(D) is that a 
single universal pathway responsible for its pathogenesis is highly unlikely. The majority of 
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research on intracellular hepatic FA trafficking in NAFL and IR have focused on FFA uptake 
and storage, but some evidence suggests that compensatory FA disposal may also cause harm 
(Mashek 2013). The inappropriate release of FAs from LDs via lipolysis can thus be referred 
to as the ‘leaky LD hypothesis’ for the pathogenesis of IR in NAFL. Indeed, sequestration of 
TAG in LDs highly likely protects against lipotoxicity and thus, the attempt by hepatocytes to 
alleviate steatosis by releasing FAs into the cytosol may have deleterious consequences 
(Listenberger et al. 2003). This is especially true for long-chain saturated FAs such as stearate 
and palmitate, which are known to cause lipotoxic stress, proinflammatory signalling and 
mitochondrial dysregulation in hepatocytes (Listenberger et al. 2003, Ogawa et al. 2018). 
Although the direct relationship between dysregulated LD lipolysis and pathogenesis of disease 
in non-adipocytes has not been extensively studied, intrahepatic lipolysis has been shown to be 
50% greater in individuals with NAFLD in one tracer study (Sunny et al. 2011). However, a 
look at the downstream effects of lipolytic pathways, namely VLDL-TAG secretion and 
oxidation can allude to leaky LDs. For example, although it is well known that VLDL secretion 
is heightened in NAFLD participants (Fabbrini et al. 2008), 70% of the FAs that contribute to 
the VLDL-TAG are derived from the re-esterification of FAs released from hepatic TAG 
lipolysis (Gibbons and Wiggins 1995). Further, systemic sources of FAs such as those released 
from adipose tissue lipolysis made up 43% of that incorporated into VLDL-TAG in NAFLD 
patients, and is therefore less important in hepatic FA utilization than hepatic DNL or TAG-
derived FAs (57%) (Fabbrini et al. 2008). Similarly, intrahepatic TAG lipolysis is also a source 
of FAs for mitochondria oxidation. While many studies have reported impaired hepatic FA 
oxidation in NAFLD (Hashimoto et al. 2000, Ibdah et al. 2005, Zhang et al. 2007, Stefanovic-
Racic et al. 2008, Rector et al. 2010), others have described excessive lipolysis-induced TCA 
cycling in hepatic steatotic and IR liver (Sunny et al. 2011, Satapati et al. 2012) and greater 
incorporation of U-13C-labelled FAs into CO2 in patients’ breaths (Hodson et al. 2010), 
suggesting heightened mitochondrial oxidation of hepatic-derived FAs in patients with NAFL. 
Therefore, it is likely that impaired control of FA release from LDs (i.e. leaky LDs) in the liver 
is an underestimated perturbation in the pathogenesis of NAFL and IR, alongside other 
pathways known to be impaired including FA uptake and oxidation.  
 
1.4. Lipid Droplets 
Intracellular storage of neutral lipids in LDs is a process that is evolutionarily conserved in 
almost all organisms, including prokaryotes and eukaryotes (Thiam and Beller 2017). These 
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complex organelles vary in size, spatial organization, number and composition across species 
and cell types. In mammalian adipocytes for example, LDs are generally unilocular and large, 
whereas hepatocytes have multiple smaller LDs (Natarajan et al. 2017). Since the discovery of 
proteins on LDs in the 1990’s, studies have demonstrated their importance in managing FA 
utilization, ER and oxidative stress, protein turnover and even in modulating immune responses 
towards pathogens (Khatchadourian and Maysinger 2009, Hapala et al. 2011, Welte 2015, 
Bersuker and Olzmann 2017, den Brok et al. 2018). Extensive research has been specifically 
conducted on the role of LDs in the pathogenesis of metabolic diseases, such as obesity, 
NAFLD, and type 2 diabetes due to the central role that lipids and proteins in LDs play in TAG 
esterification, lipolysis, oxidation and secretion. This section will summarize what is currently 
known about LD structure, formation and interactions and elaborate on the relationship 
between LDs and disease.  
 
1.4.1. General Properties 
LDs are composed of a phospholipid monolayer coated with an array of proteins that surround 
a hydrophobic core of neutral lipids. Although the lipid composition may differ between 
species and cell types, the majority of LDs contain TAG, cholesterol esters (CE) and retinyl 
esters (Khor et al. 2013). Recently, Senkal and colleagues (Senkal et al. 2017) reported the 
sequestration of acylceramides in hepatic LDs for the first time in mice, indicating a potentially 
novel mechanism by which LDs exacerbate IR in NAFL. Hepatocytes generally have multiple 
smaller LDs approximately 10 µm in diameter, but can reach up to 100 µm in steatotic livers 
(Kochan et al. 2015). The lipid monolayer consists of free cholesterol and a variety of 
phospholipids that are thought to help with maintaining LD stability and facilitate interactions 
with other organelles (Bartz et al. 2007). Over 50 different species of phosphatidylcholine 
make up 50-60% of the phospholipid content of the LD membrane, followed by roughly 45 
types of phosphatidylethanolamine, and up to nine species of phosphatidylinositol (Krahmer 
et al. 2011). Interestingly, LD surfaces have less cholesterol and more phospholipids than other 
membranes, However, during periods of LD growth or shrinkage, membranes can accumulate 
more lipid intermediates such as DAG, FAs and sterols to act as fluidifiers (Thiam et al. 2013). 
 
A large number of proteins associated with LD surfaces have been identified across species 
and cell types in the last two decades. There are thought to be 50 core proteins that are found 
in the majority of mammalian LDs and can act as distinguishing markers of this organelle. The 
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perilipin (PLIN) family are integral LD proteins that upregulate with increased LD growth and 
abundance (Itabe et al. 2017). Out of the five isoforms, PLIN2, 3 and 5 are expressed in the 
liver and have a variety of functions related to LD generation and stabilization. Overexpression 
of PLIN2 in liver promoted TAG storage in LDs and protected against autophagy in lipid-rich 
environments (Tsai et al. 2017). Similarly, PLIN5 facilitates lipid storage by disrupting the 
interaction of ATGL with its coactivator, CGI-58 in order to prevent lipolysis (Wang et al. 
2015). This protective affect against lipotoxicity exacerbates hepatic steatosis without affecting 
insulin resistance (Trevino et al. 2015). There has also been a large number of additional 
proteins that have been identified on LDs, ranging from 8-200 proteins in plants and yeast to 
generally over 1000 in humans and rodents (Jolivet et al. 2004, Wu et al. 2009, Xie et al. 2010, 
Ding et al. 2012, Horn et al. 2013, Krahmer et al. 2013, Currie et al. 2014, Khan et al. 2015). 
The protein composition of LDs largely depends on the environment and life cycle stage they 
are in. For instance, LDs can be considered nascent or mature, localize in the cytosol or the 
nucleus, be small or steatotic in size, and interact with mitochondria for FA oxidation or ER 
for lipid synthesis; all of which can influence LD proteome.  
 
1.4.2. The Lipid Droplet Life Cycle 
1.4.2.1. Biogenesis and Growth 
As described in 1.2.3.1.3, TAGs can be synthesized via the DNL pathway or through re-
esterification of MAGs and DAGs, both of which are catalysed by DGAT enzymes in the final 
step (Yen et al. 2008). DGAT1 is exclusively localized at the ER and primarily synthesises 
TAG from the re-esterification of recycled DAG, whereas DGAT2 is found in both the ER and 
LDs and is mainly involved in DNL-mediated TAG generation from the esterification of 
newly-formed DAG (Yen et al. 2008). TAG is formed at the ER wherever these two enzymes 
are found in excess and they are deposited into the ER bilayer until the membrane forms a 
bulge of lipids called an ‘oil lens’ (Hamilton and Small 1981, Wilfling et al. 2014) (Fig 1.6). 
Lenses are formed to reduce the costs of entropy when disrupting the ER bilayer during TAG 
formation. The ER is composed of different domains that vary in their curvature, where sheets 
are considered flat with no curvature and tubules have curvature in one or both directions of 
the leaflet (Nixon-Abell et al. 2016). Lens and subsequent LD formation occurs in tubules and 
therefore proteins that are involved in maintaining ER tubule structure can affect LD biogenesis 
(Jacquier et al. 2011). For example, atlastin is an ER protein that is critical for the fusion of ER 
network tubules and is required for LD expansion from the ER (Klemm et al. 2013). 
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Knockdown of atlastin is associated with less dense ER networks, reduced TAG content, and 
formation of smaller LDs with diameter less than half of controls. Likewise, LD budding and 
expansion from the ER are affected by lipid composition and ER proteins, although the exact 
mechanisms remain unclear. Fat-storage-inducing transmembrane 2 (FIT2) is an ER protein 
that colocalizes with newly emerging LDs and was recently reported to have lipid phosphate 
phosphatase activity associated with modified LD phospholipid composition (Becuwe et al. 
2018). Membrane phospholipids are key components in adjusting LD curvature for emergence 
from the ER. Further, FIT2 regulates DAG levels in LDs as an additional point of control in 
LD expansion , whereby a reduction in DAG is required for budding to occur (Choudhary et 
al. 2018). As more TAG is deposited in between the bilayer, the contact angle because the 
newly forming LD and the ER increases until eventually fission occurs (Thiam and Foret 
2016). It is hypothesized that seipins are required to form ER membranes with extreme 
curvature, such as the angle required for budding of newly formed LDs (Han et al. 2015). 
Although the full extent of seipin’s function remains unclear, they were recently reported to 
collect and transfer phosphatidylamines to phosphatases to reduce surface tension (Ben 
M'barek et al. 2017). Elevated levels of phosphatidylamines in membranes of emerging LDs 
increases ER surface tension, thereby blocking LD growth (Yan et al. 2018). SThe importance 
of seipins in maintain appropriate phospholipid composition for LD biogenesis is supported by 
the presence of aberrant LDs in seipin-deficient HeLa cells (Yan et al. 2018).  
 
Proteins can associate with LDs by either migrating to LDs via ER-LD membrane bridges, 
defined as class I proteins, or by targeting to the LD surface from the cytosol, termed class II 
proteins (Kory et al. 2016). Membrane bridges can be stabilized by Arf and COPI/coatomer 
protein machinery, allowing for the relocation of TAG synthesis enzymes such as DGAT2 and 
GPAT4 from the ER to the LD surface (Wilfling et al. 2013, Wilfling et al. 2014). Nascent 
LDs with localized enzymes for lipid synthesis are called expanding LDs (eLDs), which are 
also initial LDs (iLDs) that are now specialized . TAG synthesis enzymes on eLDs facilitate 
the expansion and growth of LDs that have separated from the ER. When lipolysis and 
subsequent LD shrinkage is required, class I proteins generally remain bound due to their 
higher affinity compared to class II proteins (Rowe et al. 2016). In contrast, class II proteins 
can associate to LDs via hydrophobic domains such as the amphipathic helices in PLIN 
proteins that act as LD-binding motifs (Li et al. 2017). Other unclassified proteins may also 
bind to LDs using lipid anchors, such as the palmitoylation of ELMOD2 (Suzuki et al. 2015) 
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or via protein-protein interactions, such as the Jabba-mediated LD association of histones in 
Drosophila (Li et al. 2012).  
 
 
Figure 1.6 Lipid droplet biogenesis, growth and expansion. 
TAG is synthesized and accumulated within the bilayer membrane of the ER, causing an oil lens to bulge. The lens expands 
until an LD forms and buds off the membrane as nascent LDs.  Figure taken from (Walther et al. 2017). 
 
1.4.2.2. Lipid Droplets as Dynamic Interactors 
Traditionally considered as mere depots for fat storage, LDs are now known as dynamic 
organelles with a multitude of functions, some of which entail association with other key 
players (Fig 1.7). Being a major metabolic hubs of the cell, LDs require tight communication 
with almost every organelle in the cell to maintain energy homeostasis. For example, contact 
between LDs and ER are primarily concerned with lipid synthesis and protein storage, whereas 
interactions with mitochondria and peroxisomes are necessary for FA catabolism and ATP 
generation. Furthermore, LDs interact with each other to share neutral lipid pools, mediate 
pressure differences or alter their lipase interface. Being one of the most active and social 
organelles, transport and trafficking of LDs are a key method of communication during nutrient 
load, cellular stress and much more.  
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Figure 1.7 LD contact sites with organelles. 
Molecular tethers are utilized by LDs to link with organelles, particularly mitochondria, peroxisome, ER and other LDs, to 
modulate lipid metabolism. Figure taken from (Schuldiner and Bohnert 2017).  
 
1.4.2.2.1. Contact Sites and Transport of Lipid Droplets 
The majority of organelles, such as the ER, mitochondria and nucleus, consist of an aqueous 
lumen with at least one amphipathic bilayer membrane to separate the core from the cytosol. 
In contrast, LDs have a concentrated hydrophobic core with a single phospholipid monolayer 
to separate the lipids from the outer hydrophilic environment. Unsurprisingly, the distinct 
anatomy of LDs from other organelles necessitates alternative mechanisms for LD organellar 
contact instead of regular fission and fusion. Contact sites are positions between two organelles 
that mediate the transfer of lipids, ions or proteins without compromising the structural 
integrity of either organelle (Schuldiner and Bohnert 2017). Regardless of the organelle, almost 
all contact sites enlist molecular tethers to increase stability and stay in close proximity to each 
other, usually between 10-70 nm. Additionally, proteins may also reside at contact sites to 
facilitate a specific type of interorganellar transfer (called effectors) or to adapt features of 
contact site such as size and abundance (called regulators) (Eisenberg-Bord et al. 2016). 
Interactions with membrane-bound organelles are possible via bidirectional LD movement on 
microtubules (Welte et al. 2005). Indeed, LDs engage with the cytoskeleton and even house 
motor proteins on its surface to aid in moving LD cargo to and from organelles. Although LD 
interactions and transport are fairly similar, there are distinctions that can be made between the 
various organelles. 
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1.4.2.2.2. Protein Transfer with Endoplasmic Reticulum 
While biogenesis of LDs occurs at the ER, recent findings suggest that it is possible to form 
lipidic bridges between the LD and ER, even after droplets have reached full maturation 
(Schuldiner and Bohnert 2017). Lipidic bridges are defined as hemifusion intermediates that 
are continuous with the LD monolayer and the outer leaflet of the ER membrane bilayer. It is 
hypothesized that the majority of LD-associated proteins are ER residents and protein targeting 
between the two organelles requires contact via these bridges (Wilfling et al. 2013, Wilfling et 
al. 2014). Arf1/COP1 activity can result in the formation of nano-LDs via the removal of 
phospholipids from the LD surface (Wilfling et al. 2014). Subsequent increase in LD surface 
tension allows the formation of membrane bridges between the LD and ER when in close 
proximity. Proteins targeted for LD localization can then move from ER to LDs by crossing 
the bridge.  Similar studies using chemicals to raise surface tension in cells without Arf/COP1 
are consistent with this model (Wilfling et al. 2014). Contact between the ER and LD are 
crucial in supplying an LD proteome that is sufficient to meet energy demands. Failure to 
appropriately curate and provide key metabolic proteins for lipid homeostasis can cause serious 
defects (Grippa et al. 2015). 
 
1.4.2.2.3. Mitochondrial and Peroxisomal Lipid Droplet Catabolism 
TAG stored in LDs can be hydrolysed by lipases to release energy-rich FFAs to the 
mitochondria for ATP generation via b-oxidation. Release of FAs into the cytosol at high 
concentrations can be cytotoxic to the cell, therefore it is beneficial for LDs to maintain close 
contact with mitochondria during times of energy deprivation (Klecker et al. 2017).  
 
Studies on the exact mechanism of LD-mitochondria contact are relatively sparse; however, 
there are several proteins reported to play a role in their interaction. The bona fide LD protein 
PLIN5 is expressed in oxidative tissues such as heart, skeletal muscles, adipocytes and the liver 
and has been reported to localise to the mitochondria when stimulated by the PKA activator 
forskolin (Wang et al. 2011). Indeed, PLIN5 overexpression induced more mitochondrial 
recruitment to LDs in cardiac myocytes, supposedly via the 20 amino acids on the C-terminal 
of the protein (Wang et al. 2011). Similarly in adipose tissue, PLIN1 knockdown rather than 
PLIN5 was associated with a reduction in LD-mitochondria interaction as evidenced by 
decreased colocalization of PLIN1 with the outer mitochondrial membrane proteins (Boutant 
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et al. 2017). Although other PLIN proteins are not reported to affect LD contact with 
mitochondria, it is possible that the PLIN-specific mechanism may be dependent on the tissue.  
 
Peroxisomes also play a critical role in FA utilization, including complete b-oxidation, TCA 
and ETC in yeast and plants, and partial oxidation of very long chain FAs in eukaryotes (Poirier 
et al. 2006). Interestingly, peroxisomes initiate contact with LDs in a unique manner using 
protrusions called pexopodia (Binns et al. 2006). These protrusions are enriched for oxidative 
proteins and can intrude into the LD core to allow for intimate involvement of the two 
organelles in lipid breakdown.  
 
1.4.2.2.4. Lipid Exchange between Lipid Droplets 
Interaction between multiple LDs, called a homotypic contact, is not uncommon, despite the 
lack of information on the protein machinery involved in facilitating their association (Murphy 
et al. 2009). One of the only players known are a family of cell death-inducing DFF45-like 
effector (CIDE) proteins which appear to be localized at contact sites between LDs (Gong et 
al. 2011). It is hypothesized that CIDE-A proteins tether LDs via an amphipathic a-helix that 
is present on two domains; however, it is uncertain whether CIDE-B, the liver isoform, 
possesses the same features (Gong et al. 2009, Barneda et al. 2015). It is important to note that 
CIDE-mediated LD-LD interactions always result in directional fusion of the droplets, whereby 
the neutral lipids from the smaller droplet are transferred to the larger droplet (Gong et al. 
2011). Exchange of lipid content is likely due to higher internal pressure in smaller LDs 
compared to larger ones. While CIDE proteins enable focal contact between LDs, fat-specific 
protein 27 (Fsp27) has been shown to increase the number of LDs greater than 5 µm in diameter 
by almost 8-fold in adipocytes (Gong et al. 2011). Together, CIDE and Fsp27 mediate LD 
growth via lipid transfer of interacting LDs with size disparity. More research is required to 
ascertain whether LDs can interact with each other without fusion.  
 
1.4.3. Lipid Droplet Proteome in Metabolic Disease 
Given the importance of LD-associated proteins in lipid homeostasis, it is of great significance 
to understand how these proteins are altered in NAFL and hepatic insulin resistance. Although 
there are numerous proteomic studies of the LD, only a handful have been investigated in 
models of liver disease. The following section outlines the advancements of this niche field 
and identifies the major holes that are left to investigate.     
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1.4.3.1. Lipids Droplet Proteome and Non-Alcoholic Fatty Liver  
Recent proteomic investigations of LDs have been revealing the intricacies and dynamics of 
hepatic LDs in a variety of environments, especially in periods of excess lipid supply. Although 
lipolytic regulators are the most prominent LD proteins examined in the pathogenesis of NAFL 
(discussed in detail in section 1.2.3), several proteomic studies have reported that the majority 
of LD proteins that alter in abundance or localization with HFD-induced hepatic steatosis are 
not primarily involved in lipid metabolism. In patients with simple steatosis, pathways such as 
retinol, xenobiotic, drug and linoleic acid metabolism were increased compared to patients 
without fatty liver (Su et al. 2014). Similarly in high fat-fed mice, the LD proteome revealed 
upregulation of ribosomal, ER and xenobiotic metabolism while glucose metabolism and liver 
X receptor signalling were downregulated (Khan et al. 2015). Whole organellar protein 
differences allow researchers to identify novel and unexpected candidates that could cause 
more disruption in lipid metabolism than obvious targets. For example, S100 calcium-binding 
protein A10 (S100A10) was found to be one of 101 proteins that were enriched in hepatic LDs 
by 10-fold with high-fat feeding (Liu et al. 2017). Although historically associated with the 
endo- and exocytosis of neurotransmitters (Milosevic et al. 2017), knockdown of S100A10 led 
to increased hepatic steatosis by inhibiting lipid transport and trafficking (Liu et al. 2017). In 
another proteomic study, the oxidoreductase 17b-hydroxysteroid dehydrogenase 13 (17b-HSD 
13) was identified on LDs in human steatotic liver and reported to induce lipogenesis and 
promote steatosis in vitro (Horiguchi et al. 2008, Su et al. 2014). Despite the value of high 
throughput research in understanding the role novel LD proteins in NAFL, the vast majority of 
studies take a more targeted and selective approach using known regulators.  
 
It is important to note that lipid stimulation intrinsically associated with large changes in 
protein localization, activation and association, even in non-diseased states (Krahmer et al. 
2018). In fact, with gradual diet-induced hepatic lipid accumulation across 12 weeks, over 20% 
of proteins are re-localized, with 6% of all proteins moving towards LDs. It is hypothesized 
that expanding LDs have larger surface areas and therefore proteins may move to LDs as a way 
to regulate protein depletion, acting as a ‘protein sink’. In steatotic mice, LDs were found to 
have increased abundance of contact site proteins, potentially facilitating the transfer of 
proteins across organelles to LDs. If this were true, LDs would consequently be at the forefront 
of regulating a vast number of pathways that can be indirectly linked to symptoms of metabolic 
 31 
syndrome. Thus, more research into the role of LDs in mediating proteomic shifts in metabolic 
disease is required to discover truly novel players that connect these pathways.  
 
1.4.3.2. Lipid Droplet Proteome and Insulin Resistance 
The intracellular accumulation of TAG in hepatocytes is strongly associated with the 
development of IR (see section 1.2.3.3.3 for more detail). However, work over the past several 
decades has shown that perturbed pathways in NAFL and IR are inextricably linked, making it 
hard to identify specific players involved in impaired insulin signalling at the LD level without 
being confounded by the effect of lipids. Since insulin resistance is fundamentally defined by 
impaired insulin action, investigating how the LD proteome is altered with stimulation by this 
hormone is a logical step forward in this field. Strikingly, there are no known high throughput 
studies that have explored the relationship between insulin stimulation and proteomic 
activation, translocation or interaction at the whole LD level, and how they change in the 
insulin resistant setting. Instead, much of the literature has focused on targeted investigation 
into the insulin-stimulated regulation of major lipolytic regulators.  
 
1.4.3.2.1. Regulation of LD Proteins by Insulin 
Several proteins critical for lipolysis are phosphorylated by protein kinase A (PKA), a 
downstream regulator of the cyclic AMP second messenger system (Duncan et al. 2007) and 
inhibited by AMP-activated protein kinase (AMPK). In particular, HSL is phosphorylated at 
sites Ser563, Ser659 and Ser660 by PKA as well as the synthetic lipolytic activator 
isoproterenol and the catecholamines glucagon and adrenaline (Anthonsen et al. 1998, 
Roepstorff et al. 2004, Duncan et al. 2007). In contrast, Ser 565 is phosphorylated to inhibit 
HSL lipolytic activity, demonstrating the strict regulation of phosphorylation events. 
Additionally, PLIN1 is phosphorylated by PKA to facilitate the translocation of HSL to the LD 
surface (Shen et al. 2009). Similarly, PKA phosphorylation of Ser406 on ATGL and Ser239 
on CGI58 further promote TAG hydrolysis in adipose tissue (Pagnon et al. 2012, Sahu-Osen 
et al. 2015). Insulin inhibits these pathways by Akt-mediated phosphorylation of 
phosphodiesterase 3B, an inhibitor of cAMP levels and PKA activity (DiPilato et al. 2015). It 
is important to note that the majority of these phosphorylation events are reported in adipocytes 
and have not been elucidated in hepatocytes, most likely due to the relatively greater role that 
adipocyte lipolysis plays in obesity-induced IR (see section 1.3.1). Although the role that 
insulin plays in regulating lipid and glucose metabolism is largely known, the exact pathways 
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and mechanistic events involved are largely unknown for the vast number of proteins, including 
key metabolic regulators. Understanding insulin and diet effects both independently and as a 
whole on LD proteins can provide great insight into their dysregulation in insulin resistance 
and NAFL, and eventually help identify potential drug targets.   
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1.5. Summary and Thesis Aims      
NAFL(D) is defined by the accumulation of TAG in the liver and is often associated with the 
development of IR.  NAFL(D) or obesity-induced IR is primarily characterized by sustained 
hepatic glucose production, DNL and adipose-specific TAG lipolysis with insulin stimulation.  
The dysregulation of other pathways that affect lipid homeostasis, such as FA uptake, b-
oxidation and VLDL-TAG secretion have also been implicated in the pathogenesis of 
NAFL(D) and IR. The central hub where the majority of these processes function is at cytosolic 
LDs which are dynamic organelles that store neutral lipids such as CE, TAG and possibly 
acylceramides. LDs host 100-1000s of proteins on its surface that not only facilitate FA 
utilization but also mediate an array of other pathways that have no straightforward connection 
to classical LD function. Many LD-associated proteins have been previously known to be 
residents of other organelles, further emphasizing the complexity of LD behaviour 
interorganellar interactions. In selected proteins, insulin and diet have been shown to alter 
proteomic translocation, activation and interaction at LDs but no known studies have 
investigated these changes at a whole LD proteome level.  
 
The thesis contains four research projects that are intended to be read independently but weave 
together to provide new knowledge on the role of proteomic, phosphoproteomic and 
ubiquitomic changes in HFD-induced IR in the liver. The first research project (Chapter 2) 
focuses on insulin and diet effects of ubiquitin-proteasomal protein degradation in the liver to 
investigate changes in protein abundance of key metabolic regulators in NAFL or IR. The 
second research project (Chapter 3) delves a little deeper to understand insulin and diet effects 
on protein translocation and phosphorylation/activation at the LD level, and how this alters 
with hepatic IR. To assist with the validation of high-throughput data, the metabolic physiology 
of a number of hepatocyte cell lines were characterized to identify the most suitable cell line 
to use for validation, which the results are described in Chapter 4. The chosen cell line was 
then used to characterize the function of a novel protein candidate from Chapter 3 in lipid and 
glucose metabolic pathways to elucidate its role in the pathogenesis of metabolic disease.  
Together, this thesis acts as the first step-wise analysis into and insulin-induced changes in 
whole and LD protein regulation and how it contributes to NAFL and IR.  
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Chapter 2  
Role of Ubiquitination in Obesity-Induced Insulin Resistance in the Liver 
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Abstract
Ubiquitin is a crucial post-translational modification regulating numerous cellular processes,
but its role in metabolic disease is not well characterized. In this study, we identified the in
vivo ubiquitin-modified proteome in rat liver and determined changes in this ubiquitome
under acute insulin stimulation and high-fat and sucrose diet-induced insulin resistance. We
identified 1267 ubiquitinated proteins in rat liver across diet and insulin-stimulated condi-
tions, with 882 proteins common to all conditions. KEGG pathway analysis of these proteins
identified enrichment of metabolic pathways, TCA cycle, glycolysis/gluconeogenesis, fatty
acid metabolism, and carbon metabolism, with similar pathways altered by diet and insulin
resistance. Thus, the rat liver ubiquitome is sensitive to diet and insulin stimulation and this
is perturbed in insulin resistance.
Introduction
The liver is exquisitely insulin-sensitive, and plays a critical role in glucose and lipid home-
ostasis as well as detoxification. Dysregulation of glucose and lipid metabolism in liver is a
major factor in the pathogenesis of metabolic diseases including type 2 diabetes and non-alco-
holic fatty liver disease (NAFLD). A primary characteristic of these metabolic diseases is the
accumulation of excess lipid in the liver, known as fatty liver or hepatic steatosis [1]. This sce-
nario is linked with impaired whole-body and hepatic insulin-stimulated glucose metabolism
[2]. High-fat feeding studies with rodents demonstrates that impairment of insulin action
in the liver precedes the development of insulin resistance in other glucoregulatory tissues,
including skeletal muscle and adipose tissue [3, 4]. Fatty liver reduces tolerance to ischemic
injury, impaired regeneration capacity [5] and increases the risk of developing hepatocellular
carcinoma [6]. As such, fatty liver is an initiating factor in the development of a range of
pathologies.
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Transcriptomic [7], lipidomic [3], and proteomic [8] studies have provided significant
insight into the mechanisms that link fatty liver and insulin resistance. Ubiquitin is a crucial
post-translational modification that regulates cellular signaling in numerous processes such as
metabolism, transcription, translation, vesicle transport and apoptosis [9]. Dysfunction of the
ubiquitin proteasome system (UPS) is observed in multiple diseases including cancer [10] but
its role in metabolic disease is relatively poorly defined. Therefore, we aimed to identify the in
vivo ubiquitin-modified proteome (ubiquitome) in rat liver and determine changes in this ubi-
quitome under acute insulin stimulation and in high-fat diet-induced insulin resistance.
Materials and methods
Animals
All surgical and experimental procedures performed were approved by the Animal Ethics
Committee (Ethics # 14/07, Garvan Institute/St. Vincent’s Hospital) and were in accordance
with the National Health and Medical Research Council of Australia’s guidelines on animal
experimentation.
Sixteen adult male Wistar rats (Animal Resources Centre, Perth, Australia) were commu-
nally housed at 22 ± 0.5˚C with a controlled 12:12h light-dark cycle. Half were fed ad libitum a
standard rodent diet (Rat Maintenance Diet; Gordons Specialty Feeds, Sydney, Australia) con-
taining (10% fat, 69% carbohydrate, and 21% (w/w) protein) while the other half was fed a high-
fat, high-sucrose diet (HFSD; 45% energy from fat, 30% energy from sucrose) made in-house
[11]. After 3 weeks of feeding, indwelling catheters were implanted as described elsewhere [12].
Insulin infusion
All animals were fasted for 5 h and randomly assigned for acute insulin stimulation or tissue
collected in the basal state, eight rats in each group. Insulin (Actrapid, Novo Nordisk, Copen-
hagen, Denmark) was infused at a rate of 0.5 U/kg/h, and a 30% (wt/vol) variable glucose
infusion was started at 4 min to maintain euglycemia, based upon [13]. In these rats, plasma
samples were taken at 0, 1, 3, 5, 7.5 and 10 min for the measurement of insulin and glucose
concentrations only. At 10 min, rats were euthanized with an overdose of sodium pentobarbi-
tone (Troy Laboratories, Australia), liver rapidly dissected, freeze-clamped with aluminum
tongs precooled in liquid nitrogen, and stored at −80˚C for subsequent analysis. Epidydimal
fat pass mass was used as an index of adiposity.
Ubiquitome analysis
Approximately 3–4 grams of liver was lysed in a 1:4 ratio (w:vol) of tissue and lysis buffer (50
mMTris-HCl (pH 7.5), 150 mMNaCl, 0.5% NP-40, 1 mMDTT, 1X EDTA-free protease inhibi-
tor cocktail, 10 mMN-ethylmaleimide, 1mM sodium orthovanadate) using a POLYTRON hand
homogenizer. The protein concentration was determined using a BCA assay and 500 μg of total
protein was used per sample to immunopurify mono- and poly-ubiquitinated proteins using
specialized ubiquitin affinity matrix (VIVAbind Ubiquitin Kit, VIVA Bioscience). After substan-
tial washing to remove residual detergent, beads were digested for 30 min at 27˚C, then reduced
with 1mMDTT and left to digest overnight at room temperature with sequencing-grade trypsin
(5 μg/mL, Promega), as described previously [14]. Samples were alkylated with 5mg/mL iodoa-
cetamide and protease digestion terminated with trifluoroacetic acid. Trypsinized eluents were
collected after brief centrifugation then purified and desalted using self-packed tips with 6 layers
of C18 Empore disks (Pacific Laboratory Products), then dried in a SpeedVac. Samples were
then resuspended in 12 μL 5% formic acid, 2% acetonitrile and stored at -80˚C.
Rat liver ubiquitome and insulin resistance
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For MS analysis, 5 μL of each of the peptide samples were loaded and separated along a C18
column (400 mm, 75 μm ID, 3 μm silica beads) and introduced by nanoelectrospray into an
LTQ Orbitrap Velos Pro coupled to an Easy-nLC HPLC (Thermo Fisher). Tandem mass spec-
trometry data was collected for the top 10 most abundant ions per scan over a 140-minute
time gradient. The order of data collection was randomized to interchange between biological
conditions with BSA run between each sample to minimize temporal bias.
MS/MS raw files were analyzed using MaxQuant (v1.2.7.4) [15] against the Uniprot Rat
database using the Andromeda search engine integrated into MaxQuant [16]. A false discovery
rate of 1% was tolerated for protein, peptide, and sites, and one missed cleavage was allowed.
MaxQuant output data were filtered to remove contaminants, reverse hits, proteins only iden-
tified by site and proteins with< 2 unique peptides, and all further analysis was performed
using filtered data in our Pegasus statistical workflow [17] (S1 Fig). An individual protein was
defined as present under a particular condition if it was detected in a minimum of two repli-
cates. Analysis of individual replicates (S2 and S3 Figs) showed a good degree of reproducibil-
ity across individual replicates within treatment groups. Protein-protein interactions and
KEGG pathway analysis among the resulting protein list was analyzed using STRING (v10)
[18] (with a confidence score of 0.700) and Cytoscape (v3.1.1) [19].
Analytical methods
Blood and plasma glucose levels were determined by an immobilized glucose oxidase method
(YSI 2300; Yellow Springs Instruments, Yellow Springs, OH, USA). Plasma insulin was mea-
sured by ELISA (Ultra-Sensitive Mouse ELISA, Crystal Chem, USA). Liver triacylglycerols
(TAGs) were extracted using the method of Folch [20], lipids were dried under N2 gas, resus-
pended in absolute ethanol and quantified using an enzymatic colorimetric method (GPO--
PAP reagent; Roche Diagnostics).
Immunoblot analysis
Protein extraction and immunoblots from liver homogenates were performed as previously
described [21]. Antibodies used were anti-phospho-Ser473 Akt and Atk (Cell Signaling Tech-
nology, Danvers, MA) and anti-Ubiquitin (Abcam, UK). Densitometry was performed using
IPLab Gel software (Signal Analytics Corporation, Vienna, VA, USA).
Statistical analysis
Differences among relevant groups were assessed using unpaired Student’s t-test or Two-Way
ANOVA using Tukey-Kramer post hoc tests as appropriate noted in figure legends. P< 0.05
was considered significant. Data are reported as mean ± seM.
Results and discussion
HFSD leads to increased adiposity, increased liver triacylglycerol
content and impaired insulin-stimulated Akt phosphorylation in liver
The HFSD fed rat is a well-established model of obesity and insulin resistance [22, 23]. In this
study, 4 weeks of high-fat feeding increased body mass (Fig 1A), absolute epidydimal fat pad
mass (Fig 1B) and percent epidydimal fat pad mass (Chow: 3.2 ± 0.2%; HFD: 6.0 ± 0.3%;
P<0.00001), and liver TAG content (Fig 1C) compared to chow-fed controls. Importantly,
there were no differences in these outputs within diet groups for those animals that did or did
not receive insulin stimulation (Fig 1A–1C).
Rat liver ubiquitome and insulin resistance
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Acute insulin infusion increased plasma insulin levels and at 10 mins post-infusion there
was no difference between Chow and HFSD groups (Fig 1D). Further, there was no difference
in blood glucose levels between groups at the end of the insulin infusion (Fig 1E). Insulin infu-
sion increased liver Akt phosphorylation in both the chow and HFSD-fed groups but this
response was blunted in the HFSD-diet group (P = 0.04; Fig 1F), indicating hepatic insulin
resistance. There was no difference in total Akt levels between groups (Chow: 1.24 ± 0.23 a.u.;
HFSD: 1.24 ± 0.09 a.u; P = 0.99). Calculating the ratio of phosphorylated Akt to total Akt pro-
tein levels resulted in similar findings, albeit with slightly less statistical significance (P =
0.055) as a consequence of combining the error of both measurements in a small number of
animals (data not shown). Collectively, these data demonstrate the effectiveness of the HFSD
diet to increase adiposity leading to a decreased response in liver for the same rise in circulat-
ing insulin.
Global ubiquitome of rat liver
Efforts to understand regulation of key metabolic functions of the liver to date have focused
mostly on post-translational modifications such as phosphorylation [24–26] and acetylation
Fig 1. High-fat, high-sucrose feeding results in obesity and insulin resistance in male rats. (A) Body mass, (B) epidydimal fat
pad mass, and (C) liver triacylglycerol content of rats fed a high fat diet for 4 weeks or chow control. * P < 0.05 vs Chow for each
condition by Two-Way ANOVA followed by Tukey’s Multiple Comparisons test. (D) Plasma insulin and (E) blood glucose levels in
rats infused with insulin for 10 mins at 0.5 U/kg/h. (F) Liver Akt phosphorylation. * P < 0.05 vs Basal for each condition, # P < 0.05 vs
Chow Insulin by Two-Way ANOVA followed by Tukey’s Multiple Comparisons test. Data are mean ± SEM, n = 4.
https://doi.org/10.1371/journal.pone.0174431.g001
Rat liver ubiquitome and insulin resistance
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[27, 28]. However, recent advances in affinity purification and proteomics techniques have
facilitated systematic assessment of the ubiquitome in vivo. To more closely examine changes
in the ubiquitin-modified liver proteome in rats following acute insulin stimulation and/or 4
weeks HFSD feeding, we applied AP-MS/MS using ubiquitin-affinity matrix to enrich for ubi-
quitinated proteins and ubiquitin binding proteins (Fig 2A). Immunoblot analysis of protein
ubiquitination in representative samples of rat liver lysates showed a characteristic broad
smear representing a complex mixture of ubiquitinated proteins in all conditions (Fig 2B).
Label-free quantitative analysis of total peptide intensities showed no significant difference in
the overall abundance of proteins isolated by ubiquitin affinity purification in each condition
(Fig 2B). We identified a total of 1279 proteins following Ub-affinity purification from liver
lysates across all four experimental conditions (Chow ± insulin, HFSD ± insulin). Of these,
831 proteins have been previously identified in the rat ubiquitome (total 7024; [29]). Hence,
we have identified 448 new ubiquitinated proteins in rat liver (Fig 2C). Detailed lists are pro-
vided in S1 Table and a protein-protein interaction map based upon STRING analysis is pro-
vided in S2 Fig. Fig 2D shows the top 30 biological pathways represented by these proteins
using ontology analysis based upon KEGG pathways. Many represent known pathways central
to liver biology such as glucose, amino acid and fatty acid metabolic pathways, steroid hor-
mone biosynthesis and drug metabolism (Fig 2D). Strikingly, we observe ubiquitination of all
but 1 enzyme (glucose-6-phosphatase) involved in glycolysis/gluconeogenesis in rat liver (Fig
2E). This widespread post-translational modification suggests that ubiquitination is a key regu-
lator of gluconeogenesis/glycolysis, acting in concert with the established transcriptional regu-
lation of key genes (including glucose-6-phosphatate and PEPCK) [30]. Crosstalk between
acetylation and ubiquitination is known to regulate the key gluconeogenesis enzyme PEPCK
[31]. As our proteomics approach cannot discriminate between different ubiquitin chain
topologies, validation studies beyond the scope of this work will be necessary to determine
downstream functional consequences of ubiquitination (i.e. degradation via K48 chains) on
regulation of signaling and metabolic pathways.
The liver ubiquitome of rats is sensitive to insulin stimulation
The liver is a key insulin-sensitive tissue that contributes to the regulation of whole-body glu-
cose homeostasis and is highly susceptible to the deleterious influences of high-fat diet [3, 4].
Of the 1279 proteins identified in this study, 788 ubiquitinated proteins were detected in chow
fed animals, with 868 proteins ubiquitinated following acute insulin stimulation (Fig 3A). In
HFSD rats, we identified 864 ubiquitinated proteins and 817 proteins following insulin stimu-
lation in this group (S1 Table). Finally, we identified 686 ubiquitinated proteins in common
across the 4 conditions.
To assess the potential role of the UPS in insulin action in the liver, we evaluated the specific
influences of insulin on the liver ubiquitome in the chow fed rat. 745 proteins were detected in
common between chow and chow + insulin conditions (Fig 3B). Of the 868 Ub-associated pro-
teins identified in liver following i.v. insulin stimulation, 123 (14%) were unique to this condi-
tion (S2 Table), compared to the 43 (5% of 788 total) Ub-associated proteins unique to the
basal state. STRING analysis of protein-protein interaction (PPI) networks within the set of
differentially ubiquitinated proteins (n = 166) following insulin stimulation identified enrich-
ment for components of OxPhos, migration signaling, focal adhesion, UPS and Ras Signaling
as putative targets of ubiquitination following insulin stimulation (Fig 3C). Further, KEGG
pathway analysis of these proteins identified enrichment of components of NAFLD, endo-
cytosis, PI3K-Akt signaling and fatty acid metabolism (Fig 3D). Ubiquitination of proteins
involved in fatty acid degradation and metabolism following insulin stimulation suggests a
Rat liver ubiquitome and insulin resistance
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Fig 2. Rat liver ubiquitome. (A) Experimental design of the ubiquitomic analysis rat liver. (B) Immunoblot analysis of protein ubiquitination in
representative samples of rat liver lysates. (C) Venn diagram of previously identified protein in this study and that in the known rat ubiquitome. (D)
Ontology analysis of identified ubiquitinylated proteins. (E) Gluconeogenesis/Glycolysis biochemical pathway with ubiquitinylated enzymes marked in red.
https://doi.org/10.1371/journal.pone.0174431.g002
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Fig 3. Insulin stimulation alters the ubiquitome of the rat liver. (A) Venn diagram of identified proteins in each group. (B)
Venn diagram of proteins ubiquitinated in Chow compared to Chow + Insulin. (C) STRING analysis of differentially ubiquitinated
proteins. (D) Ontology analysis of identified ubiquitinylated proteins.
https://doi.org/10.1371/journal.pone.0174431.g003
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Fig 4. High-fat, high-sucrose diet alters the ubiquitome of the rat liver. (A) Venn diagram of identified
proteins ubiquitinated in HFSD compared to HFSD + Insulin. (B) Ontology analysis of identified ubiquitinylated
Rat liver ubiquitome and insulin resistance
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novel mechanism contributing to insulin inhibition of fatty acid catabolism (i.e. beta oxida-
tion) and stimulation of fatty acid synthesis [32].
Targeted analysis of protein ubiquitination has demonstrated that insulin stimulation leads
to ubiquitination of a range of key insulin signaling intermediates which acts as a negative
feedback mechanism. For example, acute insulin stimulation of FAO hepatocyte cells in-
creased IRS-2 ubiquitination and lowered IRS-2 protein levels [33]. Conversely, insulin stimu-
lation of primary rat hepatocytes reportedly reduced protein ubiquitination [34]. Insulin
stimulation of mouse hepatocytes expressing HA-tagged ubiquitination increased APPL1 ubi-
quitination in a TRAF6-mediated mechanism [35]. Our systematic approach to identify the
insulin-sensitive rat liver ubiquitome did not detect IRS-1, IRS-2 or APPL1, possibly reflecting
sensitivity limitations or differences between in vitro and in vivomodels. Collectively, we have
identified a broad range of liver proteins with altered ubiquitination in response to acute in
vivo insulin stimulation. These will provide an important basis for ongoing targeted studies to
better understand regulatory mechanisms underpinning insulin action in the liver.
The rat liver ubiquitome is sensitive to high-fat diet
The liver is highly susceptible to the deleterious influences of high-fat diet, including dysregu-
lated glucose and lipid homeostasis [3, 4]. Altered signal transduction, including via differen-
tial protein phosphorylation, are proposed to underpin these systemic phenotypes [36].
However, other post-translational modifications such as ubiquitin are also likely to be impor-
tant regulators of signaling and metabolic pathways as a consequence of HFSD feeding. We
observed 744 ubiquitinated proteins in common between chow and HFSD animals (Fig 4A).
Of the 864 ubiquitinated proteins identified in HFSD, 120 (14%) proteins were unique to the
HFSD group. This compared to 44 (6%) of the 788 ubiquitinated proteins unique to chow-fed
animals (Fig 4A). Analysis of KEGG pathways and PPI networks within this set of differentially
ubiquitinated proteins identified enrichment of proteins involved in RNAmetabolism, actin
cytoskeleton, and amino acid and fatty acid metabolism (Fig 4B and 4C).
These diet-induced changes in the liver ubiquitome differ from observations made follow-
ing exposure of HepG2 hepatocellular carcinoma cells to single fatty acids in vitro. For exam-
ple, ubiquitin levels in HepG2 cells (detected by western blot) were not altered by exposure to
the polyunsaturated fatty acid linoleate with or without the addition of exogenous FABP4 [37],
which is increased in the plasma of obese patients [38]. Conversely, exposing HepG2 cells to
the saturated fatty acid palmitate did lead to ubiquitination of IR, IRS-1 and Akt [39]. Palmi-
tate does have significant effects on cell biology, but interestingly many of these effects are lost
with the addition of other unsaturated fatty acids such as linoleate or oleate [40]. Further, the
use of single fatty acids to increase extracellular lipid levels does not model the environment of
HFSD [41].
We have performed similar analyses of the binary comparisons between HFSD vs HFSD
+ Insulin (S5 Fig), and Chow + Insulin vs HFSD + Insulin (S6 Fig). Briefly, 56 proteins were
uniquely ubiquitinated in the HFSD + Insulin group compared to the HFSD group, whereas
103 were identified exclusively in the HFSD group compared to HFSD + Insulin (S5A Fig).
Additionally, only 46 proteins were uniquely identified in the HFSD + Insulin group com-
pared to the Chow + Insulin groups, whilst 97 proteins were only ubiquitinated in the Chow
+ Insulin group (S6A Fig). These proteins are involved in a diverse range of metabolic path-
ways (S5B and S6B Fig).
proteins in HFSD compared to HFSD + Insulin. (C) STRING analysis of differentially ubiquitinated proteins. (D).
Ontology analysis of identified ubiquitinated proteins responsive to insulin in Chow but not in HFSD.
https://doi.org/10.1371/journal.pone.0174431.g004
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Insulin resistance is defined as a blunted response by cells to insulin stimulation. E3 ubiqui-
tin ligases have been implicated in the pathogenesis of insulin resistance by modulating insulin
signaling (see review [42]). Much of the data underlying this model comes from targeted anal-
ysis of ubiquitination of individual insulin signaling intermediates [43, 44], rather than the sys-
tematic analysis of global changes in ubiquitome in pre-clinical models of insulin resistance
presented here. Our dataset provided a unique opportunity to characterize changes in the liver
ubiquitome associated with insulin resistance. We identified 310 ubiquitin modified proteins
that were responsive to insulin stimulation in chow or HFSD animals (S3 Table). 99 (40%) of
these 310 proteins responded to insulin stimulation in the chow group but failed to respond in
the HFSD group. Notably, these proteins are involved in oxidative phosphorylation and fatty
acid metabolism (Fig 4D), highlighting these pathways as key targets of ubiquitin in insulin
resistance. For example, one of these fatty acid metabolism proteins was ACSL4 which is
increased in patients with NAFLD compared to controls [45]. Further, we identified altered
ubiquitination of subunits of complex 2 and 5 of the electron transport chain, which is consis-
tent with a role for altered oxidative phosphorylation in the development of liver insulin resis-
tance [46]. Conversely, 89 proteins (36%) responded to insulin stimulation in the HFSD group
but not in the chow group, with 61 proteins (24%) responding to insulin in both groups.
Together with our identification of ubiquitination of all but one of the enzymes in glycolytic/
gluconeogenic pathways, these novel data suggest that ubiquitination is a key regulator of the
pathogenesis of liver insulin resistance and may play a role in fatty liver associated diseases.
Conclusion
Herein, we have described the systematic characterization of the rat liver ubiquitome and
report the effects of acute in vivo insulin stimulation and high-fat, high-sucrose diet. Specifi-
cally, we observed ubiquitination of proteins involved in key metabolic pathways, in particular
gluconeogenesis/glycolysis, oxidative phosphorylation and fatty acid metabolism. Hence, ubi-
quitination is likely a novel mechanism acting at multiple levels to regulate whole-body eugly-
cemia and lipidemia. Further, widespread changes in the ubiquitin modified proteome may
mediate the pathogenesis of fatty acid-associated diseases.
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Chapter 3 
Role of Lipid Droplet Proteome and Phosphoproteome in 
Obesity-Induced Insulin Resistance in the Liver 
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3.1. Introduction 
 
Obesity is characterized by chronic excess intracellular accumulation of lipids that is often 
associated with a higher risk of metabolic disease, including cardiovascular disease and IR. 
Subcutaneous adipose tissue has an abundant, yet limited, capacity to store exogenous lipids, 
causing the redistribution of FAs to tissues when primary lipid stores are capped (Engin 2017). 
Excessive deposition of TAG in insulin-sensitive organs such as skeletal muscle and liver is 
associated with impaired insulin signalling and often leads to IR and type 2 diabetes (Boren et 
al. 2013). This relationship is particularly strong in the liver, where temporal differences in 
tissue-specific IR point towards the liver as the site of early onset (Turner et al. 2013). This 
association is further supported by the high prevalence of type 2 diabetes in patients with 
NAFL(D) and NASH, with 23% and 44% worldwide, respectively (Younossi et al. 2016).  
 
While it is evident that increased lipid availability attenuates the metabolic competence of the 
liver, studies looking into the role of cytoplasmic lipid droplets (LDs) in the pathogenesis of 
hepatic IR have yielded relatively unclear results. These highly coordinated organelles store 
the majority of cellular neutral lipids and host a myriad of lipolytic regulators such as adipose 
triglyceride lipase (ATGL), comparative gene identification-58 (CGI58), G0/G1 switch 2 
(G0S2), hormone sensitive lipase (HSL), and perilipins (PLIN) (Krahmer et al. 2013). Genetic 
or chemical inhibition of ATGL, the primary protein involved in TAG hydrolysis, increased 
steatosis despite improving glucose clearance in some mice studies (Hoy et al. 2011, Schweiger 
et al. 2017), while decreasing hepatic insulin signalling in genetic models of ATGL deficiency 
(Kienesberger et al. 2009). Moreover, increased expression of the established ATGL inhibitor, 
G0S2, exacerbates diet-induced IR in some studies (Sugaya and Satoh 2017), yet also restored 
insulin sensitivity in others (Wang et al. 2013, Zhang et al. 2014). In clinical settings however, 
obese and NAFLD patients with IR have reduced mRNA and protein levels of ATGL, its co-
activator CGI58, and the TAG/DAG/cholesteryl ester lipase, HSL (Jocken et al. 2007, Kato et 
al. 2008). The controversy in the field largely represents the complexity of LD dynamics and 
neutral lipid homeostasis, such as protein-protein interactions, protein translocation and 
hormonal stimulation.  
 
Mass spectrometry-based proteomics has developed into a premier tool for investigating 
pathophysiology at a systems biology level, allowing for the simultaneous measurement of 
subcellular localization and post-translational modifications of proteins (Cox and Mann 2011). 
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Several studies have assessed the hepatic LD proteome of patients with NAFL(D) (Su et al. 
2014, Khan et al. 2015, Liu et al. 2017); however, changes in the movement and 
phosphorylation of the LD proteome in response to insulin in normal and insulin-resistant states 
have not been explored thus far. Defining the insulin-stimulated proteome and 
phosphoproteome of rat liver LDs and how it is perturbed in IR animals could assist in the 
delineation of LD dynamics in a stepwise manner.  
 
The aim of the experiments and analysis described in this chapter were to determine 1) insulin 
and diet-induced changes in the LD proteome and phosphoproteome and 2) compare them to 
an insulin resistant model using various biologically-relevant analytical measures.  
 
 
51 
3.2 Methods 
Samples for experiments described in this chapter were derived from animal models described 
in detail in Chapter 2. Methodology pertaining to mass spectrometry was performed by 
collaborators in the David James Metabolic Cybernetics Lab at the Charles Perkins Centre, The 
University of Sydney. Specifically, Dr. Zhiduan Su and Dr. Benjamin Parker performed the 
mass spectrometry (section 4.2.2.3-4.2.2.9) and Dr. Rima Chaudhuri performed statistical 
normalisation of the proteomic and phosphoproteomic datasets (section 4.2.2.10.1).  
 
Figure 3.1 Animal workflow for LD proteomic and phosphoproteomic enrichment 
Sixteen male adult Wistar rats were fed either a standard rodent chow or HF diet for 3 weeks. Following a 5 hour fast, half of  
the animals from each group were randomly assigned for acute insulin stimulation for 10 minutes. Once euthanized, liver 
tissue was extracted and LDs were isolated using a sucrose density gradient. LDs were then delipidated and prepared for LC—
MS/MS analysis using TMT10 labelling and TiO2 to enrich the phosphoproteome. Analysis of raw data was performed using 
MaxQuant.   
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3.2.1 Isolation of lipid droplets from rat livers 
3.2.1.1 Homogenization 
Fresh livers were placed in specimen jars on ice filled with cold hypotonic lysis medium (HLM; 
20 mM Tris-Cl pH 7.4, 1 mM EDTA, 10 mM NaF supplemented with protease and phosphatase 
inhibitors (Astral Scientific)) at a ratio of 4 ml medium/ gram of tissue. Livers were finely cut 
with scissors before being transferred to a Potter-Elvehjem tissue homogenizer for hand-driven 
homogenization by eight gentle strokes of an ice-cold pestle. Homogenates were then 
transferred to a 50 ml tube and centrifuged for 10 mins at 1000 × g at 4°C (Beckman Coulter). 
The resulting supernatant was then transferred to microfuge tubes for storage at -80°C as whole 
liver lysates or to fresh ultracentrifuge tubes for further processing.  
 
3.2.1.2 Sucrose Gradient Fractionation 
A sucrose gradient was prepared by thoroughly mixing 3 ml of liver homogenate with 1 ml of 
HLM containing 60% sucrose in a 13.2 ml ultracentrifuge tube (Beckman Coulter). Another 
5ml and 4 ml of HLM containing 5% and 0% sucrose, respectively, were layered on top. Tubes 
were carefully weighed and matched within 0.02 g of each other for balancing. Samples were 
centrifuged for 30 mins at 28000 × g at 4°C (P55ST2-636 spinout rotor, Hitachi). The rotor 
was allowed to coast to a stop with a deceleration of “F” (free). Once at rest, a pipet with a 
wide opening was used to carefully transfer 1.5 ml of the floating fat layer, containing lipid 
droplets, into a 15 ml tube (Corning).  
 
3.2.1.3 Sample Delipidation  
Tubes containing isolated lipid droplet fractions were filled with 10 volumes of ice-cold 
acetone and mixed by inversion several times to remove excess lipids from samples. Samples 
were incubated overnight at -20°C and centrifuged the next day for 1 hour at 4300 × g at 4°C 
to pellet the LD-associated proteins. A nitrogen sample concentrator was used to evaporate the 
residual acetone and dehydrate the pellet. Samples were then stored at -80°C until use.  
 
3.2.2 Proteomics 
3.2.2.1 Protein Preparation 
Delipidated protein samples were resuspended in 400 µl of urea buffer (6 M urea, 2 M thiourea, 
25mM triethylammonium bicarbonate (TEAB), and phosphatase inhibitors) and vortexed 
thoroughly. Samples were then sonicated in an ultrasonic water bath (Sonorex Digitec, 
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Bandelin) set at room temperature for 5 mins and then sonicated further using an ultrasonic 
homogenizer with the following parameters: 55 second working time, 10 second pulse with 5 
second breaks. After spinning proteins at 15,000 x g for 20 mins at room temperature, samples 
were transferred into a new QubitÔ assay tube (Thermo Fisher Scientific) and quantified using 
the Qubit 30 Fluorometer (Life Technologies).  
 
3.2.2.2 Protein Digestion 
For digestion, 800 µg of protein was added to 10 mM dithiothreitol (DTT) and incubated at 
37°C for 1 hour. After 1 hour, 25 mM indole acetic acid was added to the samples and incubated 
at room temperature for 40 mins in the dark and stopped with 10 mM DTT. Finally, LysineC 
was added to the samples at a LysineC:protein ratio of 1:50 and incubated at 30°C for 2 hours. 
Samples were then diluted five times in TEAB and trypsinized at 37°C overnight. The next 
day, 1% formic acid was added to the digested samples to decrease the pH and quench the 
digestion.  
 
3.2.2.3 Cartridge Desalting 
To separate salts from proteins, samples were desalted using the Sep-Pak Vac 1cc tC18 
cartridge kit (Waters). To activate C18, 1 ml of methanol was added to each column and 
washed once with 1 ml of elution buffer containing 80% acetonitrile (ACN) and 0.1% 
trifluoroacetic acid (TFA).  The columns were then washed three times with 1 ml of 0.1% TFA 
loading buffer. Peptides were resuspended in 1 ml of the loading buffer and loaded onto the 
column twice. After washing the columns three times with 1 ml loading buffer, peptides were 
eluted using 500 µl of elution buffer and collected. Samples were then dried using a vacuum 
concentrator (Thermo Fisher Scientific). Peptides were resuspended in 30 µl of 100 mM TEAB 
and quantified using Qubit to ensure post-digestion efficiency before labelling.  
 
3.2.2.4 Tandem Mass Tag Labelling 
Tandem Mass Tag (TMT) -10plex mass tags (Thermo Fisher Scientific) were used for the 
quantification and identification of proteins for mass spectrometry. TMT label reagent was 
added to 200 µg of peptides from each sample and incubated at room temperature. After 1 
hour, 8 µl of 5% hydroxylamine was added to the samples and incubated for 15 mins to stop 
the reaction. Samples were combined in a microfuge tube containing a total of 2 mg peptides 
and stored at -80°C. Two assays were performed to accommodate for all conditions.  
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3.2.2.5 Stage-Tip Desalting 
Peptide samples were further cleaned by stage-tip desalting prior to LC-MS/MS. Methods are 
essentially the same as those in section 4.2.2.3; however, volumes used were 10 times less.  
 
3.2.2.6 Phosphopeptide Enrichment 
Phosphopeptide enrichment consisted of titanium dioxide followed by sequential elution from 
immobilized metal ion affinity chromatography and fractionation by hydrophilic interaction 
liquid chromatography (Engholm-Keller et al. 2012). Peptides were resuspended in 1 ml of 
titanium dioxide loading buffer (1 M glycolic acid, 80% acetonitrile, 5% TFA), and a 20 µg 
aliquot was saved for total proteomic analysis. Titanium dioxide beads (15 mg in 150 µl 
acetonitrile; GL Science, Japan) were added to the peptide mixture and rotated at room 
temperature for 20 min. The mixture was centrifuged at 10000 x g for 1 min and the resulting 
supernatant was applied to a second aliquot of titanium dioxide (7.5 mg in 75 µl acetonitrile) 
and rotated at room temperature for 20 min. The mixture was centrifuged at 10000 x g for 1 
min and the supernatant was applied to a third aliquot of titanium dioxide (4 mg in 40 µl 
acetonitrile) and rotated at room temperature for 20 min. The beads were washed with 100 µL 
titanium dioxide loading buffer followed by 80% acetonitrile, 2% TFA and finally 16% 
acetonitrile, 0.4% TFA. The beads were dried briefly by vacuum centrifugation and eluted with 
50 µL of 1% ammonium hydroxide by shaking at room temperature for 15 min. The titanium 
dioxide elution slurry was loaded onto a C8-plugged micro-column and eluted with gentle air 
pressure to trap beads. The beads were eluted with an additional 50 µL 1% ammonium 
hydroxide and the elution was pooled. Enriched phosphopeptides were acidified to a final 
concentration of 10% formic acid and dried by vacuum centrifugation. The enriched 
phosphopeptides were resuspended in 500 µl of 50% acetonitrile, 0.2% TFA and rotated with 
50 µl of Fe(III)-IMAC beads (Sigma-Aldrich) at room temperature for 45 min. The IMAC 
slurry was loaded onto a crushed GeLoader microcolumn and eluted with gentle air pressure 
to trap beads. Mono-phosphorylated peptides were eluted with 50% acetonitrile, 0.1% TFA 
followed by 20% acetonitrile, 1% TFA; pooled with the flow-through and dried by vacuum 
centrifugation. Multi-phosphorylated peptides were eluted with 1% ammonium hydroxide, 
acidified to a final concentration of 10% formic acid, 0.1% TFA and desalted with C18 
microcolumns. Enriched mono-phosphorylated peptides were subjected to another round of 
titanium dioxide as described above. The enriched mono-phosphorylated peptides and non-
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phosphorylated peptides were fractionated on in-house packed TSK-amide HILIC column as 
described previously (Palmisano et al. 2010).  
 
3.2.2.7 Liquid Chromatography-Tandem Mass Spectrometry 
3.2.2.7.1 Total Proteome 
Mass Spectrometry (MS)-based total proteomic analysis was performed on an Easy nLC-1000 
UHPLC coupled to a Q-Exactive mass spectrometer in positive polarity mode. Peptides were 
separated using an in-house packed 75 µm x 40 cm column (1.9 µm particle size, C18AQ) with 
a gradient of 5-30% ACN containing 0.1% FA over 90 min at 250 nL/min at 55ºC. The MS1 
scan was acquired from 300-1750 m/z (70000 resolution, 3e6 AGC, 100 ms injection time) 
followed by MS/MS data-dependent acquisition of the top 20 ions with HCD (35,000 
resolution, 1e5 AGC, 120 ms injection time, 25 NCE, 2.0 m/z isolation width). 
 
3.2.2.7.2 Total Phosphoproteome 
MS-based phosphoproteomic analysis was performed on a Dionex chromatography coupled to 
a Q-Exactive plus mass spectrometer in positive polarity mode. Peptides were separated using 
an in-house packed 75 µm x 40 cm column (1.9 µm particle size, C18AQ) with a gradient of 
10-40% ACN containing 0.1% FA over 120 min at 300 nL/min at 55 ºC. The MS1 scan was 
acquired from 300-1750 m/z (70000 resolution, 3e6 AGC, 100 ms injection time) followed by 
MS/MS data-dependent acquisition of the top 20 ions with HCD (17500 resolution, 5e5 AGC, 
120 ms injection time, 32 NCE, 1.2 m/z isolation width). 
 
3.2.2.8 Protein Identification and Quantification 
3.2.2.8.1 Total Proteome 
Raw data was processed using MaxQuant (v1.5.1.3) against a Uniprot rat database (12/2014, 
35,579 entries) with default settings and minor changes: Oxidation of methionine and 
acetylation of protein N-terminus were set as variable modifications and carbamidomethylation 
of cysteine was set as a fixed modification. TMT10-plex of isobaric labels was enabled and 
reporter mass tolerance was set to 0.001 Da. The “second peptides searching” was enabled. 
The peptide match tolerance was set to 20 ppm and 4.5 pm for first and main searches 
respectively and MS/MS match tolerance set to 20 ppm. Both peptide spectral match (PSM) 
and protein FDR were set to 1%.  
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3.2.2.8.2 Total Phosphoproteome 
Raw data was processed using MaxQuant (v1.5.1.3) (Cox and Mann 2008) against a Uniprot 
rat database (12/2014, 35,579 entries) with default settings and minor changes: Oxidation of 
methionine, acetylation of protein N-terminus and phosphorylation of serine, threonine and 
tyrosine were set as variable modifications and carbamidomethylation of cysteine was set as a 
fixed modification. TMT10-plex of isobaric labels was enabled and reporter mass tolerance 
was set to 0.001 Da. The “second peptides searching” was enabled. The peptide match 
tolerance was set to 20 ppm and 4.5 pm for first and main searches respectively and MS/MS 
match tolerance set to 20 ppm. Both peptide spectral match (PSM) and protein FDR were set 
to 1%.  
 
3.2.2.9 Bioinformatic Analysis 
3.2.2.9.1 Normalisation  
Data was normalised using the two-step Remove Unwanted Variation (RUV-2) method, as 
previously described (Gagnon-Bartsch and Speed 2012). Briefly, RUV utilizes the curation of 
positive and negative control proteins based on hepatic LD association to adjust for systematic 
errors and normalise data.   
 
3.2.2.9.2 Determination of Novel Rattus norvegicus Phosphosites 
The proportion of novel phosphosites found in Rattus norvegicus in this study was determined 
by overlaying the 2286 phosphosite dataset with the known Rattus norvegicus phosphosite 
database (562 entries for rat, within a database of 46,248 total entries across all species) curated 
by PhosphositePlusÒ (PhosphoSite, Cell Signalling Technology). A Venn diagram was created 
using the Core Graphic Module on GeneVenn (http://genevenn.sourceforge.net/) to determine 
the rat phosphosite lists for known, overlapping and novel phosphosites.  
 
3.2.2.9.3 Enriched Pathway Analysis 
For total proteomic and phosphoproteomic pathway analysis, Uniprot IDs of all quantified 
proteins were submitted to Search Tool for the Retrieval of Interacting Genes/Proteins 
((STRING) version 10.5) for Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway 
enrichment analysis. For diet and insulin-specific pathway analysis, significant differentially 
expressed (DE) proteins and phosphoproteins were submitted for Core Canonical Pathway 
Analysis using Ingenuity Pathway Analysis (Qiagen).  
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3.2.2.9.4 Scenario Modelling 
Differentially expressed protein and phosphosite data was used to systematically identify 
“insulin-resistant” proteins and sites through biologically relevant scenario filters. For 
example, to determine proteins that normally moved to the lipid droplet with insulin-
stimulation but did not move to the lipid droplet due to perturbed insulin signaling in a high-
fat diet-induced insulin resistant state (Scenario 1), the following filters were used: 1) log2(Fold 
Change) greater than 0 and p value less than 0.05 in the chow-fed insulin stimulated condition 
compared to chow-fed basal condition and 2) p value greater than 0.05 in high-fat diet-fed 
insulin stimulated condition compared to high-fat diet-fed basal condition. Similar filters were 
used to identify proteins and phosphosites that fit scenarios 2-4 (Table 4.1).  
 
Table 3.1. Filters used to identify proteins and phosphosites in scenarios 1-4.  
 CI vs CB HI vs HB 
Scenario 1 
log2Fold change > 0 
p < 0.05 
p > 0.05 
Scenario 2 p > 0.05 
log2Fold change > 0 
p < 0.05 
Scenario 3 
log2Fold change < 0 
p < 0.05 
 
p > 0.05 
Scenario 4 p > 0.05 
log2Fold change < 0 
p < 0.05 
 
3.2.3 Western Blotting 
3.2.3.1 Protein Quantification 
Whole liver and LD isolated lysates were transferred to a clear 96-well plate (Greiner) and 
diluted with water to a factor of 25 for protein quantification using the Bicinchoninic Assay 
(BCA) Protein Kit (PierceÔ, Thermo Fisher Scientific). A standard curve ranging from 0 to 1 
mg/ml protein was prepared to interpolate the absorbance of the samples. After the reagent was 
added, the plate was incubated at 37°C for 30 mins and absorbance measured at 560 nm using 
Magellan software (TECAN Infinite M1000 PRO, Tecan Trading, AG, Switzerland). After 
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protein determination, samples of equal concentration were prepared using 6x Laemmli sample 
buffer (Cold Spring Harbor) and heated at 50°C for 10 mins or 75°C for 7 mins with gentle 
agitation (Thermomixer 5436, Eppendorf) to denature soluble proteins and allow antibody 
access to the epitope.  
 
3.2.3.2 SDS-Polyacrylamide Gel Electrophoresis 
Proteins were separated based upon their size by using 10-12% hand-casted resolving gels with 
a 4% stacking layer made of the following stock ingredients: 40% acrylamide (Thermo Fisher), 
1.5 M Tris pH 8.8 for resolving or 0.5 M Tris pH 6.8 for stacking, 10% sodium dodecyl sulphate 
(SDS), 10% ammonium persulphate and TEMED (Bio-Rad Laboratories). Gels were poured 
into 1.5 mm spaced casting plates and set with 10 or 15-well 1.5 mm combs. After 
polymerization, combs were removed, and wells were filled with 1x Tris-Glycine-SDS running 
buffer (Astral Scientific). Equivalent amount of protein (30-40 µg) were loaded onto the gels 
alongside molecular weight markers ranging from 10 to 250 kD (Precision Plus ProteinÔ 
KaleidoscopeÔ Prestained Standards, Bio-Rad Laboratories) and run at 90V until the samples 
stacked, after which it was increased to 160V until samples were appropriately separated.  
 
3.2.3.3 Protein Transfer to a PVDF Membrane 
Polyvinylidene fluoride (PVDF) membranes with 0.45 µm pores (ImmobilonÒ-P, Thermo 
Fisher Scientific) were activated in methanol for 60 seconds and then submerged in tris-glycine 
transfer buffer (Astral Scientific) for 5 mins along with two extra thick filter papers (Thermo 
Fisher Scientific). For semi-dry transfers, a tight sandwich was created in the following order: 
filter paper > gel > membrane > filter paper; and transferred using the Trans-Blot Turbo 
Transfer System (Bio-Rad Laboratories) at 25V for 30-60 mins. For wet transfers, a tight 
sandwich was created using mini gel holder cassettes in the following order: red side of cassette 
> foam pad > filter paper > gel > membrane > filter paper > foam pad > clear side of cassette. 
For both methods, bubbles were carefully removed using a roller. Cassettes were lodged into 
mini trans-blot cores alongside a bio-ice cooling unit (Bio-Rad Laboratories) and ran at 90V 
for 90 mins surrounded in ice. Wet transfers were primarily used for proteins larger than 100 
kD.  
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3.2.3.4 Antibody Probing 
Membranes were blocked in 3% BSA diluted in 1 x Tris buffered saline (TBS; Astral 
Scientific) containing 0.1% Tween-20 (Sigma) for 60 mins at room temperature on a rocker. 
For primary antibody incubation, membranes were submerged in an antibody solution made of 
3% BSA diluted in TBST containing primary antibody and kept overnight at 4°C with gentle 
agitation (Table 3.2).  
 
Table 3.2. Primary antibodies used in this chapter.  
A list of proteins of interest that were visualized for abundance using western blotting.  
Antibody Catalogue # Dilution Species Company 
anti-ATGL 2138S 1:1000 Rabbit CST 
anti-CytoC 11940S 1:1000 Rabbit CST 
anti-ERP72 5033S 1:1000 Rabbit CST 
anti-G0S2 SC-133423 1:500 Rabbit SCBT 
anti-Na/K-ATPase 3010S 1:1000 Rabbit CST 
anti-Plin1 Ab3526 1:1000 Rabbit Abcam 
anti-Rab11 3539 1:1000 Rabbit CST 
CST – Cell Signaling Technologies (CST); SCBT – Santa Cruz Biotechnology. 
  
After overnight primary antibody incubation, membranes were kept at room temperature for 
30 mins to allow for further binding before washing with TBST every 15 mins for 1 hour on a 
shaker. Membranes were then incubated in solution made of 3% BSA in TBST containing a 
selected secondary antibody for 1 hour on a rocker (Table 3.3). The following table is a list of 
all the secondary antibodies used in this chapter. Finally, membranes were washed again every 
15 mins for at least 1 hour on a shaker.   
 
Table 3.3 Secondary antibodies used in this chapter.  
A list of secondary antibodies that were used to visualize abundance of proteins of interest 
using western blotting.  
Antibody Catalogue # Dilution Species Company 
Rabbit 7074P2 1:5000 Goat CST 
CST – Cell Signaling Technologies (CST). 
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3.2.3.5 Imaging with Bio-Rad ChemiDoc MP 
Proteins were visualized after incubation with primary and secondary antibodies by placing 
membranes onto a transparent sheet onto the imaging platform and carefully pressed using a 
roller to remove bubbles and excess TBST. Membranes were evenly coated with Luminata 
Crescendo Western HRP (Merck) for at least 60 seconds before imaging using the Bio-Rad 
ChemiDoc MP Imaging System (Bio-Rad Laboratories). Quantification of protein abundance 
was performed using densitometry analysis using Image Lab software 4.1 (Bio-Rad 
Laboratories).  
 
3.2.3.6 Stripping and Re-Probing 
Restore PLUS Western Blot Stripping Buffer (Thermo Fisher Scientific) was used to remove 
primary and secondary antibodies. Membranes were incubated for 10 mins with gentle shaking, 
followed by 10 mins of PBS, and then 10 mins of TBST. Primary antibody removal was 
confirmed by incubating membranes in ECL then imaged using the ChemiDoc MP Imaging 
System for at least 5 mins. Membranes were then blocked with 3% BSA in TBST for 1 hour 
on the rocker before re-probing with a new primary antibody overnight.   
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3.3 Results 
 
3.3.1 Hepatic Lipid Droplet Morphology and Purity 
LDs were isolated from extracted livers of basal or acutely insulin-stimulated male Wistar rats 
that had been fed either a chow diet or HFD for 4 weeks to determine the hepatic LD-associated 
proteome and phosphoproteome (Fig 3.1). Rats fed a high-fat diet had greater accumulation of 
LDs in the liver compared to rats fed a chow diet (Fig 3.2A). This supports the other 
biochemical measures presented in Chapter 2 to demonstrate that rats fed a high-fat diet had 
fatty livers. 
 
Rat liver LD fractions did not contain adipocyte-derived LDs (Plin1) or widely-used markers 
of other organelles, including endoplasmic reticulum (ERP72), mitochondrial (Cytochrome C), 
plasma membrane (Na-K ATPase) and recycling endosomal (Rab11; Fig 3.2B). Importantly, 
the LD fractions were enriched for the lipid droplet protein ATGL and its co-regulator G0S2 
(Fig 3.2B). Overall, these data demonstrate that the floating fractions obtained following 
exposure to a discontinuous sucrose-gradient contain LDs.  
 
Figure 3.2 Purification of hepatic lipid droplets.  
(A) Haematoxylin and eosin stain of lipid droplets in chow (top) and high-fat fed (bottom) rats (B) Immunoblot analysis of 
lipid droplet purity.  
 
3.3.2 Intra-Group Variability and Reproducibility in Proteome and 
Phosphoproteome 
Proteins from isolated LDs were identified using mass spectrometry. Principal components 
analysis (PCA) of LC-MS/MS spectra from all replicates across 4 conditions was performed 
to visualize variance within the datasets. The PCA score plot for LD-associated proteins 
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showed that replicates within each condition associated together to form clusters, indicating 
greater intergroup rather than intragroup variability (Fig 3.3A). Furthermore, the PC coordinate 
system reduces dimensionality to indicate the direction of the highest variance (PC1), shown 
on the x axis, followed by the second highest variance (PC2) shown on the y-axis. Therefore, 
the majority of the variance between samples in Fig 3.3A were attributed to diet, as illustrated 
by the separation of chow-fed and HFD-fed replicates along the PC1 axis. Interestingly, the 
PCA score plot for LD-associated phosphosites showed an even greater separation between 
chow and HFD clusters, while basal and insulin-stimulated chow clusters overlapped slightly 
(Fig 3.3B). In general, replicates within a condition clustered together and the greater part of 
the variance were attributed to treatment conditions.  
 
Normalisation of data was performed to further reduce intragroup variance between biological 
replicates. Proteomic and phosphoproteomic box plots of log2 transformed quantile normalized 
peptide intensities are shown in Fig 3.3C and D respectively. After normalisation, distribution 
of transformed protein intensity had similar shapes (box) and extents (whiskers). Further, 
normalisation requires equivalent datasets across conditions and thus, the horizontal width of 
each box plot, which is proportional to the number of proteins, is identical between all 
conditions. Reproducibility of the proteomic and phosphoproteomic datasets were also 
quantified using standardisation correlation coefficients from duplicates (Fig 3.3E and F 
respectively). A correlation coefficient, r, close to 1.0 indicates high reproducibility, as seen 
with the proteome (r = 0.998) and phosphoproteome (r = 0.980).    
 
A multiscatter analysis was also performed to assess the reproducibility of the protein and 
phosphosite quantification between biological replicates within each condition, where each dot 
represents one protein or phosphosite. A median Pearson correlation coefficient of 0.901 was 
found for the LD-associated proteome (Fig 3.3G) and 0.822 for the LD-associated 
phosphoproteome (Fig 3.3H), indicating relatively higher biological variability particularly for 
the phosphoproteome, likely due to the low replicate number. It is important to note that while 
median values are less likely to skew results caused by outliers, they are also less likely to be 
representative of the results when there are only four replicates per conditions.     
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Figure 3.3 Quality control of proteome and phosphoproteome 
(A) Principal component analysis of proteome and (B) phosphoproteome. (C) Post-normalization box plots of proteome and 
(D) phosphoproteome. (E) Standardisation correlation of proteome and (F) phosphoproteome. (G) Multiscatter plots of 
proteome and (H) phosphoproteome.  
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3.3.3 Quantitative Analysis of Proteome and Phosphoproteome 
LC-MS/MS analysis identified 4831 LD-associated proteins based on fragmentation spectra of 
peptides obtained by the mass spectrometer (Fig 3.4A). Of those identified, 4819 proteins were 
quantified using signal intensities in order to infer relative protein abundance profiles over 
multiple conditions. Proteins that were not found in all 4 replicates and across all 4 conditions 
were then removed to allow for more comprehensive comparisons, which resulted in a final 
4115 LD-associated proteins identified in all 16 rats. Of the proteins removed from analysis, 
no condition-specific clustering of proteins was present (i.e. identified in all 4 replicates of 1 
condition). Pathway analysis on the proteome using STRING revealed enrichment of expected 
LD processes such as insulin signalling pathway, peroxisome proliferator-activated receptor 
(PPAR) signalling pathway and fatty acid metabolism (Fig 3.4B).  
 
Alongside proteomic analysis, 8616 LD protein-associated phosphosites were identified after 
phosphopeptide enrichment to determine normal and perturbed, diet and insulin-stimulated 
post-translational modifications (PTMs; Fig 3.4C). Of those identified, 6875 phosphosites were 
quantified, with 2286 sites found across all 16 rats. Similar to the proteome, no condition-
specific clustering of phosphosites was present. This list was narrowed down further to reveal 
2141 phosphorylation sites on 1362 proteins that were defined as having the highest confidence 
in localisation (Class I). Class I sites were obtained by filtering for phosphosites that had at 
least a 75% probability for the phospho-group (localization probability > 0.75) and that the 
difference in score between the first and second possible localizations was at least 5 or higher 
(probability localization score difference > 5) (Olsen et al. 2006).  It should be noted that post-
translational modification (PTM)-level data will always have higher variance than data at the 
protein-level, and this is part of the limitations of having a relatively lower number of 
replicates. This can be seen in the 67% reduction in quantified phosphosites when filtering for 
those found in all 16 rats (Fig 3.4C). The list of class I phosphosites were then compared to 
those found in the published online database of known phosphorylation sites hosted by 
PhosphoSitePlus to determine the number of novel phosphosites identified in this study. The 
comparison revealed 53 phosphosites that have previously been reported in other studies, and 
2087 newly identified phosphosites in Rattus norvegicus (Fig 3.4D). It should be noted that the 
majority of these “novel” phosphosites could have already been reported as orthologous sites 
in the more commonly studied species, Mus musculus, and would therefore not be entirely 
undiscovered. Phosphoamino acid analysis was also performed to determine if the distribution 
of phosphorylated serine, threonine and tyrosine was comparable to previously published data. 
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In accordance with classic studies by Hunter and Sefton (1980) and Olsen et al. (2006), 
phosphorylated serine sites were the most abundant with 90.47% of Class I phosphosites, 
followed by threonine (8.92%) and tyrosine (0.5%; Fig 3.4E). Finally, pathway analysis on the 
Class I phosphoproteome using STRING revealed enrichment of commonly phosphorylated 
pathways, such as insulin signalling pathway and AMPK signalling pathway (Fig 3.4F). 
  
Figure 3.4 Total proteome, phosphoproteome and associated enriched pathway analysis.  
(A) Identification and quantification of proteome (B) Enrichment pathway analysis of total proteome found across all 16 rats 
(C) Identification and quantification of phosphorylome (D) Venn diagram of previously identified phosphosites in Rattus 
norvegicus and phosphosites identified in this study (E) Proportion of phosphoamino acid in Class I phosphorylome (F) 
Enrichment pathway analysis of total phosphoproteome found across all 16 rats. 
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3.3.4 Differential Expression Analysis of LD-Associated Proteome 
Differential expression analysis was performed to determine how the relative abundance of 
proteins changed across the 4 conditions. Differentially expressed (DE) proteins were defined 
as proteins whose abundance at the LD significantly changed between two conditions (p < 
0.05). The change in protein abundance at the LD can be attributed to the synthesis of new 
proteins, the translocation of proteins to or from the LD or a combination of both. The 
abundance of 63 proteins at the LD increased and 177 proteins decreased in response to insulin 
stimulation (Fig 3.5A). Furthermore, 105 proteins increased and 203 proteins decreased at the 
LD in response to high-fat feeding. Strikingly, both treatments resulted in roughly double the 
number of proteins that decreased in abundance at the LD compared to those that increased in 
abundance. In contrast, insulin stimulation in the HFD-induced insulin resistant state was 
associated with a similar number of proteins with increased and decreased abundance at the 
LD (132 increased, 129 decreased).  
 
Canonical pathway analysis was performed to determine the functional enrichment of these 
DE proteins (Fig 3.5B). The top significantly increased pathways in response to insulin were 
oxidative phosphorylation, mitochondrial dysfunction and sirtuin signalling, all of which 
encompass the same group of mitochondrial proteins of the electron transport chain (ETC). 
While the majority of the LD fraction is free from impurity (Fig 3.2B), the crude LD isolation 
method is likely contain some proteins from other organelles, consistent with previously 
reported LD proteomic studies (Zhang et al. 2011, Crunk et al. 2013, Khan et al. 2015). It is 
also important to note that the frequent crosstalk between LDs and mitochondria is not only to 
direct fatty acids for breakdown in times of starvation, but also to move fatty acids back to LDs 
for re-acylation to prevent lipotoxic mitochondrial dysfunction (Schrauwen et al. 2010, Bosma 
et al. 2012, Gao and Goodman 2015). This is further supported by the upregulation of the same 
pathways with HFD (Fig 3.5C). Strikingly, 3 of the top 10 pathways that decreased with insulin 
(Fig 3.5B), and 5 of the top 10 pathways that decreased with HFD (Fig 3.5C) are related to 
cholesterol biosynthesis, which is consistent with downregulation of de novo cholesterol 
synthesis when hepatic cholesterol needs have been capped.  
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Figure 3.5 Enriched pathway analysis of differentially expressed proteins.  
(A) Number of differentially expressed proteins represented as up- or downregulated between any two conditions (B) Enriched 
pathway analysis of proteins that were significantly up- or downregulated with high-fat diet in basal conditions (C) Enriched 
pathway analysis of proteins that were significantly up- or downregulated with insulin stimulation in chow-fed mice. 
 
3.3.5 Differential Expression Analysis of LD-Associated Phosphoproteome 
Alongside proteomic analysis, identification of DE phosphorylated sites revealed 55 
phosphosites that increased and 86 phosphosites that decreased in abundance at the LD with 
insulin stimulation (Fig 3.6A). Similarly, 41 phosphosites increased and 86 phosphosites 
decreased at the LD with high fat feeding. Therefore, insulin stimulation and HFD was 
associated with a net decrease in phosphorylation at the lipid droplet which is similar to DE 
analysis at the proteomic level (Fig 3.5A). Interestingly, there were five times as many 
detectable phosphosites that increased at the LD than decreased, despite a lack of change in 
protein abundance in insulin stimulated HF-fed rats. Phosphosites that significantly changed in 
response to insulin showed an enrichment for participating in mTOR signalling, AMPK 
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signalling and TAG synthesis pathways (Fig 3.6B). Although this upregulation is consistent 
with insulin signalling, it is unclear how these pathways interact at the LD. These same 
pathways as well as insulin receptor signalling pathway were also enriched in the LD 
phosphoproteome of liver LDs from animals fed a HFD (Fig 3.6C). Furthermore, 
phosphorylation of TAG degradation enzymes HSL and PNPLA3 were increased with HFD. 
It is important to note that many regulated proteins, such as HSL, have multiple antagonistic 
phosphorylation sites, and levels of phosphorylation may be dependent on protein levels. 
Consequently, pathway analysis that is largely dependent on protein IDs may not be the most 
informative method of investigation. In order to tackle one of these complexities, the 
phosphoproteome, containing 1304 unique phosphorylated proteins, was overlapped with the 
proteome, containing 4068 proteins, to reveal 784 proteins found in both datasets (Fig 3.6D). 
Of those 784 proteins identified, DE phosphosites that had no significant changes in abundance 
at the proteomic level were mapped, with 36 sites that were phosphorylated and 56 sites that 
were dephosphorylated upon insulin stimulation (Fig 3.6E). Moreover, 24 sites were 
phosphorylated and 56 sites were dephosphorylated with high-fat diet feeding. Taken together, 
these results suggest a role for PTM modifications in the regulation of LD dynamics, regardless 
of changes at the proteome-level.  
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Figure 3.6 Enriched pathway analysis of differentially expressed phosphosites. 
(A) Number of differentially expressed phosphosites represented as up- or downregulation between any two conditions (B) 
Enriched pathway analysis of proteins that were significantly up- or downregulated with high-fat diet (C) Enriched pathway 
analysis of proteins that were significantly up- or downregulated with insulin stimulation (D) Venn diagram of proteins found 
in both the proteomic and phosphoproteomic datasets (E) Number of differentially expressed phosphosites with insignificant 
protein fold change. 
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3.3.6 Modelling Insulin Resistance via Binary Differential Expression  
The data was visualised using volcano plots to further define the changes to the LD proteome 
and phosphoproteome in insulin stimulated and insulin resistant rat liver. Volcano plots assist 
in visualizing large datasets by highlighting proteins with high fold change and statistical 
power. A notable responder to insulin stimulation in chow fed animals (i.e. insulin-stimulated 
chow-fed vs chow basal) was glutathione S-transferase alpha 5 (GSTa5; Fig 3.7A), which has 
been reported to be upregulated with insulin stimulation in rat hepatocytes (Kim et al. 2003), 
and preferentially bound to TAG-enriched LDs vs CE-enriched LDs (Khor et al. 2014). 
However, GST1a5 was not detected in the phosphoproteome. In contrast, two phosphosites of 
AKT1s1 (otherwise known as PRAS40) were in the top 5 phosphosites with greatest statistical 
power (Fig 3.7B), which is consistent with previously reported studies on its phospho-
regulation by insulin and localisation at the LD (Hao et al. 2014). These results provide insight 
into the insulin-stimulated processes involved on LDs in healthy rats.  
 
Perturbed insulin signalling can be viewed two ways in this study using binary comparisons: 
1) insulin signalling in normal (Chow-Insulin condition) versus insulin resistant (HFD-Insulin 
condition) rats, and 2) insulin resistant rats with acute insulin stimulation (HFD-Insulin 
condition) compared to basal (HFD-Basal condition). The protein levels of apolipoprotein A4 
(ApoA4) on LDs was different between the insulin stimulated, chow-fed animals and the 
insulin stimulated, HFD-fed animals (Fig 3.7C). ApoA4 is a chylomicron marker that is 
increased in response to insulin stimulation and meal feeding and inhibits hepatic 
gluconeogenesis (Li et al. 2014). Here, ApoA4 increased in abundance at the LD in the 
‘perturbed insulin signalling’ state compared to normal, suggesting an expansion of the role of 
the LD in potentially regulating glucose metabolism.  
 
The phosphorylation of Ser185 on the serine/threonine protein kinase WNK1 had the greatest 
statistical power and second highest fold-change between insulin stimulated, chow-fed animals 
and the insulin stimulated, HFD-fed animals (Fig 3.7D). WNK1 is directly phosphorylated by 
PKB/Akt in response to insulin (Jiang et al. 2005) and its phosphorylation (Ser2032) has been 
identified as a marker of simple steatosis (i.e. compared to normal and NASH samples) 
(Wattacheril et al. 2017). This is consistent with its increased abundance at the LD in our model 
of insulin resistant steatotic liver (Fig 3.7D).  
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Analysis of the insulin-responsive proteomes of HFD-fed rats, which are characterised by 
perturbed insulin signalling, identified dermcidin (DCD) as a striking outlier, with the highest 
significance and greatest decrease in fold change (Fig 3.7E). Although DCD is commonly 
known as a antimicrobial peptide secreted from sweat glands, adenovirus-mediated knockdown 
of DCD in mouse adipose tissue resulted in increased HSL and decreased Plin1 mRNA levels 
(Kim et al. 2008). Interestingly, this study also observed translocation of DCD and HSL away 
from LDs in response to insulin stimulation in HFD-fed mice.  
 
On the other hand, the analysis of the phosphoproteome revealed a family of spectrin 
phosphosites (spectrin alpha sites Ser1039 and Ser1031, and spectrin beta site Ser2234) that 
were increased in response to insulin in HFD-fed rats (Fig 3.7F). Spectrin is a scaffolding 
protein that localises to LDs in rat liver (Turro et al. 2006), interacts with various phospholipids 
(Maksymiw et al. 1987, Janmey and Lindberg 2004, Grzybek et al. 2006), and functions as a 
liaison between lipid uptake and LD growth in Drosophila melanogaster (Diaconeasa et al. 
2013). Conceivably, the increased phosphorylation of spectrin proteins in response to insulin 
stimulation in the liver of HFD-fed rats suggests greater lipid uptake, potentially from the lack 
of suppression of adipose lipolysis that is a characteristic of obesity-induced insulin resistance 
(Kim et al. 2017). 
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Figure 3.7 Volcano plots of proteome and phosphoproteome.  
The volcano plots show protein or phosphosite abundance at the lipid droplet based on -log10(p-value) and fold change. 
Proteins or sites that were insignificant (p > 0.05), significant (0.01 > p  < 0.05) or very significant (p  < 0.01) were indicated 
as black-filled circles, dark grey-filled circles, and red-filled circles, respectively. Key lipolytic regulators (PLIN2, PLIN3, 
PLIN4, PLIN5, CGI-58, G0S2, PNPLA3, ATGL and HSL) were distinguished according to the legend. The plots include 
binary comparisons of (A) the proteome and (B) the phosphoproteome of chow-fed acutely insulin stimulated rats compared 
to basal, (C) the proteome and (D) the phosphoproteome of HFD-fed acutely insulin-stimulated rats compared to chow-fed 
rats, and (E) the proteome and (F) the phosphoproteome of HFD-fed acutely insulin-stimulated rats compared to basal. 
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Volcano plots are a simple and effective way to discover changes in large data-sets. The 
changes, or lack thereof, of known key regulators of lipolysis were mapped on the volcano 
plots presented in Fig 3.7. The majority of proteins (Plin2, Plin5, G0S2, Pnpla3, ATGL and 
HSL) were found in both the proteomic and phosphoproteomic datasets; however, Plin3, Plin4 
and CGI-58 were not detected in the enriched phosphoproteome (Fig 3.7). In chow fed rats, 
Plin2 protein levels remained unchanged in response to insulin stimulation (Fig 3.7A) but 
phosphorylation of Ser254, a novel Plin2 phosphosite, was decreased (Fig 3.7B). Similarly, 
Plin2 protein levels did not change (Fig 3.7E) but phosphorylation of Ser253 and Ser417 was 
significantly decreased (Fig 3.7F) with insulin stimulation in HFD-fed rats. Interestingly, Plin5 
protein levels remained constant in all conditions (Fig 3.7A, C, E) but phosphorylation of 
Ser163 was increased in insulin stimulated, HFD-fed rats compared to chow animals (Fig 3.7D) 
and decreased phosphorylation in high fat-fed insulin stimulated rats compared to basal (Fig 
3.7F). The discrepancy suggests a diet vs insulin effect on Plin5 phosphorylation, specifically 
upregulation with HFD, and downregulation with insulin in HFD-induced insulin resistance. 
HSL contains many well characterised phosphosites including Ser565, Ser565, Ser659 or 
Ser660 (Hornbeck 2015), which were all detected in this study. Somewhat remarkably, the 
phosphorylation of these sites did not differ in any of the comparisons (Fig 3.7), but protein 
abundance was decreased with insulin stimulation in HFD-fed rats compared to insulin-
stimulated, chow-fed animals (Fig 3.7C). Taken together, acute insulin stimulation and/or HFD 
feeding had little effect on the protein levels of key LD-associated regulators of lipolysis, 
whereas there were greater changes in the phosphorylation patterns. 
 
3.3.7 Modelling Insulin Resistance via Biologically Relevant Scenarios 
3.3.7.1 Identification of “Insulin Resistant” Proteins 
The two-dimensional aspect of differential expression analysis is limited in its ability to clearly 
illustrate the behaviour of proteins in multiple conditions simultaneously. This is especially 
important when investigating insulin resistance, which is defined as a condition where cells 
fail to respond normally to the insulin. To identify proteins that fit this definition, four potential 
scenarios were created on the basis of protein abundance or translocation at the LD (Fig 3.8). 
Each of the scenarios represent a distinct difference in insulin-stimulated protein behaviour at 
the LD in healthy animals vs HFD-induced insulin resistant animals. For example, scenario 1 
captures proteins that normally increase in abundance at the LD with insulin stimulation, but 
fail to in insulin resistant liver. Similarly, in scenario 2 proteins normally do not increase in 
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abundance at LDs with insulin stimulation, but they do in the insulin resistant setting. Protein 
lists were generated by using DE fold change and p-values for two specific comparisons 1) 
chow-insulin vs chow-basal and 2) HFD-insulin vs HFD-basal. There were 42 proteins that fit 
into scenario 1 (Table 4.2), 87 proteins into scenario 2 (Table 4.3), 130 proteins in scenario 3 
(Table 4.4), and 79 proteins in scenario 4 (Table 4.5).  
 
Interestingly, all members of the electron transport chain (ETC) were identified as ‘insulin 
resistant’ despite residing in the mitochondrial. These results are likely indicative of changes 
in interorganellar contact between LD and mitochondria in HFD-induced IR compared to 
control. Although numerous studies have described the relationship between dysregulated 
mitochondrial oxidation and insulin sensitivity (Goodpaster 2013, Montgomery and Turner 
2015, Fazakerley et al. 2018), the majority have not explored this correlation in hepatocytes. 
Further, most of the ETC proteins appear in Scenario 1, whereas insulin stimulation has been 
shown to reduce FA oxidation in the liver (see Chapter 4), potentially due to altered LD-
mitochondria contact. Alternatively, many proteasomal proteins were also identified as 
“insulin resistant”, and their translocation to the LD during impaired signalling may be 
indicative of increased ubiquitination of proteins at the LD. This is consistent with published 
reports on the role of LDs as storage depots for degradation (Cermelli et al. 2006, Bersuker and 
Olzmann 2017). Markedly, no lipases or known lipolytic regulators, such as ATGL, HSL, 
CGI58 or G0S2, were identified in any of the proteomic scenarios, consistent with results 
presented in Fig 3.7.  
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Figure 3.8 Modelling of insulin-resistance in hepatic lipid droplet proteome. 
A list of 338 LD-associated insulin resistant proteins were identified through systematic filtering. An increase or decrease in 
abundance at the LD is defined as p < 0.05 with fold change greater than or less than 1. No change in abundance was defined 
as p > 0.05. Comparisons were made between 1) chow-insulin versus chow-basal and 2) HFD-insulin vs HFD-basal.   
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Table 3.4 List of hepatic lipid-droplet associated proteins in scenario 1  
Name Symbol Uniprot ID 
Apoptosis inducing factor mitochondria associated 1 Aifm1 Q924M6 
Aly/REF export factor Alyref D3ZXH7 
ATP synthase subunit beta Atp5b G3V6D3 
ATP synthase subunit epsilon, mito Atp5e P29418 
ATP synthase F(0) complex subunit B1, mito Atp5f1 P19511 
ATP synthase subunit e, mito Atp5i P29419 
ATPase, H trnasporting, lysosomal V1 subunit G1 Atp6v1g1 B2GUV5 
ATPase inhibitor, mito Atpif1 Q03344 
BRICK1, SCAR/WAVE actin nucleating complex subunit  Brk1 D3ZUP5 
Chaperonin containing Tcp1, subunit 6B (zeta 2) Cct6b Q6AYJ7 
Isoform 2 of cyclin-dependent kinase 12 Cdk12 Q3MJK5-2 
Cytochrome c oxidase subunit 4 isoform 1, mito Cox4i1 P10888 
Cytochrome c oxidase subunit 6C-2 Cox6c2 P11951 
Density regulated re-initiation and release factor Denr B0BNB2 
Enoyl-CoA hydratase domain-containing protein 3, mito Echdc3 Q3MIE0 
Eukaryotic translation initiation factor 3 Eif3d Q6AYK8 
Eukaryotic translation initiation factor 4E family member 2 Eif4e2 A0A096MK14 
Fumarylacetoacetase Fah P25093 
Family wih sequence similarity 134 member A Fam134a Q3MHU5 
Haloacid dehalogenase-like hydrolase domain-containing protein 2 Hdhd2 Q6AYR6 
Heterogeneous nuclear ribonucleoprotein A0 Hnrnpa0 F1M3H8 
IQ motif-containing GTPase activating protein 1 Iqgap1 G3V7Q7 
Importin subunit alpha Kpna3 Q56R18 
LOC100362640 LOC100362640 X1WI37 
LOC100910934 LOC100910934 Q4V797 
Macrophage migration inhibitory factor Mif P30904 
Meiosis-specific nuclear structural protein 1 Mns1 Q6AXQ8 
3-mercaptopyruvate sulfurtransferase Mpst P97532 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 2 Ndufa2 D3ZS58 
NADH dehydrogenase (ubiquinone) 1 alpha Ndufa4 B2RZD6 
Poly(A) binding protein, nuclear 1, isoform CRA_a Pabpn1 G3V7Z8 
Proteosome subunit alpha 7 Psma7 F1LSQ6 
Proteosome subunit beta type-7 Psmb7 Q9JHW0 
Prostaglandin G/H synthase 1 Ptgs1 Q66HK3 
Glycogen phosphorylase, liver form Pygl P09811 
RGD1564804 RGD1564804 D4A7G9 
60S ribosomal protein L34 Rpl34 B2RZD4 
Ribosomal protein S29 Rps29 P62275 
Succinate dehydrogenase (ubiquinone) flavoprotein subunit, mito Sdha Q920L2 
TatD DNase domain-containing 3 Tatdn3 M0R5U3 
Transketolase Tkt P50137 
Tetratricopeptide repeat domain 9C Ttc9c Q6P5P3 
In scenario 1, proteins are listed as insulin-resistant if their protein abundance at the LD significantly increases with insulin 
stimulation in the chow-fed group but does not change in abundance with insulin stimulation in the HFD-fed group.  
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Table 3.5. List of hepatic lipid-droplet associated proteins in scenario 2 
Name Symbol Uniprot ID 
ATP binding cassette subfamily A member 6 Abca6 M0R890 
Ankyrin repeat and SOCS box containing 13 Asb13 D3ZEJ6 
ATP synthase subunit d, mito Atp5h P31399 
ATP synthase-coupling factor 6, mito Atp5j P21571 
BCL2 interacting protein 2 Bnip2 D3ZGE0 
Cingulin Cgn D4A4X4 
Charged multivesicular body protein 5  Chmp5 Q4QQV8 
Cytokine induced apoptosis inhibitor 1 Ciapin1 Q5XID1 
Calponin-3  Cnn3 P37397 
Collagen alpha-2(I) chain  Col1a2 P02466 
Cytochrome c oxidase subunit 5B, mito Cox5b P12075 
Carboxypeptidase B2  Cpb2 Q9EQV9 
Cytoplasmic polyadenylation element binding protein 3 Cpeb3 D3Z9M2 
CWF19-like 1, cell cycle control (S. pombe) (Predicted)  Cwf19l1 D3Z863 
Cytochrome P450 2C11 Cyp2c11 P08683 
DEAH (Asp-Glu-Ala-His) box polypeptide 38 (Predicted), isoform CRA_a  Dhx38 D4A321 
Dual specificity phosphatase 19 (Predicted), isoform CRA_b  Dusp19 D4A8F3 
Eukaryotic translation initiation factor 2B subunit epsilon Eif2b5 Q64350 
Family with sequence similarity 98 member C Fam98c F1LQ27 
Dimethylaniline monooxygenase [N-oxide-forming] 3  Fmo3 Q9EQ76 
Isoform 2 of Fibronectin  Fn1 P04937-2 
Gamma-glutamylaminecyclotransferase Ggact Q4KM86 
Vitamin K-dependent gamma-carboxylase Ggcx F7FCW3 
Glutamine synthetase  Glul P09606 
 LOC688393 protein Gpn1 B1WBZ7 
General transcription factor IIIC, polypeptide 5  Gtf3c5 A1L1K6 
Hydroxyacid oxidase 2  Hao2 Q07523 
Hemoglobin alpha, adult chain 2  Hba1 B1H216 
HD domain containing 2 Hddc2 D3ZKT8 
Histone H2B  Hist1h2bl M0R4L7 
Insulin-like growth factor-binding protein 4  Igfbp4 P21744 
IlvB acetolactate synthase like Ilvbl D4ACG2 
Type I inositol 3,4-bisphosphate 4-phosphatase  Inpp4a D3ZAN1 
Inositol polyphosphate-5-phosphatase K  Inpp5k Q5XIU8 
Lactamase, beta (Predicted)  Lactb D3ZFJ6 
Ragulator complex protein LAM Lamtor3 Q5U204 
Legumain  Lgmn Q5PPG2 
LOC100364175 LOC100364175 Q5FVP9 
Peptidylprolyl cis/trans isomerase, NIMA-interacting 1  LOC364561 B0BNL2 
LOC366772 LOC366772 Q5VLR6 
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LOC501233 LOC501233 F1LQJ4 
LSM2 homolog, U6 small nuclear RNA associated  Lsm2 Q6MG66 
Putative MAGE-like protein  Maged2 Q9EPI7 
Mast cell protease 1  Mcpt1 P09650 
Mast cell protease 2  Mcpt2 P00770 
Magnesium dependent phosphatase 1 Mdp1 D4A4U3 
Multifunctional protein ADE2 Paics P51583 
PDGFA associated protein 1 Pdap1 Q62785 
Polymerase (RNA) II (DNA directed) polypeptide J (Predicted)  Polr2j D3ZQI0 
Polymerase I and transcript release factor  Ptrf G3V8L9 
Sodium/nucleoside cotransporter 2  Q91WW8 Q91WW8 
RNA binding motif protein 26 Rbm26 D3ZRC3 
RGD1309730 RGD1309730 B2RYT8 
Ribosomal protein S6 kinase  Rps6ka3 D3Z8E0 
Ras-related 2 Rras2 Q5BJU0 
Stromal cell derived factor 2 Sdf2 D4A4H5 
Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mito Sdhb P21913 
SEC63 homolog, protein translocation regulator Sec63 D4A2Z6 
Selenoprotein  SEPT.15 Q923V8 
SET nuclear proto-oncogene Set B0BMV1 
Splicing factor 3a subunit 3 Sf3a3 Q4KLI7 
Solute carrier family 43 member 3 Slc43a3 D4A832 
Solute carrier organic anion transporter family member 1A1  Slco1a1 P46720 
Beta-synuclein  Sncb Q63754 
Small nuclear ribonucleoprotein F  Snrpf D4AAT4 
Sorting necin family member 21 Snx21 F1M3C9 
Sorting necin family member 30 Snx30 D4A060 
SPRY domain containing 7 Spryd7 Q5M7T2 
Stomatin Stom Q5XI04 
Sulfatase modifying factor 2 Sumf2 Q5BK78 
Transgelin Tagln P31232 
Tubulin folding cofactor E like Tbcel Q5PQJ7 
Serotransferrin Tf P12346 
Transforming growth factor beta-1-induced transcript 1 protein Tgfb1i1 Q99PD6 
Mitochondrial import inner membrane translocase subunit  Timm8a Q9WVA1 
Tight junction protein 3 Tjp3 D3Z8G7 
Transmembrane protein 106B Tmem106b Q6AYA5 
Tropomyosin 1 Tpm1 P04692-5 
TNFRSF1A associated via death domain Tradd D3ZZC5 
Cdc42-interacting protein 4  Trip10 M0R3P9 
Transthyretin Ttr P02767 
Taxilin gamma Txlng Q4FZU5 
Upstream binding transcription factor Ubtf P25977-2 
UBX domain-containing protein 1  Ubxn1 Q499N6 
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Urinary protein 2  UP2 P81828 
Cytochrome b-c1 complex subunit 7 Uqcrb B2RYS2 
Cytochrome b-c1 complex subunit Rieske, mito Uqcrfs1 P20788 
In scenario 2, proteins are listed as insulin-resistant if their protein abundance does not change at the LD with insulin 
stimulation in the chow-fed group, but increases in abundance at the LD with insulin stimulation in the HFD-fed group.  
 
 
Table 3.6. List of hepatic lipid-droplet associated proteins in scenario 3 
Name Symbol Uniprot ID 
Acyl-CoA-binding domain-containing protein 6  Acbd6 Q5RJK8 
Long-chain-fatty-acid--CoA ligase 3  Acsl3 Q63151 
ARP10 actin-related protein 10 homolog (S. cerevisiae)  Actr10 Q5M9F7 
Alcohol dehydrogenase 1  Adh1 F1LSR9 
Afamin  Afm G3V9R9 
Alpha-2-HS-glycoprotein  Ahsg P24090 
Apoptosis-inducing factor, mitochondria-associated 2 Aifm2 D4AA14 
Annexin A5  Anxa5 P14668 
AP-2 complex subunit mu  Ap2m1 P84092 
Apolipoprotein A-IV  Apoa4 P02651 
Isoaspartyl peptidase/L-asparaginase  Asrgl1 Q8VI04 
Autophagy-related 2A Atg2a D3ZT64 
Lys-63-specific deubiquitinase BRCC36  Brcc3 B2RYM5 
Bromodomain-containing 4 Brd4 D3ZGX8 
Basic leucine zipper and W2 domain-containing protein 2  Bzw2 Q9WTT7 
Complement C1r subcomponent C1r D4A1T6 
Complement C3  C3 M0RBJ7 
C4b-binding protein beta chain C4bpb A0A5C5 
Complement component C6  C6 Q811M5 
Oxidation resistance protein 1 (Fragment)  C7 F1M7F8 
Complement component 8, alpha polypeptide (Predicted)  C8a D3ZWD6 
Carbonic anhydrase 2  Ca2 P27139 
Carbonic anhydrase 3  Ca3 P14141 
Coiled-coil domain-containing 9 Ccdc9 M0RA86 
CD2 antigen (Cytoplasmic tail) binding protein 2 (Predicted), isoform CRA Cd2bp2 B4F786 
Protein-glutamate O-methyltransferase CF211 Q6AYT5 
B-factor, properdin  Cfb Q6MG74 
Complement inhibitory factor H  Cfh Q91YB6 
Complement factor I  Cfi Q9WUW3 
Clusterin  Clu Q6P7S6 
COMM domain containing 9  Commd9 Q3MIE7 
Crystallin, zeta (Quinone reductase)-like 1  Cryzl1 Q5XI39 
RNA polymerase II subunit A C-terminal domain phosphatase Ctdp1 D3ZMS2 
Isoform 3 of NADH-cytochrome b5 reductase 3  Cyb5r3 P20070-3 
N(G),N(G)-dimethylarginine dimethylaminohydrolase 2  Ddah2 Q6MG60 
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DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 (Predicted) Ddx58 D4ADT5 
Type I iodothyronine deiodinase Dio1 P24389 
Protein kintoun Dnaaf2 F1LMB5 
Eukaryotic translation initiation factor 6  Eif6 Q3KRD8 
ELMO domain-containing protein 2 Elmod2 D3ZNV6 
Erlin-2  Erlin2 B5DEH2 
ERO1-like protein alpha Ero1l Q8R4A1 
Exosome complex component CSL4 Exosc1 M0R5B6 
Coagulation factor X  F10 Q63207 
Prothrombin  F2 G3V843 
FAS-associated factor 1  Faf1 Q924K2 
FAS-associated factor 2  Faf2 Q5BK32 
Fam45a protein (Fragment)  Fam45a B2RZA3 
Family with sequence similarity 96, member A  Fam96a Q5RJS3 
F-box and WD-40 domain protein 11 (Predicted) Fbxw11 D3ZXC6 
Fibrinogen beta chain Fgb P14480 
Fggy carbohydrate kinase domain-containing protein Fggy F1LSP9 
Fibronigen-like protein  Fgl1 Q8K583 
Flotillin-1  Flot1 Q9Z1E1 
Glucose-6-phosphatase  G6pc A0A096MK74 
Group specific component  Gc Q68FY4 
Glyoxalase domain-containing protein 4 Glod4 Q5I0D1 
Guanine nucleotide binding protein beta 2 (Fragment)  Gnb2 Q45QL6 
Glucosamine 6-phosphate N-acetyltransferase Gnpnat1 B1H249 
Golgi reassembly stacking protein 2  Gorasp2 Q68G33 
Gelsolin 1  Gsn Q68FP1 
Beta-globin chain  Hbe2 Q63067 
Dynein, axonemal, assembly factor 5 Heatr2 G3V943 
Histidine-rich glycoprotein  Hrg Q99PS8 
Estradiol 17-beta-dehydrogenase 11  Hsd17b11 Q6AYS8 
Heat shock 70 kDa protein 1A/1B  Hspa1a Q07439 
Hsp70-binding protein 1  Hspbp1 Q6IMX7 
Ifi47 protein Ifi47 Q6NYB8 
Insulin-like growth factor-binding protein complex acid labile subunit 
(Fragment)  Igfals F1LRE2 
Il1rap protein  Il1rap Q4V8K9 
Importin 9 (Predicted)  Ipo9 D4A857 
Immunity-related GTPase family M protein  Irgm Q6AYC2 
Integrin subunit alpha 2b Itga2b D3ZAC0 
Integrin alpha-4 Itga4 D3ZMQ3 
Inter-alpha trypsin inhibitor heavy chain H2 Itih2 D3ZFH5 
Isoform 2 of Kinesin-like protein KIF1B Kif1b O88658-2 
Kallikrein B, plasma 1  Klkb1 Q5FVS2 
Kininogen-2 Kng2 Q5M8A0 
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Lecithin cholesterol acyltransferase  Lcat O35849 
Lipopolysaccharide responsive and beige-like anchor protein Lrba F1LZG6 
Lymphocyte specific 1, isoform CRA Lsp1 Q4QQV6 
O-acetyl-ADP-ribose deacetylase MACROD1  Macrod1 G3V8V6 
Mitotic spindle assemble checkpoint protein MAD1 Mad1l1 D3ZIV3 
tRNA (guanine-N(7)-)-methyltransferase Mettl1 M0R637 
Murinoglobulin-1  Mug1 Q03626 
Myosin light chain 1/3, skeletal muscle isoform  Myl1 P02600 
Nicotinate phosphoribosyltransferase  Naprt1 G3V709 
Nitric oxide synthase adaptor protein c  NOS1AP D5LG85 
Neurogranin  Nrgn Q04940 
Nuclear pore complex protein Nup214 Nup214 D4ACK1 
NUS1 dehydrodolichyl diphosphate synthase Nus1 D3ZFM4 
Poly (A) polymerase alpha (Predicted), isoform CRA Papola D3ZK96 
Programmed cell death 6 (Predicted), isoform CRA Pdcd6 G3V7W1 
3-phosphoinositide-dependent protein kinase 1  Pdpk1 O55173 
Phosphoacetylglucosamine mutase Pgm3 B2RYN0 
Phosphatidylinositol 3-kinase regulatory subunit beta  Pik3r2 Q5FVS6 
PITH domain containing 1 Pithd1 D4ABS5 
Peptidyl-prolyl cis-trans isomerase  Ppil1 Q4KLI4 
E3 ubiquitin-protein ligase PPP1R11 Ppp1r11 Q6MFY6 
Vitamin K-dependent protein Z Proz D3ZKM4 
Proteasome subunit beta type-2  Psmb2 P40307 
Ras-related protein Rab-18  Rab18 Q5EB77 
Ras-related protein Rab-32 Rab32 D4AEG2 
Ras-related protein Rab-7L1 Rab7l1 Q66HQ8 
Rab-like protein 6 Rabl6 D3ZKQ4 
Retinoblastoma-binding protei 5 Rbbp5 D3ZC01 
CapZ-ineracting protein Rcsd1 F1M4V3 
Retinol dehydrogenase 10 Rdh10 Q80ZF7 
RGD1306556 RGD1306556 F1M8B8 
E3 ubiquitin-protein ligase RNF123  Rnf123 F1LMI7 
Serpin family A member 4 Serpina4 Q5M8C3 
Serpin family F member 2 Serpinf2 Q68FT8 
SH2-B PH domain containing signaling mediator 1, isoform CRA Sh2b1 M0R617 
Carbohydrate kinase-like, isoform CRA Shpk Q3MID4 
Spartin Spg20 E9PT90 
Signal transducing adaptor family member 2  Stap2 Q5BK28 
Metalloreductase STEAP4  Steap4 Q4V8K1 
Transcription elongation factor B polypeptide 2  Tceb2 P62870 
Transmembrane protein 263 Tmem263 B2RZ08 
Transmembrane protein 33  Tmem33 Q9Z142 
Torsin-1A  Tor1a Q68G38 
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tRNA (guanine (26)-N(2))-dimethyltransferase Trmt1 Q5U4E4 
Ubiquitin/ISG15-conjugating enzyme E2 L6  Ube2l6 Q4V8J2 
Ubiquitin carboxyl-terminal hydrolase 33 Usp33 Q569A1 
Vacuolar protein-sorting associated protein 13C Vps13c D4A4K4 
Vacuolar protein-sorting associated protein 37B Vps37b D3ZU64 
WW domain binding protein 2, isoform CRA Wbp2 G3V721 
Protein yuppee-like 5 Ypel5 D4A4Q3 
Terminal uridylultransferase 4 Zcchc11 F1M466 
Zinc finger protein 330 Zfp330 D3ZSN4 
In scenario 3, proteins are listed as insulin-resistant if their protein abundance decreases at the LD with insulin stimulation in 
the chow-fed group, but does not change in protein abundance at the LD with insulin stimulation in the HFD-fed group.  
 
 
Table 3.7. List of hepatic lipid-droplet associated proteins in scenario 4 
Name Symbol Uniprot ID 
Steroid 5 alpha-reductase (Fragment)  A1E0X5 A1E0X5 
Abhydrolase domain containing 2 (Predicted)  Abhd2 D4A7W1 
Annexin 7 Anxa7 Q8VIN2 
Armc8 protein Armc8 B4F7A2 
Ataxin-10  Atxn10 Q9ER24 
Uncharacterized protein B1H247 B1H247 
BET1 homolog Bet1 Q62896 
Complement component C9  C9 Q62930 
CDK2-associated and cullin domain-containing protein 1  Cacul1 Q5XI53 
Coiled-coil domain-containing protein 47  Ccdc47 Q5U2X6 
Cyclin-dependent kinase 4 (Fragment)  Cdk4 Q71VC8 
Cytidine/uridine monophosphate kinase 2 Cmpk2 D3ZC63 
Coatomer subunit alpha  Copa G3V6T1 
Casein kinase II subunit alpha Csnk2a1 P19139 
DDHD domain containing 1  Ddhd1 Q3ZAU5 
Neutrophil antibiotic peptide NP-3B  DEF3B Q9Z1F1 
Protein Dr1 Dr1 Q5XI68 
Down syndrome critical region gene 3 (Predicted), isoform CRA Dscr3 E9PU42 
Eukaryotic translation initiation factor 3 subunit M  Eif3m D3ZAZ0 
Echinoderm microtubule associated protein like 4 (Predicted), isoform CRA Eml4 F1LT71 
Isoform 2 of Endoplasmic reticulum aminopeptidase 1  Erap1 Q9JJ22-2 
SEC3-like 1 Exoc1 Q4V8H2 
Exosome component 3 Exosc3 D3ZT51 
Family with sequence similarity 115, member C Fam115c M0RBL7 
Family with sequence similarity 160, member B1 Fam160b1 D4A3I5 
F-box only protein 4 (Predicted)  Fbxo4 D3ZIH4 
Fermitin family member 3 Fermt3 B2GVB9 
FIP1-like 1  Fip1l1 B6RIU0 
Isoform 2 of Fragile X mental retardation protein 1 homolog Fmr1 Q80WE1-2 
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GIMAP9 Gimap9 Q3ZAV4 
GNAS complex locus  Gnas B0BMW4 
Golgin subfamily A member 2  Golga2 F1LSS0 
Golgi phosphoprotein 3  Golph3 Q569C9 
Histone deacetylase 1  Hdac1 Q4QQW4 
Heme oxygenase 1  Hmox1 P06762 
Importin 7 (Predicted), isoform CRA Ipo7 D4AE96 
Interleukin-1 receptor-associated kinase 4 Irak4 D4A7K4 
Interferon, alpha-inducible protein (Clone IFI-15K) (Predicted)  Isg15 D4A3X3 
T-kininogen 2  KNT2 P08932 
Leucine carboxyl methyltransferase 1  Lcmt1 G3V7V9 
Hormone-sensitive lipase  Lipe P15304-2 
LOC100912386 LOC100912386 M0RAK8 
M0R9D9 M0R9D9 M0R9D9 
Dual specificity mitogen-activated protein kinase kinase 2  Map2k2 P36506 
Metallo-beta-lactamase domain-containing 2 Mblac2 D4A249 
Histidine protein methyltransferase 1 homolog  Mettl18 Q4KM84 
Metallothionein 1 (Fragments)  Mt1f Q7M082 
Metallothionein  Mt1m D3ZHV3 
Myotubularin related protein 2 (Predicted), isoform CRA Mtmr2 D3ZA31 
Myosin V1 Myo6 D4A5I9 
Nuclear cap-binding protein subunit 2  Ncbp2 B1WC40 
Isoform Cytoplasmic of Cysteine desulfurase, mitochondrial  Nfs1 Q99P39-2 
Aminopeptidase-like 1 (Predicted)  Npepl1 D4A3E2 
Aminopeptidase Npepps F1M9V7 
Nuclear pore complex protein Nup54  Nup54 P70582 
Alpha-1-acid glycoprotein  Orm1 P02764 
Peflin  Pef1 Q641Z8 
Peroxisome assembly factor 2  Pex6 P54777 
Parvalbumin alpha  Pvalb P02625 
Pyridine nucleotide-disulfide oxidoreductase domain-containing protein 2  Pyroxd2 Q68FT3 
RGD1309995 RGD1309995 D4A7I6 
RGD1310429 RGD1310429 D3ZEJ9 
N-terminal kinase-like protein  Scyl1 Q5M9F8 
Sodium-coupled neutral amino acid transporter 4  Slc38a4 Q9EQ25 
Smu-1 suppressor of mec-8 and unc-52 homolog (C. elegans)  Smu1 G3V702 
Signal recognition particle 54 kDa protein  Srp54 Q6AYB5 
Non-specific serine/threonine protein kinase Stk38 G3V9Q4 
Sulfotransferase  Sult2a1 M3ZCQ0 
Similar to CG9339-PA (Predicted) Tbc1d24 D4A3Z3 
Tia1 cytotoxic granule-associated RNA-binding protein-like 1 Tial1 Q5BJN3 
Mitochondrial import inner membrane translocase subunit Tim8 B  Timm8b P62078 
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FLN29 gene product, isoform CRA Trafd1 G3V959 
Similar to tripartite motif protein 47 Trim47 D3ZA22 
Ubiquitin-activating enzyme E1-like (Predicted) Uba7 D3ZEU5 
Ube2g2 protein Ube2g2 B2RYD0 
Voltage-dependent anion-selective channel protein 3  Vdac3 Q9R1Z0 
Similar to vacuolar protein sorting 26 homolog, isoform CRA_a Vps26b B1WBS4 
WD repeat domain phosphoinositide-interacting protein 4  Wdr45 Q5U2Y0 
Similar to zinc finger FYVE domain containing 19 Zfyve19 Q499R6 
In scenario 4, proteins are listed as insulin-resistant if their protein abundance does not change at the LD with insulin 
stimulation in the chow-fed group, but decreases in abundance at the LD with insulin stimulation in the HFD-fed group.  
 
 
3.3.7.2 Identification of “Insulin Resistant” Phosphosites 
Protein phosphorylation is most meaningful when the protein levels are known, thus 
phosphosites were overlaid with the proteomic data. It should be noted that the illustration in 
Fig 3.9 only represents one of multiple interpretations of the phosphorylation data. An increase 
in a particular phosphosite at the LD could be due to increased phosphorylation, as shown in 
Fig 3.9, or due to translocation of previously phosphorylated protein to the LD (not shown). A 
list of 252 LD-associated ‘insulin resistant’ phosphosites were identified following data 
filtering through the four scenarios (Fig 3.9). In general, there were 37 phosphosites on 36 
different proteins that fitted scenario 1, 26 of which were found in the proteomic dataset as 
well (Table 4.8). Similarly, 118 phosphosites on 96 phosphoproteins were identified in scenario 
2, 64 of which were in the proteomic dataset (Table 4.9). In scenario 3, 77 phosphosites on 70 
phosphoproteins with 52 of them in the proteomics dataset were identified (Table 4.10). 
Finally, 20 phosphosites on 19 phosphoproteins fit scenario 4, 14 of which were quantified in 
the proteomic dataset (Table 4.11).  
 
In contrast to the proteome, phosphosites identified as having abnormal phosphorylation with 
acute insulin treatment in the HFD-induced IR group generally belonged to proteins involved 
in diverse and non-canonical LD processes, such as translation factors and scaffolding proteins. 
The exception to this observation was the identification of phosphosites on several lipolytic 
regulators listed in scenario 3 and 4 (Table 4.12). Despite a lack of change in the proteome, 
phosphorylation of Ser422 on PNPLA2 (otherwise known as ATGL) was found to decrease 
with insulin stimulation at the LD, but remained there in the HFD-fed animals. Although 
Ser422 has previously been identified as a phosphosite on ATGL in human, mouse and rat 
studies (Lundby et al. 2012, Wilson-Grady et al. 2013, Bian et al. 2014), its role in modulating 
ATGL activity has not been characterised. However, published reports in non-hepatocytes on 
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the effect of alternative phosphosites on ATGL indicate insulin responsiveness and regulation 
of LD localization (Chakrabarti et al. 2013, Xie et al. 2014). Additionally, phosphorylation of 
Ser410 on PNPLA3 and Ser253 and S417 on Plin2 were found to not respond to insulin in 
chow-fed animals, but decreased in those fed a HFD (Table 4.12). The phosphorylation of 
Ser410 on PNPLA3 and Ser417 on Plin2 are both novel points of regulation that are 
unidentified in any species, while Ser253 on Plin2 has been identified in a proteogenomic study 
using human breast cancer (Mertins et al. 2016). These results suggest that a key regulator of 
lipolysis, ATGL, is phospho-regulated in response to acute insulin stimulation in hepatocytes, 
and this cannot be accounted for by changes in protein abundance at the LD. Further, 
phosphorylation of ATGL, PNPLA3 and Plin2 in response to insulin is perturbed in obese and 
insulin-resistant rats, suggesting an underestimated role for altered PTMs of proteins involved 
in lipolysis in the pathogenesis of IR.  
 
Figure 3.9 Modelling of insulin resistance in hepatic lipid droplet phosphoproteome 
LD-associated insulin resistant phosphosites were identified through systematic filtering. An increase or decrease in 
phosphosites at the LD is defined as p < 0.05 with fold change greater than or less than 1. No change was defined as p > 0.05. 
Comparisons were made between 1) chow-insulin versus chow-basal and 2) HFD-insulin vs HFD-basal.   
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Table 3.8. List of hepatic lipid-droplet associated phosphosites in scenario 1 
Name Symbol Uniprot ID AA Site 
40S ribosomal protein S6 (Fragment) Rps6 M0RD75 S 233 
Afadin Afdn O35889 S 1282 
Alanine and glycine-rich protein-like LOC103694328 D3ZBC4 S 274 
Betaine--homocysteine S-methyltransferase 1 Bhmt O09171 S 330 
Cytoplasmic polyadenylation element binding 
protein 4 (Predicted) Cpeb4 D3ZKL3 S 97 
Enhancer of mRNA-decapping protein 4 Edc4 Q3ZAV8 S 924 
Enthoprotin Clint1 Q6DGF2 T 308 
EPS8-like 2 (Predicted), isoform CRA Eps8l2 F7DLY1 S 528 
Erythrocyte membrane protein band 4.1 Epb41 D3ZKF7 S 535 
Eukaryotic translation initiation factor 4 gamma, 
1 Eif4g1 D4AD15 S 1140 
Golgi brefeldin A-resistant guanine nucleotide 
exchange factor 1 Gbf1 F1M8X9 S 1786 
Isoform 4 of Tuberin Tsc2 P49816-4 S 939 
KH domain-containing, RNA-binding, signal 
transduction-associated protein 1 Khdrbs1 Q91V33 S 38 
KN motif and ankyrin repeat domains 1 Kank1 D4AE58 S 318 
La ribonucleoprotein domain family, member 1 Larp1 F1M062 S 627 
Lipin 1 Lpin1 Q5XIM8 S 328 
Membrane-associated guanylate kinase, WW and 
PDZ domain-containing protein 3 Magi3 F1M7S0 S 702 
Mitochondrial antiviral-signaling protein Mavs Q66HG9 S 152 
MLLT1, super elongation complex subunit Mllt1 M0R462 S 307 
Neuroprotective protein 8 Zwint B3SVE5 S 206 
Phosphoinositide kinase, FYVE-type zinc finger 
containing Pikfyve D3ZYT8 S 1753 
Pumilio 2 Pum2 D3ZQL8 S 181 
RCG40648, isoform CRA_b Sec23ip G3V8Q8 S 749 
Rho guanine nucleotide exchange factor 5 Arhgef5 E9PT59 S 699 
RNA-binding protein 3 Ranbp3 M0R5Q3 S 58 
Scaffold attachment factor B1 Safb M0RBF0 S 367 
Scaffold attachment factor B1 Safb M0RBF0 S 466 
Serine/arginine repetitive matrix protein 1 Srrm1 B2RYB3 S 657 
Serine/arginine repetitive matrix protein 2 Srrm2 F1LRJ2 S 231 
Serine/threonine-protein kinase PRP4 homolog Prpf4b Q5RKH1 S 387 
Serine/threonine-protein phosphatase 1 regulatory 
subunit 10 Ppp1r10 F1LQE9 S 313 
Splicing factor, arginine/serine-rich 19 Scaf1 Q63624 S 495 
Symplekin Sympk Q561R4 S 293 
Tetratricopeptide repeat domain 4 Ttc4 Q5XI93 S 51 
Thyroid hormone receptor-associated protein 3 Thrap3 Q5M7V8 S 405 
Ubiquitin-conjugating enzyme E20 Ube2o F1M403 S 892 
Zinc finger CCCH domain-containing protein 18 Zc3h18 Q6TQE1 S 887 
In scenario 1, phosphosites are listed as insulin-resistant if their intensity at the LD increases with insulin stimulation in the 
chow-fed group, but does not change at the LD with insulin stimulation in the HFD-fed group. AA and site refer to the amino 
acid residue and position that is phosphorylated on that protein.  
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Table 3.9. List of hepatic lipid-droplet associated phosphosites in scenario 2 
Name Symbol Uniprot ID AA Site 
A kinase anchor protein 13 Akap13 F1M3G7 T 932 
A-kinase anchor protein 2  Akap2 F1LPQ9 S 789 
Actin-binding LIM protein 1  Ablim1 Q3KR72 S 304 
Adducin 3 (Gamma), isoform CRA Add3 D3ZCH7 S 648 
Afadin  Mllt4 O35889 S 1090 
Aldehyde oxidase 3  Aox3 Q5QE80 S 196 
Alpha-parvin  Parva G3V818 S 19 
AP2-associated protein kinase 1  Aak1 P0C1X8 S 679 
DNA-(apurinic or apyrimidinic site) lyase Apex1 Q99PF3 S 13 
Arf-GAP with coiled-coil, ANK repeat and PH 
domain-containing protein 2  Acap2 Q5FVC7 S 384 
ATPase WRNIP1  Wrnip1 Q8CG07 S 153 
B-cell CLL/lymphoma 6  Bcl6 B2GUV8 S 334 
BUD13 homolog  Bud13 G3V8F3 S 135 
Calcium-transporting ATPase  Atp2b1 D3ZAX3 S 1142 
CD2AP/CMS  Cd2ap Q80ZE7 S 233 
Desmuslin  Synm Q810D0 S 1042 
Epithelial protein lost in neoplasm  Lima1 F1LR10 S 488 
Epithelial splicing regulatory protein 2  Esrp2 B2RYJ8 S 562 
Etoposide-induced protein 2.4 homolog  Ei24 Q4KM77 S 47 
Eukaryotic translation initiation factor 4E binding 
protein 2  Eif4ebp2 Q497A9 S 65 
FERM, RhoGEF and pleckstrin domain-
containing protein 1  Farp1 F1LYQ8 T 24 
Gap junction beta-1 protein  Gjb1 P08033 S 266 
General transcription factor IIF subunit 2  Gtf2f2 Q63489 S 248 
Glycogen phosphorylase, brain form (Fragment)  Pygb P53534 S 15 
Glycogen phosphorylase, liver form  Pygl P09811 S 15 
GTP-binding protein 1  Gtpbp1 D2XV59 S 24 
H2-K region expressed gene 4, rat orthologue  Slc39a7 Q6MGB4 S 276 
Hepatocyte nuclear factor 1-alpha  Hnf1a P15257 S 247 
High mobility group nucleosomal binding domain 
3, isoform CRA Hmgn3 M0R5I3 S 6 
Interferon regulatory factor 2-binding protein-like  Irf2bpl M0R567 S 320 
Isoform 2 of E3 ubiquitin-protein ligase TRIP12  Trip12 F1LP64-2 S 1069 
Isoform 2 of ERBB receptor feedback inhibitor 1  Errfi1 P05432-2 S 256 
Kinesin 13B  Kif13b Q70AM4 S 1718 
Kinesin 13B  Kif13b Q70AM4 S 1719 
Lamin A, isoform CRA Lmna G3V8L3 S 390 
Lamin A, isoform CRA Lmna G3V8L3 S 22 
Lamin A, isoform CRA Lmna G3V8L3 S 392 
Lamina-associated polypeptide 2, isoform beta  Tmpo Q62733 S 155 
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Leukocyte common antigen  Ptprc Q6LDZ3 S 633 
Leukocyte common antigen  Ptprc Q6LDZ3 S 898 
Map3k3 protein  Map3k3 B5DF98 S 250 
Methyl-CpG-binding protein 2 (Fragment)  Mecp2 F1LWH6 S 359 
Monocarboxylate transporter 1  Slc16a1 P53987 S 213 
Nuclear factor 1  Nfic O70188 S 333 
Nuclear factor 1  Nfib O70187 S 265 
Nuclear ubiquitous casein and cyclin-dependent 
kinase substrate 1  Nucks1 Q9EPJ0 S 39 
Nuclear ubiquitous casein and cyclin-dependent 
kinase substrate 1  Nucks1 Q9EPJ0 S 229 
Palmdelphin  Palmd Q4KM62 S 371 
Palmdelphin  Palmd Q4KM62 S 376 
Paralemmin-1  Palm Q920Q0 T 145 
Plectin 4  N/A Q6S3A1 S 4153 
Polyhomeotic like 3 (Drosophila) (Predicted)  Phc3 D3ZS50 S 109 
Polymerase I and transcript release factor  Ptrf G3V8L9 S 42 
Adipogenesis-associated, Mth938 domain-
containing Aamdc D3ZZQ4 S 48 
Apoptotic chromatin condensation inducer 1 Acin1 E9PST5 S 1004 
Apoptotic chromatin condensation inducer 1 Acin1 E9PST5 S 216 
Neuroblast differentiation-associated protein Ahnak M0R9D5 S 136 
Neuroblast differentiation-associated protein Ahnak M0R9D5 S 5211 
Neuroblast differentiation-associated protein Ahnak M0R9D5 S 94 
Neuroblast differentiation-associated protein Ahnak M0R9D5 S 217 
Cingulin Cgn D4A4X4 S 91 
CCR4-NOT transcription complex, subunit 3 Cnot3 D3ZUV9 S 299 
Cordon-bleu WH2 repeat protein-like 1 Cobll1 F1M124 S 567 
Eukaryotic translation initiation factor 4 gamma, 
1 Eif4g1 D4AD15 S 1588 
Erythrocyte membrane protein band 4.1-like 2 Epb41l2 D3ZM69 S 58 
Erbin Erbb2ip M0R5K2 S 571 
Family with sequence similarity 114, member A1 Fam114a1 D4A777 S 119 
WASH complex subunit 2C Washc2c F1LPG9 S 387 
Ubiquitin carboxyl-terminal hydrolase MINDY-1 Fam63a Q5BJQ2 S 16 
H1 histone family, member X H1fx D3ZIX4 S 134 
Family with sequence similarity 234, member A Fam234a Q5M7W6 S 21 
LOC100911677  LOC100911677 M0R7L9 S 590 
LOC100911677  LOC100911677 M0R7L9 S 594 
LOC680377  Anp32a M0R9D0 T 13 
Leucine-rich repeat-continaing 47 Lrrc47 F1LT49 S 429 
MLLT1, super elongation complex subunit Mllt1 M0R462 T 306 
Par-3 family cell polarity regulator beta Pard3b F1LW22 S 338 
Pinin, desmosome-associated protein Pnn D3ZAY8 S 346 
Serine/threonine-protein phosphatase 2A 56 kDa 
regulatory subunit Ppp2r5e D3ZHI9 S 32 
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Uncharacterized protein N/A F1LT30 S 149 
RNA-binding protein 27 Rbm27 F1LWJ2 S 100 
Ras-related GTP-binding C Rragc Q0D2L6 S 381 
Protein transport protein sec16 Sec16a D3ZN76 S 1365 
SWI/SNF-related, matrix-associated, actin-
dependent regulator of chromatin, subfamily c, 
member 2 Smarcc2 D4A510 S 302 
Spectrin beta chain Sptbn1 G3V6S0 S 2334 
Spectrin beta chain Sptbn1 G3V6S0 S 2096 
Spectrin beta chain Sptbn1 G3V6S0 S 2158 
SFRS protein kinase 2 Srpk2 B1WBT4 S 10 
Serine/arginine repetitive matrix protein 2 Srrm2 F1LRJ2 T 965 
Serine/arginine repetitive matrix protein 2 Srrm2 F1LRJ2 S 1383 
Serine/arginine repetitive matrix protein 2 Srrm2 F1LRJ2 S 1481 
Serine/arginine repetitive matrix protein 2 Srrm2 F1LRJ2 S 772 
Serine/arginine repetitive matrix protein 2 Srrm2 F1LRJ2 S 1723 
RCG61762, isoform CRA_d Srsf7 D4A720 S 183 
START domain containing 10, isoform CRA_b Stard10 Q5BJN1 S 283 
TBC1 domain family member 22B Tbc1d22b F1LNA5 S 40 
Tight junction protein 1 Tjp1 F1M4A0 S 915 
Tight junction protein 1 Tjp1 F1M4A0 S 166 
Tensin 1 Tns1 F1LN42 S 1365 
Trafficking protein particle complex subunit 12 Trappc12 M0R780 S 232 
USP6 N-terminal like (Predicted), isoform 
CRA_a Usp6nl D3ZL57 S 701 
USP6 N-terminal like (Predicted), isoform 
CRA_a Usp6nl D3ZL57 S 392 
Zinc finger CCCH type-containing 13 Zc3h13 E9PSN4 S 1271 
Rat glutathione S-transferase  Gstm1 Q6LDP3 S 199 
Regulator of microtubule dynamics protein 2  Rmdn2 Q498D5 S 121 
RNA polymerase-associated protein LE Leo1 Q641X2 S 642 
Serine/threonine-protein kinase WNK1  Wnk1 Q9JIH7 S 1776 
Sharpin  Sharpin Q9EQL9 S 307 
Sister chromatid cohesion protein PDS5 homolog 
B  Pds5b D3ZU56 S 1187 
Sorbin and SH3 domain-containing protein 1 
(Fragment)  Sorbs1 F1M866 S 329 
Sorbin and SH3 domain-containing protein 1 
(Fragment)  Sorbs1 F1M866 S 330 
Spectrin alpha chain, non-erythrocytic 1 Sptan1 Q6IRK8 S 1029 
Spectrin alpha chain, non-erythrocytic 1 Sptan1 Q6IRK8 S 1031 
Starch-binding domain-containing protein 1  Stbd1 Q5FVN1 S 192 
UBX domain-containing protein 1  Ubxn1 Q499N6 S 188 
Vimentin  Vim P31000 S 72 
Zinc finger CCCH domain-containing protein 18  Zc3h18 Q6TQE1 S 531 
Zinc finger CCCH domain-containing protein 18  Zc3h18 Q6TQE1 S 529 
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In scenario 2, phosphosites are listed as insulin-resistant if their intensity at the LD does not change with insulin stimulation 
in the chow-fed group, but increases at the LD with insulin stimulation in the HFD-fed group. AA and site refer to the amino 
acid residue and position that is phosphorylated on that protein. 
 
Table 3.10. List of hepatic lipid-droplet associated phosphosites in scenario 3 
Name Symbol Uniprot ID AA Site 
1,4-alpha-glucan-branching enzyme Gbe1 A0A096MJY6 S 133 
3 beta-hydroxysteroid dehydrogenase type 5  Hsd3b5 P27364 S 372 
Ac1873 Fga Q7TQ70 S 46 
Adaptor-related protein complex AP-4, beta 1  Ap4b1 D4AD35 S 593 
Alpha-2-HS-glycoprotein  Ahsg P24090 S 309 
Alpha-2-HS-glycoprotein  Ahsg P24090 S 313 
Ankyrin repeat and SAM domain containing 1  Anks1a D4AC12 S 640 
Ankyrin repeat and SAM domain containing 1  Anks1a D4AC12 S 638 
Antisecretory factor  Psmd4 O88321 T 267 
Arf-GAP domain / FG repeat-containing protein 1  Agfg1 F1M9N7 T 179 
Arf-GAP domain / FG repeat-containing protein 1  Agfg1 F1M9N7 T 177 
Arsenite methyltransferase  As3mt Q8VHT6 S 46 
Autophagy related 2B Atg2b F1MAF8 S 379 
Autophagy related 2B Atg2b F1MAF8 S 496 
Calcium-regulated heat stable protein 1  Carhsp1 Q9WU49 S 32 
Calmodulin  Calm1 P62161 S 102 
CAP-Gly domain-containing linker protein 2  Clip2 O55156 S 353 
cGMP-inhibited 3',5'-cyclic phosphodiesterase A  Pde3a Q62865 S 310 
Cysteine-rich protein 2  Crip2 P36201 S 104 
Cytochrome P450 2A1  Cyp2a1 P11711 S 130 
Dihydropyrimidinase-related protein 2  Dpysl2 P47942 S 522 
Dihydropyrimidine dehydrogenase [NADP(+)]  Dpyd O89000 S 905 
Diphosphoinositol pentakisphosphate kinase 2 Ppip5k2 A0A096MK18 S 593 
DNA damange-inducible 1 homolog 2 Ddi2 A0A096MJP9 S 85 
DNA fragmentation factor subunit beta  Cad D4A8A0 S 1406 
Dopey family member 1 Dopey1 D3ZY24 S 1261 
Elongation factor for RNA polymerase II Ell D4A753 S 310 
Epidermal growth factor receptor pathway 
substrate 15-like 1  Eps15l1 D3ZJR1 S 255 
Epithelial protein lost in neoplasm  Lima1 F1LR10 S 225 
Eukaryotic translation initiation factor 4B  Eif4b Q5RKG9 S 459 
F-box only protein 30  Fbxo30 Q5XI67 T 385 
FAM122A Fam122a Q6AYT4 S 188 
FAS-associated factor 1  Faf1 F1LSQ0 S 22 
FCH domain only protein 2  Fcho2 D3ZYR1 S 403 
Fructose-1,6-bisphosphatase 1  Fbp1 P19112 S 353 
Glucocorticoid receptor  Gr A8IRI3 S 154 
High density lipoprotein binding protein (Vigilin)  Hdlbp Q3KRF2 S 645 
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Isoform 2 of Adenylate kinase 2, mitochondrial  Ak2 P29410-2 T 30 
Isoform 2 of Alpha-endosulfine  Ensa P60841-2 S 109 
Isoform 2 of Programmed cell death protein 4  Pdcd4 Q9JID1-2 S 313 
Kinesin family member 16B Kif16b D3ZFN9 S 662 
LOC100361087  LOC100361087 D4A2R8 S 69 
LOC100912115  LOC100912115 D3ZVL1 S 606 
Methyltransferase like 7A  Mettl7a Q3KRE2 S 218 
Nuclear receptor binding SET domain protein 1 
(Predicted), isoform CRA Nsd1 D4AA06 S 2161 
Nuclear ubiquitous casein and cyclin-dependent 
kinase substrate 1  Nucks1 Q9EPJ0 S 181 
O-phosposeryl-tRNA(Sec) selenium transferase Sepsecs B2GV97 S 469 
Optineurin Optn Q8R5M4 S 346 
Optineurin Optn Q8R5M4 S 217 
Oxidation resistance protein 1  Oxr1 Q4V8B0 S 83 
Patatin-like phospholipase domain-containing 
protein 2  Pnpla2 P0C548 S 422 
Patched domain containing 1, isoform CRA_b Ptchd1 D3ZX73 S 672 
Phosphoinositide phospholipase C  Plcg1 G3V845 S 1248 
Protein kinase C eta type (Fragment)  Prkch R9PXS6 S 196 
Protein phosphatase 1 regulatory subunit 12  Ppp1r12a D4ACS0 S 526 
Protein phosphatase 1 regulatory subunit 12  Ppp1r12a D4ACS0 S 527 
Pseudouridylate synthase 7-like Pus7l D4ABN2 S 92 
RCSD domain containing 1, isoform CRA_b Rcsd1 F1M4V3 S 53 
RGD1305117 RGD1305117 A0A059NZV6 S 173 
Rho GTPase-activating protein 25 Arhgap25 D3ZGL1 S 363 
Rhophillin, Rho GTPase binding protein 2 Rhpn2 D4A8N7 T 655 
Rhophillin, Rho GTPase binding protein 2 Rhpn2 D4A8N7 S 654 
Ribosome-binding protein 1 Rrbp1 F1M5X1 S 135 
Serine/threonine-protein kinase 24 (Fragment)  Stk24 H9KVF3 T 329 
SIK family kinase 3 Sik3 M0RD40 S 671 
Spermatogenesis-defective protein 39 homolog  Vipas39 Q5PQN6 S 119 
Sterile alpha and TIR motif containing 1 
(Predicted) Sarm1 D3ZUM2 S 572 
Sterol-4-alpha-carboxylate 3-dehydrogenase, 
decarboxylating  Nsdhl Q5PPL3 T 17 
T-complex protein 1 subunit epsilon  Cct5 Q68FQ0 S 485 
Trio and actin binding protein isoform 1a 
(Fragment)  Triobp A2TIS7 S 170 
Ubiquitin carboxyl-terminal hydrolase  Usp5 D3ZVQ0 S 785 
Ubiquitin carboxyl-terminal hydrolase 10  Usp10 Q3KR59 S 361 
Unconventional myosin-IXb  Myo9b Q63358 S 1649 
Vacuolar protein sorting 13 homolog D Vps13d D3ZKC6 S 2455 
Zero beta-globin (Fragment)  N/A Q63011 S 89 
Zinc finger protein 148  Znf148 Q62806 S 784 
Zinc finger Rab-binding domain-containing 2  Zranb2 O35986 S 290 
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In scenario 3, phosphosites are listed as insulin-resistant if their intensity at the LD decreases in intensity with insulin 
stimulation in the chow-fed group, but does not change at the LD with insulin stimulation in the HFD-fed group. AA and site 
refer to the amino acid residue and position that is phosphorylated on that protein.  
 
 
Table 3.11. List of hepatic lipid-droplet associated phosphosites in scenario 4 
Name Symbol Uniprot ID AA Site 
60S ribosomal protein L13  Rpl13 P41123 S 140 
Acyl-CoA synthetase long-chain family member 
5  Acsl5 Q6IN15 S 408 
Arginine/serine-rich protein 1  Rsrp1 Q5U2S0 S 17 
C3G protein Rapgef1 Q9QYV3 S 203 
Cullin 4A Cul4a B2RYJ3 S 10 
Deltex E3 ubiquitin ligase 3L Dtx3l D3Z8X6 S 9 
Interferon-inducible double-stranded RNA-
dependent protein kinase activator A  Prkra G3V7J2 T 20 
Lupus La protein homolog  Ssb Q66HM7 S 92 
Patatin-like phospholipase domain-containing 3 Pnpla3 D3Z9J9 S 410 
Perilipin 2 Plin2 Q5U2U5 S 253 
Perilipin 2 Plin2 Q5U2U5 S 417 
PPFIA-binding protein 2 Ppfibp2 G3V9H6 T 517 
Protein transport protein sec16 Sec16a D3ZN76 S 1311 
Pseudopodium-enriched atypical kinase 1 Peak1 D4A563 S 281 
RalBP1-associated Eps domain-containing 
protein 2 Reps2 F1M0T5 S 172 
RGD1564606 (Fragment)  RGD1564606 F1LT35 S 43 
RGD1565685  RGD1565685 B1WBZ6 T 315 
RNA polymerase II-associated protein 1  Rpap1 Q3T1I9 S 201 
Serine/threonine-protein kinase D1  Prkd1 Q9WTQ1 S 403 
Superoxide dismutase [Cu-Zn]  Sod1 Q6LDS4 S 104 
In scenario 1, phosphosites are listed as insulin-resistant if their intensity at the LD does not change with insulin stimulation 
in the chow-fed group, but decreases at the LD with insulin stimulation in the HFD-fed group. AA and site refer to the amino 
acid residue and position that is phosphorylated on that protein.  
 
 
Table 3.12. Lipolytic regulators identified as ‘insulin resistant’ 
Name Symbol Phosphosite Scenario CI vs CB  HI vs HB  
Patatin-like phospholipase 
domain-containing protein 2 PNPLA2 S422 3 ¯ n.s 
Patatin-like phospholipase 
domain-containing protein 3 PNPLA3 S410 4 n.s ¯ 
Perilipin 2 Plin2 S253 4 n.s ¯ 
Perilipin 2 Plin2 S417 4 n.s ¯ 
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3.4 Discussion 
 
LDs are dynamic and specialized organelles that govern the storage and turnover of neutral 
lipids, namely triglycerides and sterol esters, and can include retinol esters and acylceramides 
in certain cell types (Blaner et al. 2009, Senkal et al. 2017). Surrounding this lipid core is a 
monolayer of phospholipids that are decorated by a catalogue of proteins involved in traditional 
pathways such as energy metabolism (Greenberg et al. 2011, Walther and Farese 2012), and 
non-canonical processes such as viral, bacterial and parasitic propagation (Jackson et al. 2004, 
Samsa et al. 2009, Daniel et al. 2011). These non-canonical examples of LD-associated 
processes collectively highlight the diverse functions that occur at the LD. These ubiquitous 
lipid depots are conserved across nearly all organisms, including bacteria and plants, and are 
found in the majority of cell types, particularly adipose and liver (Yang et al. 2012). Research 
into the biology of LDs in a broad range of cell types has dramatically increased in the past 
decade due to its demonstrated role in the pathogenesis of obesity, NAFL, IR and associated 
cardiovascular complications (Xu et al. 2018). Proteomic analysis of LDs have identified 
hundreds to thousands of proteins localized at their surface, including enzymes involved in 
lipid metabolism, structural proteins for LD biogenesis and inter-organelle contact, and 
signalling proteins implicated in a number of diseases (Ducharme and Bickel 2008, Arrese et 
al. 2014, Lin et al. 2017, Schuldiner and Bohnert 2017). Moreover, studies have shown clear 
differences in the proteome of LDs in models of hepatic steatosis and IR compared to control 
(van Loon and Goodpaster 2006, Bostrom et al. 2007, Su et al. 2014, Khan et al. 2015). The 
aim of the experiments described in this chapter was to systematically elucidate the influence 
of acute insulin stimulation and diet on the LD proteome and phosphoproteome in order to 
unravel the actions of known candidates while also identifying novel targets in the pathogenesis 
of NAFL and IR. The key results obtained from this descriptive analysis revealed that 1) the 
abundance of neutral lipases at the LD did not differ between healthy and HFD-induced insulin 
resistant animals, but 2) the levels of the co-regulators of ATGL activity were altered in a 
manner that suggests dysregulation and increased ATGL activity in IR, and 3) did demonstrate 
a significant impairment in phosphorylation between the conditions, suggesting the importance 
of post-translational modifications in metabolic diseases. 
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3.4.1 Proteomic Characterization of LDs 
The analysis presented in the results of this chapter identified 4116 proteins associated with 
hepatic LDs across all 16 rats, many of which have been previously reported in other LD 
proteomic studies. Although it is not uncommon to identify over a thousand proteins on 
mammalian liver or even insect LDs (Khan et al. 2015, Rosch et al. 2016, Kramer et al. 2018), 
this number is generally larger than that reported by others (Zhang et al. 2011, Khor et al. 2014, 
Konige et al. 2014, Saka et al. 2015, Wang et al. 2015). This discrepancy may be due to the 
higher sensitivity of the mass spectrometer used for this study, or because of the variability in 
LD isolation protocols in the field. In particular, LDs were isolated from whole liver tissue that 
encompasses a heterogenous cell population of 80% hepatocytes and 20% vitamin A-storing 
stellate cells, macrophagic Kupffer cells and sinusoidal endothelial cells. (Damania et al. 2014). 
The proteome of LDs differ between cell types in order to cater to distinct functions of that 
cell, such as the retinol hydrolases found in LDs of hepatic stellate cells to aid in retinol 
metabolism (Molenaar et al. 2017). Further, LDs are highly gregarious organelles that form 
strong interactions with other organelles and this can contribute to contaminants that are not 
bona fide LD proteins, despite the post-isolation assessment of the purity of enriched LD 
fractions by western blot. Additionally, it is impossible to imagine that all 4115 proteins are 
found on every LD at any given time but rather populate in distinct LD populations that are 
diverse and multifunctional even within a single cell. For instance, nucleating LDs are rich in 
proteins involved in TAG synthesis such as DGAT and budding/scission such as Arf1/COP1 
(Wilfling et al. 2014). In contrast, expanding LDs contain proteins involved in fusion and pore 
formation such as Rab8 and CIDE proteins (Hashemi and Goodman 2015, Xu et al. 2016). 
Additionally, catabolic LDs associated with lysosomes or mitochondria are high in Atg7, ATP 
synthase subunits and COX proteins (Hashemi and Goodman 2015, Benador et al. 2018). As 
such, all of these proteins from distinct subpopulations are found in the LD proteome of this 
study. Thus, the dynamic nature of LDs allow them to host a large variety of proteins to 
facilitate diverse functions.   
 
3.4.1.1 Influence of HFD on LD Proteome 
High fat feeding for 4 weeks led to changes in the abundance of a number of LD-associated 
proteins, particularly the prominent LD marker in hepatocytes, PLIN2 (Itabe et al. 2017). 
Increase in the availability of lipids increased the number and size of LDs in the liver and was 
therefore associated with elevated expression of LD-associated PLIN2. This is consistent with 
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proteomic studies in hepatocytes, myoblasts and enterocytes that administered a chronic fat 
challenge rather than short-term lipid supply, as the latter is generally associated with an 
increase in PLIN3 rather than PLIN2 (Crunk et al. 2013, Beilstein et al. 2016, Chen et al. 2016). 
Additionally, several pathways that were upregulated with HFD feeding participate in TAG 
catabolism, which is consistent with previous studies reporting increased fat oxidation when 
fed a HFD (Schrauwen et al. 2000, Cole et al. 2011, Sikder et al. 2018). Amongst these 
upregulated oxidative or lipophagic proteins is PLIN5, a member of the perilipin family known 
to promote interactions between LDs and mitochondria (Bosma et al. 2012). PLIN5 is 
correlated with higher oxidation rates fueled by increased lipolysis (Bosma et al. 2012, Kimmel 
and Sztalryd 2014), consistent with studies that have demonstrated increased interorganellar 
contact related to oxidation in HFD-fed rats (Krahmer et al. 2018). While elevated availability 
of FFAs are known to promote increased fatty acid oxidation rates and increase the expression 
of proteins that facilitate oxidative phosphorylation (Schrauwen et al. 2000), it is unlikely that 
plasma FFAs are driving this change. Indeed, the rate of FA oxidation is governed by glycogen 
stores rather than lipids in hepatocytes and muscles (Randle et al. 1963) and thus a diet lacking 
in carbohydrates may boost FA oxidation and elevate oxidative phosphorylation. Therefore, at 
rest, the FAs that enter oxidation when on a HFD are likely derived from TAG stores rather 
than plasma (Schrauwen et al. 2000). The regulators that facilitate the release of TAG-derived 
FAs, such as ATGL and HSL, did not change in abundance at the LD; however, the LD protein 
CGI58 was significantly upregulated with a HFD. As described in section 1.2.3.2.2, CGI58 
binds to ATGL to promote its activation and stimulate TAG hydrolytic activity. Therefore, 
molecular interactions rather than total expression levels of lipases are regulatory drivers of 
FA release, which likely go on to act as substrates for oxidation.   
 
3.4.1.2 Influence of Insulin on LD Proteome 
Insulin primarily promotes TAG synthesis in hepatocytes while suppressing TAG lipolysis in 
adipocytes. Despite this fundamental regulatory pathway, the effect of insulin signaling on the 
LD proteome has not been explored in any other cell type. In the current study, lipolytic 
regulators such as ATGL, HSL, CGI58 and G0S2 did not change in abundance at the LD of 
livers in response to insulin stimulation in the chow-fed group. While acute stimulation is 
unlikely to be not long enough to see changes in total protein expression, it is likely that primary 
regulation of lipolytic activity is via protein-protein interactions at the LD such as that between 
ATGL and G0S2 in response to insulin (Wang et al. 2013, Zhang et al. 2016). Unexpectedly 
in this study, half the pathways enriched with insulin treatment were related to the 
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downregulation of cholesterol synthesis and lipoprotein metabolism. In particular, lanosterol 
synthase and cholestenol delta-isomerase, enzymes involved in the last step of the mevalonate 
pathway and the second last step of the Kandutsch-Russell pathway in cholesterol synthesis 
respectively, were both decreased with insulin stimulation (Sharpe and Brown 2013, Cerqueira 
et al. 2016). Similarly, proteins responsible for generating cholesteryl ester-rich lipoproteins 
from intestinal absorption of dietary substrates such as apolipoprotein A-4 and lecithin-
cholesterol acyltransferase were also downregulated with insulin (Wang et al. 2015, Zannis et 
al. 2017). Although insulin is known to decrease levels of cAMP, which in turn promotes the 
activation of cholesterol synthesis (Bathaie et al. 2017), it appears that 10 minutes was 
insufficient to see these expected physiological responses. Further, cholesterol synthesis 
traditionally occurs at the ER and thus the extent of these effects at the LD, which has a large 
pool of cholesteryl esters, is unknown. It is known that insulin’s stimulatory effect in rat 
hepatocytes takes approximately 6 hours to measure changes in the expression of the rate-
limiting enzyme, HMGCR, and roughly 24 hours to observe differences in incorporation of 
acetate into cholesterol (Wiss and Wiss 1977). It is likely that the downregulation of cholesterol 
synthesis enzymes was not reflective of the post-insulin treatment. Although not all proteins 
require such long effect times, these results present an interesting challenge in analyzing 
proteomic data in response to acute hormonal treatment.  
 
3.4.2 Phosphoproteomic Characterization of LDs 
The major mechanism that insulin utilizes to control the activity of downstream proteins is 
reversible phosphorylation. Briefly, insulin binds to its receptor on the cell surface and results 
in receptor autophosphorylation of tyrosine residues, thereby transducing the phosphorylation 
of substrates via their tyrosine kinase activity (Kruger et al. 2008). These substrates then 
activate PI3K, which initiates PKB/Akt signalling, leading to downstream phospho-stimulation 
or inhibition of metabolic pathways, such as activation of glycogen synthesis and attenuation 
of lipolysis and gluconeogenesis (Bevan 2001). In eukaryotic cells, phosphorylation most often 
occurs on the serine residue (84%), followed by threonine (15%) and tyrosine (<1%) 
(Humphrey et al. 2015), relatively similar to the proportions found in this study. Although 
protein phosphorylation is not exclusive to the insulin signalling pathway, insulin-sensitive 
phosphorylation of proteins at the LD has been largely unexplored. However, the majority of 
phosphoproteomic studies have focused on upstream effectors of insulin signalling in the whole 
cell (Kruger et al. 2008, Parker et al. 2015, Zhang et al. 2017) rather than downstream targets 
which associate with the LD. In the current study, 2141 class I phosphosites on 1362 LD-
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associated proteins were quantified from the isolated livers of all 16 rats. Over 97% of these 
phosphosites were considered novel sites in rattus norvegicus which are less characterised than 
mus musculus when it comes to proteomic and phosphoproteomic research. It is likely that the 
majority of these novel phosphosites are orthologs of phosphosites identified in mus musculus.  
The number of identified phosphosites was far greater than that reported in a previous 
phosphoproteomic study performed on LDs in HeLa cells, whereby 8 sites on 7 proteins were 
quantified after overnight oleate stimulation (Bartz et al. 2007). Of these 7 proteins, only 4 
were identified in the current study - ACC1, PLIN2, ATGL and PLA2G4A. In particular, both 
studies pinpointed the phosphorylation of ATGL on Ser422 in rat liver, otherwise known as 
Ser428 in human HeLa cells (Bartz et al. 2007), and has been identified in over 45 mass 
spectrometry studies in human, rat and mouse total lysates (Hornbeck 2015) and validated in 
mouse adipocytes (Lundby et al. 2012). In contrast, all other phosphosites were not described 
in this study, potentially due to differing phosphorylation events in response to oleate versus 
insulin treatment.  
 
3.4.3 Phospho-Proteomics and HFD-Induced Insulin Resistance 
The pathogenesis of NAFL and IR is associated with dysregulation of numerous pathways in 
the metabolism of lipids and glucose, causing major disorder in protein activity, distribution 
and intermolecular interactions. Almost 20% of proteins in hepatocytes completely shift their 
subcellular localization as a result of hepatic steatosis, which is in contrast to their behaviour 
in healthy organs (Krahmer et al. 2018). Further, 6% of proteins move away from important 
processes in other organelles and are drawn toward LDs in steatosis (Krahmer et al. 2018), 
demonstrating the importance of not only total protein abundance but protein localization as 
well. A high proportion of proteins residing on LDs were also shown to be phosphorylated or 
have uncharacterised phosphorylation sites compared to organelles such as peroxisome, Golgi 
apparatus, endosomes, lysosomes and mitochondria, despite enrichment of fewer absolute 
phosphosites (Krahmer et al. 2018). Thus, the movement and abundance of phosphorylated 
proteins suggests the importance of post-translational modifications in organelles such as LDs, 
and that steatosis could be linked to aberrant phosphorylation events. Indeed, analysis of 54 
kinase substrates in insulin-mediated pathways of adipose tissue revealed differentiated protein 
phosphorylation in patients with NAFLD, particularly those sites phosphorylated by PKCd, 
AKT and SHC (Calvert et al. 2007). In the liver, 12 phosphorylation sites were identified to 
distinguish NASH patients from those with simple steatosis (Wattacheril et al. 2017). Since the 
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hallmark feature of NAFL is the accumulation of LDs in hepatocytes, it is conceivable that 
many of these aberrant phosphorylation events occur at the LD.    
 
In the current study, many of the regulators of lipolysis that have been suggested to participate 
in the pathogenesis of NAFL, namely ATGL, HSL, CGI58 and G0S2, were not changed in 
abundance at the LD between chow and HFD-fed rats. These results are consistent with 
subcellular proteomic analysis performed by Krahmer et al. (2018), whereby canonical LD 
markers were localized to LDs independent of diet in hepatocytes. Interestingly, these lipolytic 
regulators had the greatest fold change in phosphosite intensity at the LD and revealed 
disparities between normal and ‘insulin-resistant’ states that could not be attributed to changes 
at the proteomic level. In particular, ATGL was phosphorylated on Ser422, a site which has 
not been extensively characterized despite being a known phosphosite that has been identified 
in various rat and mouse tissues (Lundby et al. 2012, Humphrey et al. 2013, Wilson-Grady et 
al. 2013). Data presented in this chapter suggest that Ser422 is an insulin-sensitive phosphosite 
that is affected by impaired insulin action in HFD-induced IR. In contrast, Ser410 on PNPLA3 
and Ser253 and Ser417 on PLIN2 are not sensitive to insulin stimulation but unexpectedly 
increase in intensity at the LD when stimulated with insulin on a HFD. Ser253 on PLIN2 has 
been previously reported (Mertins et al. 2016) but its function remains to be determined, while 
the other two phosphosites on PNPLA3 and PLIN2 are novel. PNPLA3 is one of the strongest 
candidate biomarkers for NAFL but its underlying mechanism still remains unclear (Romeo et 
al. 2008, Graff et al. 2013, Salameh et al. 2016). In the liver, PNPLA3 is a resident LD protein 
with predicted TAG hydrolase capacities. However, after generating a PNPLA3 mutant via 
substitution of methionine for isoleucine at residue 148 (I148M), the hydrolase activity was 
lost and resulted in hepatic fat accumulation (He et al. 2010). However, both gain and loss-of-
function studies revealed no change in intrahepatic TAG levels, lending to the hypothesis that 
the PNPLA3 mutant is a neomorph with new functions (Chen et al. 2010, Basantani et al. 
2011). The novel phosphosite identified on PNPLA3 in the current study may present a new 
perspective on its regulation in hepatocytes; specifically, the phosphorylation that occurs in 
HFD-induced IR. Finally, a number of lipolytic regulators increased in phosphorylation with 
HFD-feeding only and were not insulin-sensitive in either diet group. One of these regulators 
was G0S2, which was identified as a phosphoprotein for the first time in this study. The 
phosphoregulation of G0S2 is conceivable considering that ATGL, HSL and CGI58 are all 
known phosphoproteins.    
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Collectively, these results point to novel phosphosites and new perspectives on the importance 
of post-translational modifications in regulating LD proteins. Specifically, studies into the total 
expression levels of canonical LD proteins have presented contradictory results and this 
suggests the importance of alternative reversible regulation such as phosphorylation. 
Consistent with previous findings, abundance levels of key lipid regulators does not appear to 
be a key regulatory mechanism when compared to “activation” by phosphorylation, or 
translocation and protein-protein interactions that may arise from being phosphorylated. This 
study provides the first step in establishing new regulatory mechanisms for lipid metabolism 
at the LD and its role in the progression of NAFL and IR. 
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Abstract 
The liver is a critical tissue for maintaining glucose, fatty acid and cholesterol homeostasis. 
Primary hepatocytes represent the gold standard for studying the mechanisms controlling 
hepatic glucose, lipid and cholesterol metabolism in vitro. However, access to primary 
hepatocytes can be limiting and therefore other immortalized hepatocyte models are commonly 
used. Here we describe substrate metabolism of cultured AML12, IHH and PH5CH8 cells, 
hepatocellular carcinoma-derived HepG2s and primary mouse hepatocytes (PMHs) to identify 
which of these cell lines most accurately phenocopy PMH basal and insulin-stimulated 
metabolism. Insulin-stimulated glucose metabolism in PH5CH8 cells, and to a lesser extent 
AML12 cells, responded most similarly to PMH. Notably, glucose incorporation in HepG2 
cells were 14-fold greater than PMH. The differences in glucose metabolic activity were not 
explained by differential protein expression of key regulators of these pathways, for example 
glycogen synthase and glycogen content. In contrast, fatty acid metabolism in IHH cells was 
the closest to PMHs, yet insulin-responsive fatty acid metabolism in AML12 and HepG2 cells 
was most similar to PMH. Finally, incorporation of acetate into intracellular free cholesterol 
was comparable for all cells to PMH; however, insulin-stimulated glucose conversion into 
lipids and the incorporation of acetate into intracellular cholesterol esters were strikingly 
different between PMHs and all tested cell lines. In general, AML12 cells most closely 
phenocopied PMH in vitro energy metabolism. However, the cell line most representative of 
PMHs differed depending on the mode of metabolism being investigated, and so careful 
consideration is needed in model selection.  
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Abbreviations: 
ACAT1, Acetyl-CoA acetyltransferase, mitochondrial; ACC1, Acetyl-CoA carboxylase, 
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Comparative gene identification; CPT1a, Carnitine palmitoyltransferase I; DGAT, 
Diacylglycerol acyltransferase; DNL, De novo lipogenesis; FASN, Fatty acid synthase; 
FATP5, Fatty acid transport protein; G0S2, G0/G1 switch gene 2; GLUT, Glucose transporter; 
GSK3B, Glycogen synthase kinase 3 beta; HCC, Hepatocellular carcinoma; HMGCR, 3-
hydroxy-3-methyglutaryl-CoA reductase; HSL, Hormone sensitive lipase; LDL, Low-density 
lipoproteins; NAFLD, Non-alcoholic fatty liver disease; NEFA, Non-esterified fatty acids; 
PDHK1, Pyruvate dehydrogenase kinase isozyme 1; PLIN, Perilipin; PMH, Primary mouse 
hepatocytes; TAG, Triacylglycerol; TCA, Tricarboxylic acid; VLDL, Very low-density 
lipoproteins  
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INTRODUCTION 
The liver plays an essential role in substrate homeostasis and detoxification. In fact, the liver 
ensures that roughly 70 functions within 12 prime metabolic domains, including carbohydrate, 
lipid and lipoprotein metabolism, progress continuously, in periodic cycles, or upon necessity 
(2008). For example, 33% of post-prandial glucose is cleared by the liver and can be broken 
down to pyruvate via glycolysis, oxidized through the TCA cycle to produce ATP, stored as 
glycogen, or converted into fatty acids or amino acids through de novo synthetic pathways that 
use glycolytic products (Moore et al. 2012, Sharabi et al. 2015). Conversely, whole-body 
euglycemia is maintained in the fasted state by the production of glucose in the liver via 
glycogen breakdown or the synthesis of new glucose using lactate, pyruvate or other substrates 
such as amino acids from extrahepatic tissues. The liver also plays a critical role in lipid 
homeostasis. This includes the incorporation of meal-derived triacylglycerols (TAG) and 
circulating non-esterified fatty acids into intracellular TAG pools for storage in lipid droplets 
or secreted as very low-density lipoproteins (VLDL). Moreover, the liver performs 
peroxisomal and mitochondrial oxidation of fatty acids to produce ATP and ketone bodies 
which can be transported to extrahepatic tissues for energy when carbohydrates are scarce 
(Mannaerts et al. 1979). Additionally, de novo synthesized cholesterol in the liver can be 
esterified for storage in lipid droplets, packaged and secreted as LDLs, or serve as a source for 
a diverse array of cellular functions including the synthesis of bile acids, steroid hormones and 
vitamins (see review (Dietschy et al. 1993)). These pathways are regulated by a range of 
hormones, in particular insulin, which stimulates glycolysis and glycogenesis, de novo fatty 
acid and lipid synthesis and suppresses gluconeogenesis, glycogenolysis and lipolysis (Rui 
2014). 
Studying the mechanisms controlling these crucial metabolic functions of the liver, not only in 
healthy physiology but also in perturbed conditions such as obesity, insulin resistance, non-
alcoholic fatty liver disease (NAFLD) or other metabolism-linked pathologies, requires 
appropriate and robust models that closely resemble normal physiology. The gold standard 
model for studying hepatocyte biology in vitro is isolated primary human or rodent 
hepatocytes, which require access to fresh human or animal liver tissue. Despite the 
optimization of cell culture conditions, primary hepatocytes present the added challenge of 
having limited ex vivo proliferative capacities and eventually lose their hepatic phenotype 
(Ramboer et al. 2015). Consequently, many studies have used immortalized hepatocyte cell 
lines such as hepatocellular carcinoma HepG2 and Huh7 cells. While these cell lines present 
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with liver-like functions including albumin synthesis (Hosoya et al. 2014), and VLDL and 
triglyceride secretion (Clayton et al. 2005), these neoplasm-derived cells exhibit a phenotype 
closer to liver cancer than healthy primary tissue. In fact, one study reported that out of 25 
hepatocellular carcinoma cell lines, the gene expression profile of HepG2 and Huh7 cells are 
amongst the most highly correlative to primary hepatocellular carcinoma tumors (Chen et al. 
2015), re-enforcing the notion that these are ideal cells to study hepatocellular carcinoma 
biology and not normal hepatocyte biology. At present, non-cancerous hepatocyte cell lines for 
the study of hepatic metabolism are poorly characterized and are often overlooked as an 
alternative to primary cells for in vitro hepatocyte research. 
The aim of this study was to characterize glucose and lipid metabolism in a range of 
immortalized hepatocyte cell-lines to identify non-cancerous hepatocyte cells that reflect (i.e. 
phenocopy) the metabolism of primary mouse hepatocytes. This comprehensive comparison 
of in vitro hepatocyte models provides an important resource for the field of hepatocyte biology 
and pathophysiology.   
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METHODS 
Cell Culture 
AML12 and IHH cells were kindly provided by Prof Rob Parton (Institute for Molecular 
Bioscience, University of Queensland) and A/Prof Carsten Schmitz-Peiffer (Garvan Institute 
of Medical Research) respectively and cultured in Dulbecco’s Modified Eagle Medium 
supplemented with F12 (DMEM-F12; Life Tech), containing 11 mM glucose. PH5CH8 and 
HepG2 cells were kindly provided by A/Prof Susan McLennan (University of Sydney) and 
were cultured in DMEM (Life Tech), containing 5 mM glucose or 25 mM glucose respectively. 
All cell culture media were supplemented with 10% fetal calf serum (Hyclone) and 1% 
penicillin/streptomycin (Sigma-Aldrich). All cell lines were seeded at > 98% viability. 
 
Animals and primary hepatocyte isolation 
Primary hepatocytes were isolated from 8-12 week old male C57BL/6 mice which were normal 
(untransduced) controls for in vivo studies of transgene expression following administration of 
AAV vectors (approved by the University of Sydney Animal Ethics Committee under protocols 
2013/5946 and 2017/1253). Hepatocytes which were surplus to need for the gene expression 
studies were made available immediately following isolation. Mice were not fasted prior to 
hepatocyte isolations which were performed between 9 and 11 am. Groups of 5 mice were 
maintained on a standard 12 hour light-dark cycle in individually-ventilated cages (Tecniplast) 
with autoclaved 1/8-inch corn-cob bedding (Andersons Lab Bedding, Maumee, OH), crinkled 
paper nesting material and red perspex domes, cardboard tubes, and aspen wood blocks (Able 
Scientific, Perth, Australia) as enrichment. They had access to standard rodent chow (irradiated 
rat and mouse diet, Specialty Feeds, Glen Forrest, Australia), and water ad libitum. 
Midline laparotomy was performed under anesthesia and the IVC identified. A 22G cannula 
was introduced distal to the renal bifurcation and secured using a 5-0 silk tie. Retrograde 
perfusion of the liver was achieved via the IVC cannula. The hepatic portal vein was transected 
to allow outflow of perfusate. The liver was sequentially perfused with the following solutions 
at a flow rate of 5 ml/min (administered using a Masterflex L/S 7528-30, Thermo Fisher 
Scientific, USA); firstly with 25 ml of Hanks’ Balanced Salt Solution (HBSS, Lonza, USA), 
then with 25 ml of HBSS with 0.5 mM EDTA (Sigma-Aldrich, USA), followed by 25 ml of 
HBSS and finally with 25 ml of HBSS plus 5mM CaCl2 (Sigma-Aldrich, USA) and 0.05% of 
collagenase Type IV (Gibco, USA). All solutions were warmed to 37°C. The gall bladder was 
removed and discarded. Lobes of the liver were collected taking care to avoid damage and 
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transferred into a Petri dish containing RPMI 1640 medium (Lonza) with 2% FCS 
(RPMI/FCS2) at 4°C and gently agitated to disperse the hepatocytes. The hepatocyte slurry 
was transferred to a 50 ml conical tube and washed with RPMI/FCS2 by centrifugation at 50 x 
g for 3 minutes. The hepatocyte pellet was gently resuspended in 15 ml PBS at room 
temperature, then 9 ml of isotonic Percoll PLUS (GE Healthcare Life Sciences, Australia) 
added and mixed. The mixture was centrifuged at 500 x g for 15 minutes at room temperature 
with no brake. Debris and excess solution were aspirated, and the hepatocyte pellet washed 
twice as above. Viable hepatocytes were resuspended in RPMI containing 10% FCS and 
counted on a hemocytometer using Trypan Blue exclusion. Cells were then seeded with 
DMEM plating media supplemented with F12 and containing 5 mM glucose, 10% fetal calf 
serum, 1% penicillin/streptomycin (P/S), 400 nM dexamethasone, 100 nM insulin and 1.5 nM 
epidermal growth factor (Turpin et al. 2011). 
 
Lipid Loading  
Cells were incubated in DMEM containing 5 mM of glucose supplemented with 1% P/S and 
10% FBS with the addition of 0, 150, 300 or 450 µM of oleate or a lipid mixture of 
palmitate:oleate:linoleate (1:2:1 v/v/v) for 24 h.  
 
Insulin Stimulation  
Immunoblots: Cells were serum-starved for 2 h in DMEM containing 5 mM glucose 
supplemented with 1% P/S and 0.2% BSA then replaced with fresh serum-free medium 
containing 0 and 100 nM of insulin and incubated for 20 min.  
Glucose production: Cells were serum-starved for 2 h in DMEM containing 5 mM glucose 
supplemented with 1% P/S and 0.2% BSA then replaced with Krebs buffer (Fazakerley et al. 
2015) supplemented with 1 mM CaCl2, 20 mM sodium lactate, 2 mM sodium pyruvate and 
increasing doses of insulin (0, 0.1, 1 nM) incubated for 2 h.  
 
Fatty Acid and Glucose Metabolism 
Cells were incubated in low glucose (5.5 mM) DMEM medium consisting of 0.5 mM oleate, 
1 mM carnitine, 2% BSA, 0.5 µCi/ml [1-14C]-oleate or 0.2 µCi/ml [U-14C]-glucose (Perkin 
Elmer) with or without 100 nM insulin and incubated for 4 h. Fatty acid and glucose oxidation 
was determined by measuring 14CO2 in half of the culture media by the addition of an equal 
volume of 1 M perchloric acid and liberated 14CO2 trapped in 1 N sodium hydroxide. 
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Cells were harvested in PBS to determine [1-14C]-oleate or [U-14C]-glucose incorporation into 
complex lipids using a Folch extraction of cellular lipids (Folch et al. 1957). 14C activity in the 
upper aqueous phase was defined as acid soluble metabolites. Secreted TAG into the media 
was determined using a Folch extraction of the remaining half of the media. Intracellular and 
extracellular (media) lipids were resuspended in chloroform:methanol (2:1), spiked with 
glycerol tripalmitin (Sigma) and separated by TLC using hexane:isopropyl ether:acetic acid 
(60:40:3 v/v/v) as the developing solvent. 14C activity in the TAG bands determined by liquid 
scintillation counting. Fatty acid uptake was defined as the sum of total lipid synthesis (14C 
activity in the organic phase following Folch extraction), oxidation, acid soluble metabolites, 
and extracellular TAG synthesis. Total 14C-glucose incorporation was defined as the sum of 
14C activity in aqueous and organic phases following a Folch extraction of cell lysates and 
oxidation. 
 
Glycogen Synthesis and Quantification 
Cells were scraped and lysed in 1M KOH and heated to 65°C for 30 min. Lysates were then 
diluted in saturated Na2SO4 and absolute ethanol followed by centrifugation at 15,000 g for 15 
minutes at 4°C. The supernatant was discarded and the pellet was resuspended in water 
followed by 95% ethanol. Supernatant was discarded once more and the glycogen pellet 
digested with amyloglucosidase (Sigma A1602) at 37°C in 1 ml of 0.25 M acetate buffer. After 
overnight incubation, samples were vortexed and a glucose assay performed or the [U-14C]-
glucose incorporated into glycogen determined. 
 
Glycogenolysis 
Cells were seeded in high glucose (25 mM) DMEM medium to promote maximum glycogen 
storage. After 24 hours, cells were incubated in 0.5 ml of phosphate buffered saline (Astral 
Scientific) without or with 10 µg/ml glucagon (Sigma Aldrich) for 1 hour and harvested in 300 
µl of KOH (Farghali et al. 2008). Glycogenolysis was determined by extracting glycogen from 
lysates and performing a glucose assay on extracted samples. 
 
Biochemical Measures 
Cell triacylglycerols and cholesterol were extracted using a Folch extraction (Folch et al. 1957) 
and quantified using an enzymatic colorimetric method for TAG (GPO-PAP reagent, Roche 
Diagnostics) or fluorometric method for cholesterol (Amplex Red Cholesterol, Thermo 
Fisher).  Cell protein content was determined using Pierce Micro BCA protein assay (Thermo 
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Fisher Scientific). Media glucose levels and cell glucosyl units from glycogen quantified using 
the HK glucose assay (Sigma GAHK20). 
 
Cholesterol Synthesis 
Cells were incubated in medium containing 0.5 mM oleate, 1 mM carnitine, 0.2% BSA, 0.2 
µCi/ml [1-14C]-acetate with or without 100 nM insulin and incubated for 2 h. Cell lysates and 
media samples were exposed to chloroform: methanol (2:1) as described above to extract lipids 
and resuspended in chloroform: methanol (2:1) spiked with cholesterol (Sigma) and cholesteryl 
oleate (Sigma). Fractions were separated by TLC in a solvent system of chloroform: methanol: 
water (60:30:5, v/v/v) to 30% of the plate, followed by diethyl ether: benzene: ethanol: acetic 
acid (40:50:2:0.2, v/v/v/v) to 60% of the plate, and hexane: diethyl ether: acetic acid (80:20:1.5, 
v/v/v) to 90% of the plate. 14C activity in the cholesterol and cholesterol ester bands determined 
by liquid scintillation counting. 
 
Western Blot Analysis 
Cells were scraped, homogenized in RIPA lysis buffer (65 mM Tris, 150 mM NaCl, 5 mM 
EDTA, 1% NP-40, 0.5% Na-Deoxycholate, 0.1% SDS, 10% glycerol, 1M DTT, protease and 
phosphatase inhibitors) lysed using a 29G syringe and centrifuged at 15,000 g for 15 minutes. 
Equal amounts of solubilized proteins were loaded on 10% SDS-PAGE gels and transferred 
onto polyvinylidene fluoride membranes (Merck) Membranes were incubated at room 
temperature for 1 h with blocking buffer (TBS, PHM 4.5, with 0.1% Tween 20 (TBST) and 
3% nonfat milk or BSA). Membranes were incubated overnight at 4°C with a specific primary 
antibody in TBST and 3% BSA. Antibodies used were as follows: pY1162/3-insulin receptor 
(1:1000, 44804G, Invitrogen), insulin receptor β (1:1000, 3025S, CST), pS473-AKT (1:1000, 
9271, CST), AKT (1:1000, 4685S, CST), pS256-FOXO1 (1:1000, 9461, CST), FOXO1 
(1:1000, 2880, CST), pS9-GSK3β (1:1000, 9323S, CST), GSK3β (1:1000, 9315S, CST), GS 
(1:1000, 3893S, CST), GLUT1 (1:1000, kindly gifted by Prof. David James, University of 
Sydney), GLUT2 (1:1000, 400061, Merck), Mitomix (1:500, ab110413, Mitosciences), 
PDHK1 (1:1000, 3820S, CST), ATGL (1:1000, 2138S, CST), HSL (1:1000, 4107S, CST), 
CD36 (1:1000, 14347, CST), CPT1α (1:1000, ab128568, Abcam), DGAT1 (1:1000, ab54037, 
Abcam), DGAT2 (1:1000, ab59493, Abcam), SLC27A5 (1:1000, HPA007292, Sigma), FASN 
(1:1000, 3180, CST), ACC1 (1:1000, 3676, CST), HMGCR (1:1000, PA5-37367, Thermo 
Fisher Scientific), ACAT1 (1:1000, SC-69836, Santa Cruz Biotechnology) GAPDH (1:1000, 
2118S, CST). Subsequently, membranes were incubated with secondary HRP-coupled 
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antibodies (CST). Membranes were washed again for 1 h and incubated with enhanced 
chemiluminescence reagent (Merck) for 1 min prior to visualization using the ChemiDoc 
System. Data was analyzed using the ImageLab 5.2 version software (Bio-Rad Laboratories, 
Hercules, USA).  
 
Statistical Analysis 
All statistical analyses were performed using GraphPad Prism 6.0 for Mac or 7.02 for PC 
(GraphPad Software Inc., San Diego, CA). Differences among groups were assessed with 
appropriate statistical tests noted in figure legends. P < 0.05 was considered significant.  Data 
are presented as mean + SEM.  
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RESULTS 
Hepatocyte Glucose Storage 
The liver is a critical regulator of glucose homeostasis. In particular, liver glycogen is a major 
contributor to the maintenance of euglycemia during fasting and exercise, and depletion of this 
pool is associated with the onset of exercise-induced fatigue (Baldwin et al. 1975). Firstly, we 
measured basal glycogen levels in primary mouse hepatocytes (PMH) and compared these 
levels to non-carcinoma hepatocyte cells (AML12, IHH, PH5CH8) and the widely used HepG2 
cells (Table 1). PH5CH8 and HepG2 had similar levels of glycogen compared to PMH (Figure 
1A). Insulin stimulation for 4 h increased glycogen content in all hepatocytes except IHH 
(P=0.1) and HepG2 cells (Figure 1A). The differences in basal glycogen content did not 
correlate with glycogen synthase protein levels (Figure 1B; R2=0.009, P=0.5) or protein levels 
of insulin receptor β (Figure 1C). However, insulin-stimulated increases in glycogen content 
correlated with the change in Akt phosphorylation (i.e. no change in HepG2) in response to 
insulin, although this was not the case for phosphorylation of the insulin receptor β, and Akt 
substrates FOXO1 or GSK3β (Figure 1C). 
Hepatocyte Glucose Utilization 
Next, we assessed the cellular fate of extracellular 14C-glucose to determine whether 
differences in glycogen content were explained by variances in intracellular handling of 
extracellular glucose in the basal and insulin stimulated states. Total 14C-glucose incorporation 
was defined as the sum of 14C activity in aqueous and organic phases following a Folch 
extraction of cell lysates and 14CO2 generated, although this did not account for labeled glucose 
secreted back into the media. IHH and PH5CH8 cells had the same basal rates of glucose 
incorporation compared to PMH, whilst AML12 cells had very low basal glucose incorporation 
rate (P=0.99 by two-way ANOVA followed by Tukey’s Multiple Comparisons test; P<0.0001 
by unpaired Student’s t-test vs PH; Figure 1D). Most strikingly and as expected, glucose 
incorporation in the hepatocellular carcinoma HepG2 cells was 14-fold greater compared to 
PMH. HepG2 cells were also the only cells to increase glucose incorporation in response to 
insulin stimulation (Figure 1D). GLUT1 and GLUT2 protein levels did not correlate with 
glucose incorporation (Figure 1E). 
We then examined whether the discrepancies between glucose incorporation and glycogen 
content was associated with glucose oxidation rates. AML12 and HepG2 cells had lower basal 
glucose oxidation rates, whilst IHH had higher rates, compared to PMH (Figure 1F). Only 
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PMH responded to insulin stimulation to increase glucose oxidation although AML12 cells 
showed a strong trend for an increase (P=0.08 by two-way ANOVA followed by Tukey’s 
Multiple Comparisons test, P<0.0001 Student’s t-test; Figure 1F). The differences in glucose 
oxidation were inversely associated with pyruvate dehydrogenase kinase 1 (PDHK1) protein 
levels (Figure 1G; R2=0.42, P<0.0001), which phosphorylates pyruvate dehydrogenase to 
inhibit its activity and thereby reduce glucose oxidation rates. However, glucose oxidation rates 
did not associate with protein levels of subunits of the mitochondrial electron transport 
complexes (Figure 1H).  
Hepatocyte Glucose Output 
Hepatocytes are the primary cell population that generates glucose from a range of 
gluconeogenic substrates including pyruvate and lactate. PMH had greater glucose production 
in basal conditions compared to the other cell lines (Figure 2A) and were the only cell type to 
show dose-dependent decreases in absolute glucose production with increasing concentrations 
of insulin (Figure 2A). However, when normalized to basal, all cells exhibited a ~20-30% 
decrease in glucose production with 1 nM of insulin (Figure 2B), including AML12 cells 
(P=0.44 by two-way ANOVA followed by Tukey’s Multiple Comparisons test, P<0.001 by 
one-way ANOVA followed by Tukey’s Multiple Comparisons test for individual cells; data 
not shown). 
During times of fasting, hepatocytes respond to glucagon stimulation to mobilize glucose from 
glycogen stores. PMH, AML12 and PH5CH8 cells had lower glycogen levels following 
glucagon stimulation whilst IHH and HepG2 cells did not (Figure 2C). Collectively, these 
measures of glucose metabolism highlight striking differences between the range of hepatocyte 
cells assessed, with no single immortalized cell line resembling PMH in basal conditions. 
However, PH5CH8 cells, followed by AML12 cells, most closely phenocopied PMH in terms 
of basal and insulin-stimulated changes in glycogen content, glucose incorporation , glucose 
oxidation and glycogenolysis. In particular, HepG2 cells exhibited classical Warburg 
metabolism with increased glucose incorporation and no compensatory increase in oxidation 
and have basal and insulin stimulated glucose metabolism that is different to PMH. 
Hepatocyte Fatty Acid Uptake & Storage 
The liver is a critical regulator of whole-body lipid homeostasis, in particular fatty acid-based 
complex lipids (i.e. TAG). Basal stores of intracellular TAGs in IHH and HepG2 cells were 
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similar to PMH, whilst PH5CH8 and AML12 cells TAG stores were 4-fold and 9-fold greater 
than PMH, respectively (Figure 3A).  
Dietary fatty acids contained in TAG and adipose tissue-derived non-esterified fatty acids are 
the main sources for TAG pools in the liver. In fact, ~60% of hepatic TAG is derived via fatty 
acid uptake in humans with metabolic disorders such as NAFLD (Donnelly et al. 2005). In this 
study, we defined fatty acid uptake as the sum of 14C activity in total stored lipids, extracellular 
TAG, acid soluble metabolites and CO2. AML12 and HepG2 cells had a similar rate of fatty 
acid uptake compared to PMH, whilst IHH and PH5CH8 cells had significantly lower rates 
(Figure 3B). The rate of uptake did not correlate with the expression of key fatty acid transport 
protein FATP5 (R2=0.02, P=0.3) but were somewhat explained by CD36 levels in all cells 
except IHH (Figure 3C). Only PMH and HepG2 cells were able to increase fatty acid uptake 
with acute insulin stimulation (Figure 3B). 
Hepatocyte Fatty Acid Utilization 
In the liver, fatty acids are esterified and stored as TAG in lipid droplets. PMH had the highest 
rate of fatty acid esterification as complex lipids compared to the other cells, with IHH cells 
having relatively very low rates (Figure 3D). The vast majority of extracellular oleate was 
stored as TAG, specifically ~70% in PMH and ~45% on average for the other cells (Figure 
3D). Insulin stimulation increased the rate of extracellular oleate stored as complex lipids in 
PMH, AML12 and HepG2 cells (Figure 3D). Newly synthesized TAG can also be secreted as 
very-low density lipoproteins for distribution to extrahepatic tissues. The basal incorporation 
of extracellular oleate into secreted TAG was much greater in AML12 and HepG2 compared 
to PMH (Figure 3E). As expected, 4 h insulin stimulation suppressed TAG secretion in AML12 
and HepG2 cells, as well as PMH (P>0.99 by two-way ANOVA followed by Tukey’s Multiple 
Comparisons test, P=0.01 Student’s t-test). However, this effect was not observed in IHH and 
PH5CH8 cells (Figure 3E). TAG synthesis somewhat correlated with DGAT1 but not DGAT2 
protein levels (Figure 3F; DGAT1: R2=0.19, P=0.004). Specifically, high TAG secretion in 
AML12 cells relative to PMH corresponded with increased expression of DGAT2 and 
decreased expression of DGAT1 (Figure 3F). While DGAT1 and DGAT2 are primarily 
responsible for TAG anabolism, the lipolytic enzymes ATGL and HSL are crucial regulators 
of TAG catabolism (Ong et al. 2011). AML12 cells had greater protein levels of ATGL 
compared to PMH, whilst all cells had lower levels of HSL protein compared to PMH (Figure 
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3G). These patterns did not correlate with basal TAG levels (Figure 3A) or with the rate of 
oleate incorporation into intracellular TAG (Figure 3D). 
PMH had the greatest rate of extracellular-derived fatty acid oxidation compared to the other 
cells (Figure 3H). HepG2 cells had the lowest basal fatty acid oxidation rate, which was ~2% 
of basal fatty acid oxidation rate of PMH, potentially due to the higher rates of glucose 
incorporation (Figure 1F). These rates did not align with the expression of CPT1a protein levels 
(Figure 3I). As expected, insulin suppressed fatty acid oxidation in PMH; however, this effect 
was not observed in the other cell lines (Figure 3H).  
We further examined fatty acid metabolism by fatty acid handling of cells by determining the 
relative distribution of extracellular-derived fatty acids into oxidation, intracellular 
esterification into total lipids and extracellular TAG pools. Despite having the lowest absolute 
rates of fatty acid uptake and metabolism (Figure 3B, D, E, H), IHH cells were most similar to 
PMH in terms of fatty acid handling (Figure 3J). In contrast, AML12 and HepG2 cells 
predominantly partitioned fatty acids into TAG that was secreted into the media, whereas 
PH5CH8 cells partitioned fatty acids into intracellular storage (Figure 3J). 
We next assessed the response of hepatocytes to varying concentrations of oleate and a 
physiologically relevant FA mixture. All immortalized cell lines accumulated TAG in a dose-
dependent manner significantly more than PMH, with PH5CH8 and AML12 cells increasing 
TAG levels the greatest (Figure 4A). When the media was supplemented with the fatty acid 
mixture of 1:2:1 palmitate:oleate:linoleate, representing the predominant fatty acid species in 
human plasma (Bondia-Pons et al. 2007, Quehenberger et al. 2010), AML12 cells stored almost 
4 times as much TAG than other hepatocytes, while TAG levels in IHH cells dropped (Figure 
4B) due to the toxicity of the FA mixture (data not shown, visual inspection by microscopy). 
Interestingly, IHH and HepG2 cells had the greatest fold-change in TAG content with 
increasing concentrations of oleate after accounting for differences in the basal levels (Figure 
4C), whereas PH5CH8 and HepG2 cells showed the greatest fold-change when exposed to FA 
mixture (Figure 4D). Only PMH had a similar increase in TAG levels when cultured in media 
supplemented with either oleate or the fatty acid mixture (Figure 4E-I). The differences in the 
ability of cells to accumulate extracellular fatty acids into intracellular TAG was correlated 
with the protein levels of DGAT1 and DGAT2 (Figure 3F), but not ATGL and HSL (Figure 
3G).  
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Hepatocyte de novo Lipid Synthesis 
The liver is a major lipogenic tissue converting excess glucose carbons (and other non-lipid 
nutrients) into lipids for long-term storage. The basal rate of glucose incorporation into 
intracellular lipids was lower in AML12, PH5CH8 and HepG2 cells but higher in IHH cells 
compared to PMH (Figure 5A). Only PMH increased the rate of glucose conversion into lipids 
in response to insulin stimulation (Figure 5A). Similar patterns were observed when assessing 
the incorporation of glucose into intracellular TAG (Figure 5A). We also observed cell-specific 
differences in the rate of the incorporation of glucose into TAG secreted into the media. 
Specifically, IHH and PH5CH8 cells had greater rates, whilst AML12 and HepG2 cells were 
not different from PMH (Figure 5B). Interestingly, insulin stimulation did not alter this pattern 
(Figure 5B), although PH5CH8 cells showed a strong trend for an increase in glucose into 
secreted TAG (P=0.058). These measures of de novo lipid synthesis did not correlate with the 
protein levels of the key enzymes, FASN and ACC1 (Figure 5C).  
Hepatocyte Cholesterol Metabolism 
Cholesterol homeostasis is tightly controlled by the liver both in terms of both synthesis and 
excretion as bile. AML12, IHH and HepG2 cells had similar basal levels of intracellular 
cholesterol as PMH, while PH5CH8 had higher levels (Figure 6A). All hepatocytes except for 
IHH cells had similar levels of cholesterol ester (Figure 6A). Basal rates of cholesterol 
synthesis from acetate that was incorporated into membranes as free cholesterol was similar 
for AML12, IHH and PH5CH8 cells (Figure 6B), whilst the rate of newly synthesized 
cholesterol that was exported into the media was greater in IHH, PH5CH8 and HepG2 cells 
compared to PMH (Figure 6C). The rate of cholesterol synthesis did not correlate with HMG-
CoA reductase protein levels (Figure 6D). PMH incorporated newly synthesized cholesterol 
into intracellular cholesterol esters at greater rates than the 4 immortalized cell lines (Figure 
6B) but the rate of incorporation into cholesterol esters that were exported into the media was 
similar between PMH and AML12, IHH and HepG2 cells (Figure 6C). Cholesterol ester 
synthesis is catalyzed by ACAT1 and PMHs had the highest protein levels compared to the 
cell lines (Figure 6D).  
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DISCUSSION  
The liver plays a vital role in nutrient homeostasis and dysregulation of hepatic metabolic 
pathways are central to many pathologies including NAFLD, HCC and type 2 diabetes. The 
aim of this study was to identify non-malignant hepatocyte cell lines that most closely 
recapitulates the metabolic activities of PMH. Here, we present data on the metabolism of 
glucose, fatty acids and cholesterol, and protein levels of key regulators of these pathways in 
normal hepatocyte cell lines and compared them to PMH and the commonly used 
hepatocellular carcinoma HepG2 cells. Overall, no one cell line resembled the glucose, fatty 
acid and cholesterol metabolic pathways of PMH. However, in general, the normal hepatocyte 
cell lines more closely phenocopy PMH than the widely used HepG2 cells, specifically, the 
basal and insulin-stimulated glucose storage, uptake oxidation and production of PH5CH8 and 
AML12 cells (Table 1 and 2). Insulin-stimulated oleate uptake and esterification into 
intracellular TAG and suppression of lipid secretion in AML12 and HepG2 cells were very 
similar to PMH (Table 2). Collectively, these observations highlight striking heterogeneity in 
the nutrient metabolism in a range of hepatocyte cells that was not accounted for by differences 
in the protein expression of key regulators of these diverse pathways and that choice of cell 
line is vital if using these cell lines as a surrogate for PMHs. 
 
HepG2 cells are one of the most prevalent cell lines used to investigate hepatocyte metabolism 
and broader aspects of hepatocyte biology. Our data suggest that, in most instances, HepG2 
cells do not represent a good model for PMH metabolism. Here, we observed striking 
differences in glucose incorporation rates in HepG2 cells that were 14-fold greater compared 
to PMH and the other cell lines (Figure 1D), which correlated with GLUT2 protein levels. This 
is in line with the use of fluorodeoxyglucose in positron emission tomography for the diagnosis 
of HCC (Haug 2017). HepG2 cells also had the lowest rate of fatty acid oxidation (Figure 2H) 
and somewhat surprisingly reduced de novo lipogenesis as measured by the conversion of 
glucose into lipids (Figure 5A), despite having the highest protein levels of ACC1 (Figure 5C), 
which has been previously reported (Nelson et al. 2017). These differences are likely driven 
by the unsurprising close resemblance of HepG2 cells to primary hepatocellular carcinoma 
(HCC) samples (Chen et al. 2015). Specifically, the authors compared over 1000 cancer cell 
lines, including 25 HCC cell lines, to 200 HCC tumor samples, and HepG2 cells were one of 
the top HCC cell lines where gene expression highly correlated with that in primary tumors 
(Chen et al. 2015). More recently, correlations between HepG2, Hep3B and Huh7 cell lines 
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and human liver; hierarchical cluster analysis and principle component analysis all identified 
dramatic differences in the microsomal proteome (12). Collectively, these results demonstrate 
that HepG2 cell metabolism is strikingly different to that of non-malignant hepatocyte lines 
and PMH, and therefore caution is required in the extrapolation of metabolic activity observed 
in HepG2 cells to normal hepatocyte metabolism; however, they remain an obvious, and 
appropriate, choice for analyzing HCC biology.  
 
The tight regulation of glucose levels by the liver is crucial in preventing the pathogenic 
mechanisms underlying chronic diseases such as type 2 diabetes and NAFLD. While multiple 
glucose-increasing hormones exist, insulin is the only known hormone to lower blood glucose 
levels and activate glucose-utilizing pathways. The liver is regulated by insulin in a number of 
cell autonomous actions, such as the direct insulin signaling required for lipogenesis, as well 
as non-cell autonomous actions, such as the indirect suppression of glucose production by 
reducing adipose-derived NEFA (Titchenell et al. 2016). These in vitro models are invaluable 
in teasing apart these indirect and direct effects that are usually interwoven in whole animal 
studies. In this study, PMH and the 3 normal hepatocyte cells exhibited insulin-independent 
glucose incorporation as expected. The protein levels of the glucose transporter GLUT2, which 
is not insulin-sensitive (Fukumoto et al. 1988, Gould et al. 1991), were detectable in all 3 
normal hepatic cell lines but PMH had very low levels of GLUT2 protein expression, likely 
due to downregulation of GLUT2 mRNA which occurs during the first 24 hours of primary 
hepatocyte culturing (Kim and Ahn 1998). Further, insulin increased glycogen levels in PMH 
and the 3 normal hepatocyte cell lines, which was associated with increased phosphorylation 
of GSK3β (Figure 1C). The phosphorylation of GSK3β reduces its kinase activity, leading to 
increased glycogen synthase activity (Peak et al. 1998). 
 
Insulin plays a critical role in the liver by suppressing gluconeogenesis; an important 
characteristic when defining insulin resistant hepatic models (Mortimore 1963, Edgerton et al. 
2017). In this study, PMH had a ~30% decrease in glucose production with 1 nM insulin 
treatment similar to that of IHH, PH5CH8 and HepG2 cells. Interestingly, human and mouse 
hepatocarcinoma cells are reported to have a loss of gluconeogenic capabilities due to 
decreased PEPCK and G6Pase enzymes as a consequence of abnormal regulation of 11β-
HSD1/11β-HSD2 (Ma et al. 2013). It is possible that this discrepancy is due to differences 
between glucocorticoid- versus insulin-regulated gluconeogenesis, rather than glucose 
production capacities as a whole (Ma et al. 2013). Overall, PH5CH8 cells, followed by AML12 
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cells, present themselves as the best model to use to model hepatic basal and insulin-stimulated 
glucose metabolism in the non-disease state. While elevated blood glucose levels are the 
primary sign of insulin resistance and type 2 diabetes, increased levels of triglycerides have 
become a well-established hallmark amongst these patients as well, demonstrating the link 
between glucose and lipid metabolism (Nikkila 1974, Greenfield et al. 1982, Dunn 1990). 
When glucose is abundant, insulin promotes the conversion of glycolytic substrates into fatty 
acids in a process known as de novo lipogenesis (DNL) (De Freitas and Depocas 1965). While 
none of the cell lines exhibited an insulin-stimulated increase in DNL as consistently as PMH, 
PH5CH8 cells showed a strong trend for increased incorporation of radiolabeled glucose into 
all lipids, but not TAG specifically, after acute insulin treatment. The availability of acetyl-
CoA as a lipogenic precursor appears to explain the differences in DNL rates better than the 
availability of catalytic DNL enzymes FASN and ACC1 in these cells, likely due to the central 
role that PDHK1 plays in metabolic flexibility between oxidation and biosynthesis (Strumilo 
2005, Zhang et al. 2014). Apart from changes in DNL, uptake of fatty acids in excess of 
metabolic requirements is a common precursor to obesity, NAFLD and type 2 diabetes. Fatty 
acid uptake from either dietary fat or adipose tissue lipolysis occurs mainly through CD36 or 
FATP5 proteins at the cell membrane (Febbraio et al. 1999, Doege et al. 2006). All cell lines 
had relatively low rates of oleate uptake and only HepG2 cells managed to exhibit insulin-
stimulated increases. Variance in intracellular esterification between cell lines was largely 
reflected by the differences in oleate uptake, and therefore AML12 and HepG2 cells exhibited 
the closest phenotype to primary cells. Although compensatory roles for triglyceride synthesis 
by DGAT1 and DGAT2 have previously been shown, their products have different preferential 
pathways. DGAT1 is primarily involved in the re-esterification of lipolysis-derived DAG to 
ultimately support VLDL maturation, whereas triglycerides generated by DGAT2 are 
preferentially used for fatty acid oxidation (Li et al. 2015). Similarly in this study, lower levels 
of DGAT2 in PMH occur alongside increased fatty acid oxidation, whereas the lower levels of 
DGAT1 in AML12 cells correlated with greater TAG storage and secretion than other cell lines 
(Li et al. 2015). Collectively, AML12 cells and HepG2 cells, exemplify normal fatty acid 
metabolism in hepatocytes and closely resemble that of PMH.  
 
Finally, the liver is the central organ involved in maintaining cholesterol homeostasis. In this 
study, all hepatocytes had similar intracellular free cholesterol content and synthesis rates from 
acetate, most likely attributed to the comparable protein expression of the rate-limiting 
cholesterol synthesis enzyme, HMGCR. Interestingly, the ratio between HMGCR and ACAT1 
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appears to explain the variability in the proportion and synthesis of cholesterol ester within the 
total cholesterol pool better than the expression of either protein alone, or by HSL protein 
expression. For example, PMHs had greater ACAT1 to HMGCR protein expression and this 
is reflected in the ~20-fold increase in the rate of conversion of acetate into cholesterol ester, 
compared to free cholesterol. Conversely, free cholesterol in IHH cells was ~97% of the total 
cholesterol pool compared to 70% in PMHs. This is supported by the increased HMGCR to 
ACAT1 protein expression in these cells. Strikingly, PMHs preferentially secreted cholesterol 
ester and TAG rather than storing them, which none of the immortalized cell lines phenocopied.  
A general limitation of correlating metabolic flux with protein expression data is the disregard 
of the complexity of enzyme regulation in metabolic studies. Although the central dogma of 
biology is to link protein abundance with enzyme activity and function, there are numerous 
processes beyond absolute protein concentration that contribute to establishing the activity 
level of a protein (Liu et al. 2016). These include 1) allosteric modulation, such as the careful 
balance between activator CGI-58 and inhibitor G0S2 in regulating ATGL lipase activity (Lu 
et al. 2010), 2) modulation of a protein’s half-life, like the rapid ER-associated proteasomal 
degradation of HMGCR (Jo and Debose-Boyd 2010), 3) protein translocation, such as the 
PLIN-mediated HSL translocation from the cytosol to lipid droplets for maximal lipolytic 
activity (Sztalryd et al. 2003), 4) post-translational modifications, like the 6 different types of 
modifications affecting CD36 stability and intracellular trafficking (Lauzier et al. 2011, Luiken 
et al. 2016), and 5) compensatory mechanisms, such as the numerous other flux-controlling 
points beyond HMGCR in the cholesterol synthesis pathway (Tsai et al. 2012, Sharpe and 
Brown 2013). Therefore, caution is required when interpreting basal levels of protein 
abundance of key regulators of metabolic pathways. A potential technical limitation of our 
protein expression analysis is difference in antibody avidity or affinity. To the best of our 
knowledge, the antibodies we selected were raised against sequences that are conserved in both 
human and mouse.  
 
In conclusion, we reveal that no single immortalized hepatocyte cell line broadly resembled 
isolated PMH in terms of glucose, fatty acid and cholesterol metabolism in the basal or insulin-
stimulated states (Table 2 and 3). Our results indicate that PH5CH8 or AML12 cells most 
closely exemplify basal and insulin-stimulated glucose metabolism of PMH, whereas AML12 
cells most closely approximates basal and insulin-stimulated lipid metabolism in PMHs (Table 
4). As such, our study can assist in making an appropriate choice of in vitro models for distinct 
hepatocyte substrate metabolism studies. It remains to be determined how these particular cell 
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lines correlate with other aspects of hepatocyte biology and what are the factors, beyond protein 
levels of rate limiting enzymes, that underpin the metabolic pleomorphism exhibited by these 
hepatocytes. Overall, this study has improved our understanding of the similarities and 
differences between the substrate metabolism of PMH, the commonly used hepatoma cell line 
HepG2 and non-malignant hepatocyte cell lines, of importance when developing 
physiologically relevant in vitro models of liver pathologies such as NAFLD. This study 
comprehensively examined key metabolic pathways of glucose, fatty acid and cholesterol 
metabolism, providing a valuable resource for selecting hepatic cell lines that are most relevant 
to mimic a specific metabolic phenotype in liver models.   
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TABLE 1. HEPATOCYTE CHARACTERISTICS 
 Primary 
Hepatocytes 
(C57BL/6) 
AML12 
(Wu et al. 
1994) 
IHH  
(Schippers et 
al. 1997) 
PH5CH8 
(Noguchi 
and 
Hirohashi 
1996) 
HepG2  
(Knowles and 
Aden 1983) 
Organism Mus musculus Mus 
musculus 
Homo sapiens Homo 
sapiens 
Homo sapiens 
Tissue Liver Liver Liver Liver Liver 
Disease:  None None None None Hepatocellular 
carcinoma 
Age: 8-12 weeks 3 months 59 years 58 years 15 years 
Gender: Male Male Male Male Male 
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TABLE 2. DENSITOMETRIC QUANTITATION OF PROTEIN LEVELS IN 
HEPATOCYTES 
 AML12 IHH PH5CH8 HEPG2 
Glucose Metabolism 
       GLUT1 0.41 (0.09) # 0.49 (0.17) # 2.44 (0.62) * 0.42 (0.23) # 
       GLUT2 2.08 (0.20) * 1.97 (0.26) # 2.07 (0.37) # 1.79 (0.15) # 
       GS 1.11 (0.38) 3.47 (1.08) 4.10 (1.36) 3.58 (1.74) 
       PDHK1 2.17 (0.23) # 0.72 (0.19) 0.75 (0.56) 2.41 (0.52) * 
Electron Transport Chain 
       Complex I 0.65 (0.23) 0.48 (0.27) 1.18 (0.35) 0.97 (0.47) 
       Complex II 0.71 (0.10) 0.42 (0.18) 0.57 (0.28) 0.68 (0.34) 
       Complex III 0.72 (0.13) 0.33 (0.09) * 0.33 (0.09) * 0.46 (0.13) * 
       Complex IV 0.49 (0.19) * 0.47 (0.06) * 0.56 (0.08) # 0.69 (0.12) # 
       Complex V 0.57 (0.11) * 0.48 (0.03) * 0.59 (0.05) * 0.53 (0.04) * 
Lipid Metabolism 
       ACC1 0.72 (0.11) 0.30 (0.07) # 0.36 (0.03) # 1.43 (0.74) 
       ATGL  2.39 (0.31) * 1.02 (0.25) 0.72 (0.06) 0.38 (0.04)  # 
       CD36 1.37 (0.35) 2.40 (0.70) 0.83 (0.46) 1.86 (0.51) 
       CPT1a  0.95 (0.12) 0.60 (0.04) # 1.92 (0.25) * 1.20 (0.33) 
       DGAT1 0.29 (0.04) * 0.72 (0.15) 0.75 (0.09) 0.38 (0.01) * 
       DGAT2 9.32 (2.30) # 12.07 (4.22) * 6.45 (1.87) # 0.39 (0.19) 
       FASN 1.07 (0.17) 0.92 (0.39) 0.63 (0.14) 1.17 (0.27) 
       FATP5 0.72 (0.28) 0.83 (0.34) 1.54 (1.05) 3.59 (0.96) * 
       HSL 0.95 (0.29) 0.15 (0.04) * 0.21 (0.16) * 0.19 (0.07) * 
Cholesterol Metabolism 
       ACAT1 0.51 (0.16) * 0.06 (0.01) * 0.04 (0.03) * 0.13 (0.10) * 
       HMGCR 1.35 (0.21) 1.06 (0.20) 1.00 (0.13) 0.63 (0.22) 
Data is mean (SEM) fold change from PMH. * P ≤ 0.05 compared to PMH by one-way 
ANOVA followed by Tukey’s Multiple Comparisons test. # P ≤ 0.05 compared to PMH by 
unpaired Student’s t-test.  
 124 
TABLE 3. BASAL REPONSES OF HEPATOCYTES 
 AML12 IHH PH5CH8 HEPG2 
Glucose Metabolism 
       Glycogen Content - - ++ ++ 
       Glucose Incorporation - ++ ++ - 
       Glucose Oxidation - - + - 
       Gluconeogenesis  - - - - 
Fatty Acid Metabolism 
       TAG Content - + - ++ 
       Dose TAG (Oleate)  - - - - 
       Dose TAG (Mixture)  - - - - 
       Oleate Uptake ++ - - + 
       Oleate Oxidation - - - - 
       Oleate Intra-
Esterification 
- - - - 
       Oleate Extra-
Esterification 
- - - - 
De novo Lipogenesis 
       Glucose into Intra-Lipids - - - - 
       Glucose into Extra-
Lipids 
- - - - 
Cholesterol Metabolism 
       Cholesterol Content + + - + 
       Cholesterol Ester 
Content 
+ - + + 
       Acetate into Intra-CE - - - - 
       Acetate into Extra-CE - - - ++ 
       Acetate into Intra-FC ++ ++ + - 
       Acetate into Extra-FC - - - - 
The ranking of basal metabolic responses of hepatocytes in comparison to primary hepatocyte. 
++ indicates almost exact levels to PMH, + indicates similar levels to PMH, - indicates 
dissimilar levels compared to PMH.  
Abbreviations: TAG, triacylglycerol, Intra, intracellular, Extra, extracellular, CE, cholesterol 
ester, FC, free cholesterol.   
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TABLE 4. HORMONE-STIMULATED REPONSES OF HEPATOCYTES 
 PMH AML12 IHH PH5CH8 HEPG2 
Glucose Metabolism 
       Glycogen Content + ++ - ++ - 
       Glucose Incorporation ++ ++ ++ ++ - 
       Glucose Oxidation ++ - - - - 
       Gluoneogenesis + - + + + 
       Glycogenolysis a ++ ++ - ++ - 
Fatty Acid Metabolism 
       Oleate Uptake ++ - - - + 
       Oleate Oxidation + - - - - 
       Oleate Intra-
Esterification 
++ ++ - - ++ 
       Oleate Extra-
Esterification 
- ++ - - ++ 
De novo Lipogenesis 
       Glucose into Intra-
Lipids 
++ - - - - 
       Glucose into Extra-
Lipids 
- - - - - 
The ranking of insulin or aglucagon-stimulated metabolic responses of hepatocytes. ++ 
indicates expected significant response with great fold change, + indicates expected significant 
response with mild fold change, - indicates no change.  
Abbreviations: Intra, intracellular, Extra, extracellular  
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FIGURE LEGENDS 
 
Figure 1: Regulation of insulin-stimulated glucose metabolism in hepatocytes.  (A) Basal 
and 100 nM insulin stimulated glycogen content (three independent experiments performed in 
triplicate except for primary hepatocytes (two independent experiments)) (B) Representative 
immunoblots of glycogen synthase in hepatocytes cultured in basal media (two independent 
experiments performed in duplicate). (C) Representative immunoblots of phospho-IR, IR, 
phospho-Akt, Akt, phospho-FOXO1, FOXO1, phospho-GSK3β and GSK3β in hepatocytes 
cultured basal media or 100 nM insulin for 30 mins (three independent experiments performed 
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in triplicate). (D) Basal and 100 nM insulin stimulated glucose incorporation into hepatocytes 
(three independent experiments performed in triplicate except for primary hepatocytes (two 
independent experiments)). Glucose incorporation was defined as the sum of 14C activity in 
aqueous and organic phases following a Folch extraction of cell lysates and oxidation (E) 
Representative immunoblots of GLUT1 and GLUT2 in hepatocytes cultured in basal media 
(two independent experiments performed in duplicate). (F) Basal and 100 nM insulin 
stimulated glucose oxidation (three independent experiments performed in triplicate except for 
primary hepatocytes (two independent experiments)) (G) Representative immunoblots of 
PDHK1 in hepatocytes cultured in basal media (two independent experiments performed in 
duplicate). (H) Representative immunoblots of protein subunits in the mitochondrial 
complexes (complex II-30 kDa, complex III-Core protein 2, complex IV-subunit 1, and 
complex V-alpha subunit) in hepatocytes cultured in basal media (two independent 
experiments performed in duplicate). Data are presented as mean ± SEM. A, D, F *P ≤ 0.05 
compared to primary hepatocytes; #P ≤ 0.05 compared to basal for each cell type by two-way 
ANOVA followed by Tukey’s Multiple Comparisons test. PMH: Primary mouse hepatocytes 
 
 
Figure 2: Hormone-stimulated glucose production in hepatocytes. (A) Absolute basal and 
insulin stimulated (2 h) glucose production in hepatocytes and (B) expressed as percent from 
basal. (C) Basal and 10 µg/ml glucagon (1 h) stimulated glycogen content (three independent 
experiments performed in triplicate). Data are presented as mean ± SEM. A-B *P ≤ 0.05 
compared to primary hepatocytes; $P ≤ 0.05 main effect for Insulin by two-way ANOVA 
followed by Tukey’s Multiple Comparisons test. C #P ≤ 0.05 compared to basal for each cell 
type by two-way ANOVA followed by Tukey’s Multiple Comparisons test. . PMH: Primary 
mouse hepatocytes; Gluc: Glucagon 
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Figure 3: Fatty acid partitioning in hepatocytes. (A) TAG content of hepatocytes cultured 
in basal media (three independent experiments performed with six technical replicates each 
except for primary hepatocytes (two independent experiments)). (B) Basal and 100 nM insulin 
stimulated oleate uptake into hepatocytes (three independent experiments performed in 
triplicate except for primary hepatocytes (two independent experiments)). Fatty acid uptake 
was defined as the sum of total lipid synthesis (14C activity in the organic phase following 
Folch extraction), oxidation, acid soluble metabolites, and extracellular TAG synthesis. (C) 
Representative immunoblot of CD36 and FATP5 in hepatocytes cultured in basal media (two 
independent experiments performed in duplicate). (D) Basal and 100 nM insulin stimulated 
oleate incorporation into intracellular and (E) secreted lipids (three independent experiments 
performed in triplicate except for primary hepatocytes (two independent experiments)). (F) 
Representative immunoblots DGAT1, DGAT2, and (G) ATGL and HSL in hepatocytes 
cultured in basal media (two independent experiments performed in duplicate). (H) Basal and 
100 nM insulin stimulated oleate oxidation (three independent experiments performed in 
triplicate except for primary hepatocytes (two independent experiments)). (I) Representative 
immunoblots CPT1α in hepatocytes cultured in basal media (two independent experiments 
performed in duplicate). (J) Relative basal fatty acid partitioning in hepatocytes where oleate 
uptake was expressed as 100% and the relative contribution of intracellular other lipids (total 
lipid synthesis – TAG synthesis) and TAG synthesis, oxidation, and extracellular TAG 
synthesis presented. Data are presented as mean ± SEM. A-B, D-E, H *P ≤ 0.05 compared to 
primary hepatocytes; #P ≤ 0.05 compared to basal for each cell type by two-way ANOVA 
followed by Tukey’s Multiple Comparisons test. PMH: Primary mouse hepatocytes 
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Figure 4: Effect of extracellular oleate and FA mixture on TAG content in hepatocytes. 
Cells were treated with a concentration range (0-450 µM) of (A) oleate alone or (B) a FA mix 
(1:2:1 palmitate:oleate:linoleate) for 24 hours then assayed for TAG content expressed as 
absolute values or (C-D) as fold change from basal (three independent experiments performed 
in triplicate except for primary hepatocytes (two independent experiments)). (E) primary 
mouse hepatocytes, (F) AML12, (G) IHH, (H) PH5CH8, and (I) HepG2 cells were treated 
with a concentration range (0-450 µM) of oleate alone or a FA mix (1:2:1 
palmitate:oleate:linoleate) for 24 hours then assayed for TAG content (three independent 
experiments performed in triplicate except for primary hepatocytes (two independent 
experiments)). Data are presented as mean ± SEM. A-D *P ≤ 0.05 compared to primary 
hepatocytes; $P ≤ 0.05 for main effect of FA dose by two-way ANOVA followed by Dunnett's 
Multiple Comparison test. E-I $P ≤ 0.05 for main effect of FA dose; #P ≤ 0.05 compared to 
Oleate by two-way ANOVA followed by Dunnett's Multiple Comparison test. PMH: Primary 
mouse hepatocytes 
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Figure 5: Insulin-stimulated de novo lipogenesis in hepatocytes. (A) Basal and 100 nM 
insulin stimulated glucose incorporation into intracellular and (B) secreted lipids. (C) 
Representative immunoblots for FASN and ACC in hepatocytes cultured in basal media (two 
independent experiments performed in duplicate). Data are presented as mean ± SEM. A-B *P 
≤ 0.05 compared to primary hepatocytes; #P ≤ 0.05 compared to basal for each cell type by 
two-way ANOVA followed by Tukey’s Multiple Comparisons test. PMH: Primary mouse 
hepatocytes 
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Figure 6: Cholesterol and cholesterol ester synthesis and content in hepatocytes. (A) Basal 
total cholesterol and cholesterol ester content (three independent experiments performed in 
triplicate except for primary hepatocytes (two independent experiments)) (B) Absolute rates of 
acetate incorporation into intracellular and (C) secreted free cholesterol and cholesterol ester 
(three independent experiment performed in triplicate except for primary hepatocytes (two 
independent experiments)). (D) Representative immunoblot of HMG-CoA reductase 
(HMGCR) in hepatocytes cultured in basal media (two independent experiments performed in 
duplicate). Data are presented as mean ± SEM. *P ≤ 0.05 compared to primary hepatocytes by 
one-way ANOVA followed by Dunnett’s Multiple Comparisons test. PMH: Primary mouse 
hepatocytes  
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Chapter 5  
Identification and Novel Functional Characterisation of LD-Associated 
Candidate in the Pathogenesis of NAFL and IR  
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5.1 Introduction 
 
Metabolic diseases rooted in TAG overabundance, such as obesity, metabolic syndrome and 
NAFL(D), are aptly coined ‘diseases of excessive LDs’. These diseases are often associated 
with insulin resistance, type 2 diabetes and cardiovascular complications. Although cells such 
as hepatocytes, adipocytes and myocytes likely use LDs to protect themselves from 
lipotoxicity, intracellular lipid accumulation can exceed the storage capacity of these cell 
populations and lead to dysfunction. This delicate balance of protective storage versus 
mobilisation for energy generation is likely mediated by the hundreds to thousands of proteins 
bound to the surface of LDs, alongside substrate availability. LD-associated proteins are 
involved in a large variety of functions, ranging from lipases participating in lipid catabolism 
and synthesis to proteins involved in DNA damage prevention under stressful situations (Zhang 
et al. 2017). Therefore, identifying and characterizing novel proteins that localise to LDs and 
how they respond to diet and hormone stimulation is paramount to ultimately understanding 
their role in the pathogenesis of metabolic disease and potential for therapeutic targeting. 
 
The preeminent challenge of cell biology is the ability to unveil complex regulation of proteins 
under distinct and physiologically relevant conditions on a large scale. High throughput mass 
spectrometry-based proteomics has been useful for the quantitative analysis of protein 
abundance, protein-protein interactions and post-translational modifications. As discussed in 
Chapter 3, mass spectrometry was utilized to investigate the influence of acute in vivo insulin 
stimulation on protein phosphorylation and abundance on LDs in the livers of HFD-induced 
insulin resistant rats. Apart from HSL, all known participants of lipolysis did not significantly 
change in abundance at the LD between healthy and insulin-resistant animals. This observation 
suggests the need to broaden the understanding of key players in LD metabolism and identify 
new candidates that link LD biology to the pathogenesis of NAFL and IR. One candidate that 
was identified from curation of the hepatic LD proteome was the ubiquitin binding protein 
named UBX domain containing 8 (UBXD8), also known as FAF2.  
 
Through systematic filtering, UBXD8 was identified as an ‘insulin resistant’ LD protein that 
is expressed in rat liver. Though a pool of UBXD8 is ubiquitously found on LDs, it is primarily 
an ER-associated protein that is known to migrate to LDs upon stimulation with unsaturated 
FAs (Kim et al. 2013). UBXD8 has three main domains including the UAS domain for FA 
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binding, the UBX domain required for interaction with the segregase p97, and the UBA domain 
to form polyubiquitin chains (Buchberger 2002). The UBA domain allows UBXD8 to trigger 
rapid proteasomal degradation of key metabolic proteins such as INSIG-1, which is known to 
regulate cholesterol concentrations, the major VLDL constituent ApoB-100 and the rate-
limiting enzyme in sterol biosynthesis, HMGCR (Lee et al. 2008, Suzuki et al. 2012, Loregger 
et al. 2017). UBXD8 also inhibits LD turnover by separating ATGL from its coactivator CGI58 
and inhibiting its activity in HEK cells (Olzmann et al. 2013). Collectively, these observations 
suggest that UBXD8 is an important regulator of lipid and sterol metabolism and may be 
dysregulated in LD-related diseases. The following chapter describes the changes in lipid 
phenotype and molecular interactions of UBXD8 under distinct hormonal, transcriptional and 
dietary regulation. Collectively, these analyses attempt to further outline its potential as a key 
regulator of lipid metabolism and as a novel candidate in the pathogenesis of NAFL(D) and 
IR.  
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5.2 Methods 
 
5.2.1 Cell Culture 
5.2.1.1 Cell Maintenance  
AML12 mouse hepatocytes kindly provided by Professor Rob Parton (Institute for Molecular 
Bioscience, University of Sydney) were cultured in a 1:1 mixture of Dulbecco’s modified 
Eagle’s medium and Ham’s F-12 medium (DMEM-F12) supplemented with GlutaMAXÔ, 
sodium pyruvate and 2.4 g/L sodium bicarbonate (GibcoÒ, Life Technologies), 10% fetal 
bovine serum (FBS; In Vitro Technologies) and 1% of penicillin and  streptomycin (P/S; 
GibcoÒ, Life Technologies).  
 
5.2.1.2 Treatment of Cells  
5.2.1.2.1 Insulin Treatment  
AML12 hepatocytes were serum-starved for 2 hours in low glucose DMEM (Gibco, Life 
Technologies) supplemented with 0.2% bovine serum albumin (BSA; Bovogen) and 1% P/S 
followed by fresh serum-free media containing 0, 10 or 100 nM of insulin (Sigma) incubated 
for 30 minutes, as indicated.  
 
5.2.1.2.2 FA Treatment  
Oleate and linoleate were diluted in absolute ethanol to make 100 mM stock concentration and 
stored at -30°C, whereas palmitate was resuspended in absolute ethanol to make 100 mM stock 
concentration and made fresh on the day. Before treatment, FAs are added to serum-containing 
DMEM for 30 minutes to allow FAs to solubilize in media. AML12 hepatocytes were treated 
with 300 µM of FA(s) supplementation in low glucose DMEM supplemented with 10% FBS 
and 1% P/S for 3, 6, 16 or 24 hours, as indicated.   
 
5.2.1.2.3 Peroxisome Proliferator-Activated Receptor (PPAR) a Agonist Treatment 
The PPARa agonist, WY-14643 (Sigma), was resuspended in DMSO to make a 10 mM stock 
concentration. AML12 hepatocytes were treated with 20 µM WY-14643 in low glucose 
DMEM, supplemented with 2% BSA for 6 hours if measuring protein, or 4 hours if measuring 
any other parameters.   
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5.2.1.3 siRNA-Mediated UBXD8 Knockdown 
AML12 hepatocytes were seeded at 10-20% confluence in 12-well plates (Corning) at least 24 
hours before being transiently transfected with 20 nM ON-TARGETplus Mouse FAF2 siRNA 
(Dharmacon) using RNase-free water (Dharmacon), OptiMEM I reduced serum medium 
supplemented with GlutaMAXÔ, HEPES and 2.4 g/L sodium bicarbonate (GibcoÒ, Life 
Technologies) and LipofectamineÔ RNAiMAX Reagent (Invitrogen) according to 
manufacturer’s instructions. A stable ON-TARGETplus Non-Targeting Pool siRNA was used 
as a negative control (Dharmacon). Cells were gently washed twice with warm phosphate-
buffered saline (PBS; Astral Scientific) 4 hours after transfection and replaced with low 
glucose DMEM supplemented with GlutaMAXÔ, sodium pyruvate (GibcoÒ, Life 
Technologies) and FBS for 48 hours.  
 
5.2.2 Western Blotting 
5.2.2.1 Protein Extraction and Quantification 
Cells were washed twice with ice-cold PBS then lysed with 80 µl of radioimmunoprecipitation 
assay (RIPA) buffer (65 mM Tris, 150 mM NaCl, 5 mM EDTA 1% (v/v) Nonidet P40, 0.5% 
(w/v) sodium deoxycholate, 0.1% (w/v) SDS, 10% glycerol, pH 7.4) supplemented with 1 x 
EDTA-free turbocharged protease and phosphatase inhibitor cocktail (Astral Scientific). 
Adherent cells were scraped using a cell scraper (Corning) for 20 seconds in all directions and 
lysed 8 times with a 0.3 ml 29G insulin syringe (BD) on ice. Cell lysates were transferred to 
1.5 ml microfuge tubes and spun in a Heraeus Fresco 21 Centrifuge (Thermo Fisher Scientific) 
at 15 000 × g for 15 minutes at 4°C. The resulting supernatant was kept on ice and transferred 
to a clear 96-well plate (Greiner) and diluted with water to a factor of 25 for protein 
quantification. Bicinchoninic Assay (BCA) Protein Kit (PierceÔ, Thermo Fisher Scientific) 
was used to prepare a standard curve ranging from 0 to 1 mg/ml protein to interpolate the 
absorbance of the samples. After the reagent was added, the plate was incubated at 37°C for 
30 minutes and the absorbance at 560 nm was determined using Magellan software (TECAN 
Infinite M1000 PRO, Tecan Trading, AG, Switzerland). After protein determination, samples 
of equal concentration were prepared using 6x Laemmli sample buffer and heated at 50°C for 
10 minutes or 75°C for 7 minutes with gentle agitation (Thermomixer 5436, Eppendorf) to 
denature soluble proteins and allow antibody access to the epitope. Between 30-40 µg of 
protein was loaded onto a polyacrylamide gel for best resolution.  
 143 
Refer to Section 4.2 for detailed descriptions on SDS-polyacrylamide gel electrophoresis 
(4.2.3.2), protein transfer to a PVDF membrane (4.2.3.3), imaging with Bio-Rad ChemiDoc 
MP (4.2.3.5) and stripping and re-probing of membranes (4.2.3.6). For information on 
antibodies used in this chapter, refer below.   
 
5.2.2.2 Antibody Probing 
Membranes were blocked in 3% BSA diluted in 1 x Tris buffered saline (TBS; Astral 
Scientific) containing 0.1% Tween-20 (TBST; Sigma) for 60 minutes at room temperature on 
a rocker. For primary antibody incubation, membranes were submerged in an antibody solution 
made of 3% BSA diluted in TBST containing primary antibody and kept overnight at 4°C with 
gentle agitation (Table 5.1).  
 
Table 5.1 Primary antibodies used in this chapter.  
Antibody Catalogue # Dilution Species Company 
anti-ABHD5 ab73551 1:1000 Rabbit Abcam 
anti-ACAT2 13294S 1:1000 Rabbit CST 
anti-ACC1 3676S 1:1000 Rabbit CST 
anti-ATG7 8558T 1:1000 Rabbit CST 
anti-ATGL 2138S 1:1000 Rabbit CST 
anti-CPT1a ab128568 1:1000 Mouse Abcam 
anti-CYC 11940S 1:1000 Rabbit CST 
Anti-DGAT2 ab59493 1:1000 Goat Abcam 
anti-ERP72 5033S 1:1000 Rabbit CST 
anti-ETEA 34945S 1:1000 Rabbit CST 
anti-FASN 3180S 1:1000 Rabbit CST 
anti-GAPDH 2118S 1:1000 Rabbit CST 
anti-G0S2 SC-133423 1:500 Rabbit SCBT 
anti-HMGCR PA-37367 1:1000 Rabbit Thermo Fisher Scientific 
anti-LC3A/B 12741T 1:1000 Rabbit CST 
anti-LDLR ab52818 1:1000 Rabbit Abcam 
anti-pAKT(Ser473) 4058S 1:1000 Rabbit CST 
anti-OXPAT PA1-46215 1:1000 Rabbit Thermo Fisher Scientific 
anti-PPARa C26H12 1:1000 Rabbit CST 
A list of proteins of interest that were visualized for abundance using western blotting. CST – Cell Signaling Technologies 
(CST); SCBT – Santa Cruz Biotechnology. 
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After overnight primary antibody incubation, membranes were kept at room temperature for 
30 minutes to allow for further binding before washing with fresh TBST for 15 minutes for a 
total of 1 hour on a shaker. Membranes were then incubated in solution made of 3% BSA in 
TBST containing a selected secondary antibody for 1 hour on a rocker (Table 5.2). The 
following table is a list of all the secondary antibodies used in experiments described in this 
chapter. Finally, membranes were washed again every 15 minutes for at least 1 hour on a 
shaker.   
 
Table 5.2 Secondary antibodies used in this chapter.  
Antibody Catalogue # Dilution Species Company 
Rabbit 7074P2 1:5000 Goat CST 
Mouse 7076 1:5000 Horse CST 
Goat SC-2020 1:5000 Donkey SCBT 
A list of secondary antibodies that were used to visualize abundance of proteins of interest using western blotting. CST – Cell 
Signaling Technologies (CST); SCBT – Santa Cruz Biotechnology. 
 
5.2.3 Radiolabel Metabolic Analysis 
5.2.3.1 Extracellular Fatty Acid Metabolism 
AML12 hepatocytes were incubated in 0.5 µCi/ml 1-[14C]-oleate (Perkin Elmer), 0.5 mM cold 
oleate, 1 mM carnitine and 2% BSA in low glucose DMEM (Gibco) for 4 hours to measure 
short-term changes in FA metabolism following drug or hormone stimulation. Endpoints 
measured were 1-[14C]-oleate incorporation into CO2. 
 
5.2.3.1.1 FA Oxidation 
After 4 hours, media was transferred into 25 ml borosilicate glass liquid scintillation counting 
vials (Perkin Elmer) containing 1:1 1 M perchloric acid (PCA): media and a 1.5 ml microfuge 
tube filled with 500 µl of 1 N sodium hydroxide (NaOH). Vials were capped immediately in 
order to capture [14C]-CO2 after being liberated from acidified media by PCA. Capped vials 
were incubated on a shaker at room temperature for 2 hours before transferring the NaOH into 
scintillation vials containing 3 ml of scintillant for measurement of 14C activity by Tri-Carb 
2810TR Liquid Scintillation Analyzer (Perkin Elmer).  
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5.2.3.2 Protein Quantification 
Cells were washed twice with cold PBS and replaced with 300 µl PBS. Adherent cells were 
scraped using a cell scraper (Corning) for 20 seconds in all directions and lysed 8 times with a 
0.3 ml 29G insulin syringe (BD). Cell lysates were transferred to 2 ml microfuge tubes and 25 
µl was added to a clear 96-well plate (Greiner) for protein quantification. Bicinchoninic Assay 
(BCA) Protein Kit (PierceÔ, Thermo Fisher Scientific) was used to prepare a standard curve 
ranging from 0 to 1 mg/ml protein to interpolate the absorbance of the samples. After the 
reagent was added, the plate was incubated at 37°C and read at 560 nm after 30 minutes using 
Magellan software (TECAN Infinite M1000 PRO, Tecan Trading, AG, Switzerland).  
 
5.2.4 Lipid Extraction 
Adherent AML12 hepatocytes were washed twice with ice-cold PBS and scraped for 20 
seconds in 300 – 600 µl of PBS (Astral Scientific) using cell scrapers (Corning). Cells were 
then lysed with 8 strokes of a 0.3 ml 29G insulin syringe (BD) and transferred to 12 x 75 mm 
glass tubes (Sigma). Samples were vortexed and protein concentration was measured using the 
protocol mentioned in section 5.2.3.3. Then, 3 volumes of chloroform: methanol solution in 
the ratio 2:1 was added to each glass tube and subsequently vortexed every 15 minutes for 1 
hour under the fume hood to separate the sample into organic and inorganic phases. After 1 
hour, samples were spun at 1000 x g for 10 minutes (Eppendorf). Lipids in the lower phase 
were then extracted into a new glass tube and concentrated in a Dri-Block sample concentrator 
(Techne) under a stream of nitrogen gas at 40°C until the chloroform: methanol is evaporated. 
Lipids in the remaining powdered pellet were resuspended in 10 µl of absolute ethanol and 
vortexed for 20 seconds. For TAG, concentration was quantified using GPO-PAP reagent 
(Roche Diagnostics) and absorbance was measured at 492 nm on a Tecan Infinite M1000 Pro. 
To quantify cholesterol concentrations, the Amplex Red cholesterol kit (Sigma) was used as 
per manufacturer’s instructions.  
 
5.2.5 Immunofluorescence Microscopy 
AML12 hepatocytes were seeded at 5% confluence on circular 12 mm No. 1.5 coverslips 
(Thermo Fisher Scientific) and treated with 300 µM oleate supplemented with 10% FCS and 
1% P/S for 24 hours to induce LD formation. Cells were washed with PBS twice, fixed with 
4% paraformaldehyde for 20 minutes at room temperature and then washed twice again.  
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If visualizing UBXD8 and LDs, cells were blocked in an antibody diluent mixture containing 
0.5% BSA and 0.5% saponin for 1 hour at room temperature, followed by overnight incubation 
with 1:1000 UBXD8 primary antibody (see Table 5.1) at 4°C. The next day, cells were rinsed 
three times with PBS and incubated in 5 ug/ml fluorochrome-conjugated secondary Alexa 
Fluor Far Red 647 antibody (A3273, goat anti-rabbit, Invitrogen) and 1:1000 BODIPY 493/503 
(Life Technologies) in PBS for 1 hour in the dark at room temperature. If visualizing LDs only, 
an antibody diluent mixture containing 0.5% BSA, 0.5% saponin and 1:1000 BODIPY 493/503 
in PBS was directly added to the cells for 1 hour at room temperature for LD staining.  
 
The plate was kept in a hand-made humidified chamber using wet paper towels and protected 
from light. After 1 hour, cells were washed twice with PBS and mounted onto 1.0-1.22 mm 
glass slides (Livingstone) using mounting media with DAPI (Duolink In Situ Mounting Media 
with DAPI, Sigma) or without (ProlongÒ Diamond Antifade Mountant). Clear nail polish 
(Sally Hansen) was added to the edges to seal the coverslips and let dry for 15 minutes. Stained 
cells were observed under a Zeiss Axio Scope upright microscope and obtained using DAPI, 
FITC and Cy5 filters under 40X objective and 100X objective with Type-F immersion oil 
(Olympus). Images were optimized and captured using Zen 2012 (Blue Edition) software 
(Zeiss) and color-coded using ImageJ.  
 
5.2.6 Subcellular Fractionation 
5.2.6.1 Treatment and Homogenization of Hepatocytes 
AML12 hepatocytes were seeded at 70% confluence into 5 x 100-mm dishes per condition 
early in the morning and treated with 300 µM oleate for 16 hours later that afternoon, or for 30 
minutes the next morning. Cells were washed twice with PBS, scraped in 3 ml PBS for 20 
seconds in all directions using cell scrapers (Corning) and combined to make 15 ml per 
condition. Cells were centrifuged in Eppendorf 5810 (Eppendorf) for 10 mins at 500 × g at 4°C 
and the resultant pellet was resuspended in five times the cell pellet volume in ice-cold 
hypotonic lysis medium (HLM) (20 mM Tris-Cl pH 7.4, 1 mM EDTA, 10 mM NaF, 
supplemented with protease and phosphatase inhibitors (Astral Scientific) using a pipet with a 
wide opening. Cells were homogenized using eight strokes of a hand-driven Potter-Elvehjem 
tissue homogenizer on ice and centrifuged again for 10 mins at 1000 × g at 4°C. The 
supernatant and thick fat layer were collected into a separate tube and protein quantification 
was performed using the BCA Protein Kit (PierceÔ, Thermo Fisher Scientific).  
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5.2.6.2 Sucrose Gradient Fractionation 
A density gradient was prepared in 5.1-ml ultracentrifuge tube (Hitachi) by adding 2 ml of cell 
lysate with approximately 4 mg of protein and mixing it with 1 ml of ice-cold HLM buffer 
containing 80% sucrose using a pipet tip with a wide opening. Once the density-adjusted cell 
lysate was thoroughly mixed, 1.5 ml of ice-cold HLM containing 20% sucrose was gently 
layered over the sample, followed by 1 ml of HLM buffer containing 10% sucrose over the 
previous layer. Finally, 500 ul of HLM containing 0% sucrose was added to fill the tube to the 
brim. Tubes were balanced within 0.02g of each other and centrifuged for 2.5 hours at 82,700 
× g at 4C in a P55ST2-636 spinout rotor (Hitachi). The rotor was allowed to coast to a stop 
with a deceleration of “F” (free). Once spun, a pipet with a wide opening was used to carefully 
transfer 420 ul of the most superficial layer at a time to get 12 individual fractions.  
 
5.2.6.3 Immunoblotting Fractions 
 
Equal volumes were taken from each fraction and prepared for western blot. Samples were 
denatured and reduced with 6X sample buffer and boiled on a heating block with gentle 
agitation for 5 mins at 100°C. Fractionated samples were loaded onto a 15-well 12% gel and 
run and semi-dry transferred according to section 4.2.3.3. Membranes were stained with 0.1% 
w/v Ponceau S (Sigma) and 5% w/v acetic acid in ddH2O for 5 minutes and de-stained with 
ddH2O for 15-30 minutes to confirm satisfactory protein abundance at each fraction before 
incubation with primary antibody. Cytochrome C, ERP72 and ATGL were used as organellar 
markers to track UBXD8 movement with different treatments.  
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5.2.7 Mass Spectrometry 
Methodology pertaining to mass spectrometry (5.2.7.2-4) was performed by Dr. Mark Larance 
and Dr. Dylan Hearney from the Charles Perkins Centre at The University of Sydney.  
 
5.2.7.1    Sample Preparation 
AML12 cells were seeded at 5% confluence in 6-well plates before transfection with siRNA 
for 48 hours to knock down UBXD8 (see section 5.2.1.3). Once cells reached 80% confluence, 
plates were washed with PBS twice at room temperature and replaced with 1 ml of denaturing 
lysis buffer (4% SDS, 20 mM sodium phosphate, 100 mM NaCl, 10 mM NaF, protease 
inhibitor cocktail (Astral Scientific)) Extracts were then transferred to Eppendorf tubes and 
heated at 65°C for 10 mins and sonicated using the QSonica in the following order: 30 seconds 
ON, 20 seconds OFF for 10 mins at 80% amplitude at room temperature. Lysates were 
centrifuged at 18,000 x g for 10 mins at > 18°C. Protein quantification was then performed on 
the supernatant, as described in section 5.2.3.3.     
 
5.2.7.2  Stage-Tipping 
To separate salts from proteins, samples were desalted using styrenedivinylbenzene-reverse 
phase sulfonate (SDB-RPS) stage tipping. To prepare disks for solid phase extraction, 200 ul 
tips were mounted into a 3D-printed holder over a 96-well deep well plate. The following 
solutions were added, centrifuged at 1000 x g for 3 mins and eluted before drying peptides in 
a PCR plate for 1 hour: 100% acetonitrile, 30% methanol with 1% TFA, 0.2% TFA, 1% TFA, 
0.2% TFA, 99% isopropanol with 1% TFA and 5% ammonium hydroxide with 80% 
acetonitrile. After drying, peptides were resuspended in 50 mM triethylammonium bicarbonate 
in water. Disulfide bonds were reduced using 5 mM DTT and incubated on a thermomixer at 
1000 RPM for 10 min at 95°C. Samples were then alkylated with chloroacetamide and 
incubated on a thermomixer in the same manner. Trypsin was added in a ratio of 1:20 to digest 
samples and samples were incubated for 16 hours at 37°C at 500 RPM. Digestion was halted 
the next day using a final concentration of 1% TFA.   
 
5.2.7.3 LC-MS/MS Acquisition 
The Dionex RSLCnano uHPLC (Thermo Fisher Scientific) was used to inject peptides directly 
onto a 45 cm x 75 µm C18 analytic column with a 10 µm pulled tip. Peptides were resolved 
over a gradient ranging from 5% to 40% acetonitrile for 15 to 140 mins with a flow rate of 300 
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nL per minute. Electrospray ionization at 2.3 kV was employed to ionize peptides and tandem 
mass spectrometry analysis was performed used a Q-Exactive HF or HFX mass spectrometer 
(Thermo Fisher Scientific) using HCD fragmentation.   
 
5.2.7.4 MaxQuant Analysis 
MaxQuant (version 1.5.7.10) (Tyanova et al. 2016), with the integrated search engine 
Andromeda (Cox et al. 2011), was used to analyze raw data from the mass spectrometer. A 
false discovery rate of 1% was employed using a target-decoy based strategy and used a 
database downloaded on April 18, 2018 containing 42, 325 protein sequence entries. The 
following parameters were set: mass tolerance 4.5 ppm for precursor ions and 20 ppm for 
MS/MS mass tolerance, semi-specific N-ragged trypsin for enzyme specificity, variable 
modifications for deamidation, oxidation and acetylation and fixed modification for 
carbamidomethyl. Statistical tests were performed using R software (version 3.4.3).  
 
5.2.8 Statistical Analysis 
All data were statistically analyzed using Graphpad Prism version 7 (GraphPad Software). 
Unpaired Mann-Whitney t-tests and one- or two-way ANOVA tests were conducted 
appropriately and described in detail under each figure legend. Post-hoc analyses were 
performed using Tukey’s and Sidak’s multiple comparisons tests, whereby p < 0.05 was 
considered significant.    
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5.3 Results 
 
5.3.1 UBXD8 is Abundant in Mouse Liver 
The protein expression levels of UBXD8 across organs in mouse tissue from 15-week old male 
and female mice kindly donated by Professor Greg Cooney were determined using 
immunoblotting including brain, heart, lungs, diaphragm, liver, kidney, quadriceps femoris 
muscle, gastrocnemius muscle, plasma, subcutaneous adipose, retroperitoneal adipose and 
epidydimal tissue. UBXD8 protein levels in the liver was the highest among all tissues 
assessed, followed by kidney and the brain (Fig 5.1). This is consistent with the literature, 
where the majority of studies on UBXD8 are performed in hepatocyte and renal cell lines such 
as Huh7, HepG2 and HEK293 cells (Suzuki et al. 2012, Olzmann et al. 2013, Loregger et al. 
2017). Strikingly, UBXD8 was largely undetected in other oxidative tissues such as heart and 
skeletal muscle and was not detected in plasma, indicating that it is not a circulating protein. 
There were no sex differences in UBXD8 protein levels in tissues, aside from adipose and 
diaphragm tissue. The tissue distribution of UBXD8 in murine samples are consistent with data 
obtained in the Human Protein Atlas (Uhlen et al. 2015), suggesting evolutionary conservation 
of tissue expression profiles.   
 
Figure 5.1 Tissue distribution of UBXD8 protein expression.  
Raw and quantified immunoblots of UBXD8 protein expression levels across 12 tissues in 15-week old male and female mice, 
specifically brain, heart, lungs, diaphragm, liver, kidney, quadriceps femoris muscle, gastrocnemius muscle, plasma 
subcutaneous adipose, retroperitoneal adipose and epidydimal tissue.    
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5.3.2 Upregulation and Translocation of UBXD8 Upon Insulin Stimulation 
In the results described in Chapter 3, UBXD8 was identified as an insulin-sensitive LD-
associated protein. To confirm whether insulin treatment modifies UBXD8 protein expression 
in hepatocytes, AML12 cells were stimulated with insulin and lysates were immunoblotted. 
Phosphorylation of AktSer473 increased (p < 0.01) in AML12 hepatocytes treated with 10 nM 
and 100 nM insulin after 30 minutes (Fig 5.2A), and abundance of UBXD8 total protein levels 
significantly increased (p = 0.04) with 100 nM of insulin after 6 hours of stimulation (Fig 5.2B), 
with a main effect of insulin dose (p < 0.01). To determine if protein abundance corresponds 
with translocation of proteins to LDs, AML12 hepatocytes were cultured for 24 hours in 300 
µM of oleate to induce LD formation followed by 30 minutes of stimulation with 100 nM 
insulin. Insulin stimulation resulted in translocation of UBXD8 to LDs (Fig 5.2C).  
 
 
Figure 5.2 Quantification and Visualization of UBXD8 in Response to Insulin.  
(A) Representative blots of pAKT, UBXD8 and GAPDH with 0, 10 and 100 nM of insulin stimulation. UBXD8 and pAKT 
protein expression was normalized to GAPDH. Data are presented as mean + SEM; *p < 0.05 compared to 0 nM treatment by 
two-way ANOVA followed by Tukey’s Multiple Comparisons test (3 independent experiments performed in duplicate) (B) 
Representative blots of UBXD8 and GAPDH protein expression with 0, 10 and 100 nM of insulin stimulation over 30 minutes 
and 6 hours (3 independent experiments) (C) Merged images representing the translocation of UBXD8 to the lipid droplet 
after 30 mins of stimulation with 100 nM insulin (red = UBXD8 stained with Alexa Fluor FAR  RED 647, green = LDs stained 
with BODIPY493/503). The white line in the lower right hand image is 100 µm relative to the view.    
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5.3.3 Upregulation and Translocation of UBXD8 Upon Lipid Treatment 
 
Figure 5.3 Quantification of UBXD8 Protein Expression In Response to Oleate  
(A) Representative immunoblots of UBXD8 and GAPDH protein expression with 3- and 16-hour treatment of 300 µM oleate, 
linoleate or a mixture of palmitate: oleate: linoleate (P:O:L) in a 1:2:1 ratio (three independent experiments). Quantification 
of (B) Cytochrome C (mitochondria), ERp72 (ER) and PLIN2 (lipid droplets) protein expression (C) total triglyceride (TAG) 
levels and (D) total UBXD8 protein levels across 12-fractions obtained by fractionation of sucrose density gradient.  
 
Treatment with FAs is an alternative extracellular stimuli that stimulates TAG synthesis in 
hepatocytes, as previously described in Chapter 4. In HEK293 cells, UBXD8 was reported to 
sense and polymerize in response to elevated levels of unsaturated FAs (Kim et al. 2013). To 
corroborate these results in hepatocytes, AML12 cells were incubated in 300 µM oleate, 
linoleate or a 1:2:1 mixture of palmitate, oleate and linoleate for 3 hours or overnight followed 
by protein level determination. All three overnight fatty acid treatments increased total UBXD8 
protein levels with overnight but not 3 hour of fatty acid treatment (Fig 5.3A).  
 
In HEK293 cells, treatment with unsaturated FAs leads to the translocation of UBXD8 from 
the ER to LDs to inhibit ATGL-mediated lipolysis (Kim et al. 2013) . To determine whether 
this is also evident in hepatocytes, organelles were separated into 12 distinct fractions using 
sucrose density-gradient ultracentrifugation and identified by standard organellar markers 
cytochrome C for mitochondria, ERp72 for ER and PLIN2 for lipid droplets. A greater 
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percentage of total cellular PLIN2 protein expression was enriched in the top 3 fractions and 
was noticeably separated from fractions enriched with ERp72 (fractions 8-9) and cytochrome 
C (fractions 9-12; Fig 5.3B). TAG levels were then measured to confirm the colocalization of 
PLIN2 to lipid droplets with varying lipid incubation times. TAG levels were not different 
between 0 and 30 mins of oleate stimulation, likely due to the changes being below the 
sensitivity of the biochemical assay, but did increase 2-fold in the top 3 fractions with overnight 
incubation, consistent with PLIN2 localization (Fig 5.3C). In the control and acute oleate 
treatment conditions, UBXD8 was primarily enriched in fractions 8-9 along with the ER 
marker ERp72 (Fig 5.3D). In contrast, overnight treatment with oleate was associated with a 
larger distribution of UBXD8 protein levels across fractions 1-8 (Fig 5.3D), consistent with 
intracellular movement away from the ER and towards LDs (Olzmann et al. 2013). 
 
5.3.4 UBXD8 Knockdown Attenuates ATGL Protein Expression 
When associated with LDs, UBXD8 segregates ATGL from its activator CGI58 and directly 
binds and inhibits ATGL at the LD (Olzmann et al. 2013); however, loss-of-function of 
UBXD8 studies assessing ATGL biology have not been reported. Unexpectedly, ATGL protein 
levels were decreased by almost 50% with UBXD8 KD in AML12 hepatocytes (p = 0.01; Fig 
5.4). This suggests that UBXD8 may be involved in stabilizing ATGL total protein levels.  
 
Figure 5.4 ATGL Protein Expression with UBXD8 KD 
AML12 hepatocytes were seeded and treated with UBXD8 siRNA for 48 hours before protein visualization. Data are 
representative immunoblots and quantification for UBXD8, ATGL and GAPDH with scrambled and UBXD8 siRNA (eight 
independent experiments in duplicates) and are presented as mean + SEM; *p < 0.05 compared to scrambled by unpaired 
student’s t-test. 
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5.3.5 UBXD8 Knockdown Promotes TAG Accumulation in Hepatocytes 
 
Figure 5.5 TAG Content in UBXD8 Knocked Down Hepatocytes  
AML12 hepatocytes were seeded and transfected with UBXD8 siRNA for 48 hours before incubation with 300 µM of oleate 
for 24 hours. (A) Lipids from hepatocytes were extracted and TAG was quantified by spectrophotometry. Data are 
representative of 3 independent experiments done in triplicate and presented as mean + SEM; *p < 0.05 compared to scrambled 
by unpaired student’s t-test. (B) UBXD8-KD AML12 hepatocytes treated with oleate as indicated were fixed and stained with 
BODIPY 493/503 (neutral lipids) and subjected to immunofluorescent microscopy analysis.  
 
To confirm whether the reduction in ATGL protein expression affected TAG lipolysis, TAG 
content was measured in UBXD8 KD AML12 hepatocytes. After 24 hours of treatment with 
300 µM of oleate, TAG content was greater by 28% in UBXD8 KD cells compared to 
scrambled control (p < 0.01; Fig 5.5A), consistent with reduced ATGL protein levels. To 
confirm these results, lipid-loaded AML12 cells treated with scrambled or UBXD8 siRNA 
were stained with BODIPY 493/503 to visualize LDs. Consistent with TAG levels (Fig 5.5A), 
UBXD8 KD resulted in accumulation of LDs compared to control cells (Fig 5.5B). Together, 
these results indicate that a reduction in UBXD8 protein expression in AML12 hepatocytes is 
associated with decreased ATGL-mediated TAG lipolysis.   
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5.3.6 UBXD8 is Associated with G0S2 Protein Expression 
Lipase activity of ATGL is influenced by its interaction with CGI58, which acts as co-activator, 
and G0S2, which acts as a co-suppressor (Lu et al. 2010) (Fig 5.6A) and so the protein levels 
of these key regulators of ATGL activity were measured. UBXD8 KD decreased G0S2 protein 
levels by 75% (p = 0.002) but did not significantly alter abundance of CGI58 or HSL (Fig 
5.6B). The concurrent lowering of the two proteins known to inhibit ATGL activity suggests a 
novel and intimate relationship between UBXD8 and G0S2. In HeLa cells, G0S2 was 
reportedly bound to ATGL regardless of activity or coactivator binding, and the loss of ATGL 
led to its degradation (Lu et al. 2010), consistent with results obtained in this study. 
Additionally, PLIN5 is an LD-associated protein that promotes TAG storage by binding to 
CGI58 and inhibiting lipolysis. Interestingly, UBXD8-KD increased PLIN5 protein expression 
(p = 0.03) despite the reduction in other lipolytic inhibitors. PLIN5 sequestration of CGI58 is 
reported to increase its stability at LDs, and thus the elevated levels of CGI58 following the 
loss of ATGL may contribute to increased PLIN5 protein expression(Granneman et al. 2011). 
To determine the role of UBXD8 in lipid turnover beyond lipolysis, the levels of lipogenic 
proteins were also measured. FASN protein abundance was modestly decreased with UBXD8 
KD (p = 0.06; Fig 5.6C), likely associated with the role of UBXD8 in modulating SREBP 
transcription of specific lipogenic target genes, such as FASN (Lee et al. 2010). Meanwhile, 
UBXD8 KD did not affect ACC1 or DGAT2 protein expression (Fig 5.6C). These results 
suggest that UBXD8 regulates TAG turnover exclusively via the lipolytic pathway and that 
UBXD8 may utilize G0S2 to facilitate its inhibition of ATGL. 
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Figure 5.6 Lipolytic and Lipogenesis Protein Expression 
(A) A schematic diagram of the players involved in lipid droplet turnover. Lipolytic regulators are illustrated in green while 
lipogenic enzymes are illustrated in red. The abundance of proteins related to (B) lipolysis and (C) lipogenesis were quantified. 
Data is presented as mean + SEM; *p < 0.05 compared to scrambled control by unpaired student’s t-test from eight independent 
experiments performed in duplicates.  
 
5.3.7 UBXD8 Regulates Mitochondrial Fatty Acid Oxidation 
FAs released by ATGL-mediated LD degradation can be oxidized by mitochondria to generate 
useable energy. CPT1a is the central regulator of oxidation as it facilitates the transport FAs 
across the mitochondrial membranes and into the β-oxidation pathway. In AML12 hepatocytes 
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cultured in basal media, CPT1a protein levels were decreased in UBXD8 KD cells (p < 0.01; 
Fig 5.7A), consistent with increased TAG content and decreased ATGL and G0S2 protein 
expression observed in these cells (Fig 5.4-6). Additionally, PPARa is a transcription factor 
that can be activated by FA ligands and regulates the transcription of genes involved in 
mitochondrial FA oxidation (McMullen et al. 2014). Likewise, UBXD8 KD caused a decrease 
in PPARa protein expression (p < 0.01; Fig 5.7A). These results suggest that UBXD8 not only 
regulates lipolytic proteins, but also plays a role in mediating the expression of oxidative 
proteins. To determine whether the reduction in CPT1a and PPARa affects FA oxidation, 
incorporation of radiolabelled oleate into CO2 was measured. As expected, the rate of oxidation 
was markedly decreased with UBXD8 KD (p < 0.01; Fig 5.7B). Further, treatment with the 
PPARa agonist WY1463 partially rescued the rate of FA oxidation (Fig 5.7B). These results 
were consistent with the recovery of downstream targets of oxidation, such as CPT1a, but not 
upstream regulators such as ATGL (Fig 5.7C). Collectively, these results confirms that 
UBXD8 inhibits oxidation upstream of CPT1a and is mediated by altered ATGL-PPARa 
signalling. 
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Figure 5.7 Role of UBXD8 in Fatty Acid Oxidation 
(A) Representative and quantification of immunoblots CPT1a and PPARa in scrambled or UBXD8 KD AML12 hepatocytes. 
Data are presented as mean + SEM; p < 0.05 compared to scrambled by unpaired student’s t-test from eight independent 
experiments performed in duplicate. (B) Basal and WY14643 stimulated oleate oxidation (three independent experiments 
performed in triplicate) in AML12 hepatocytes treated with scrambled or UBXD8 siRNA. Data are presented as mean + SEM; 
p < 0.05 compared to scrambled by two-way ANOVA followed by Tukey’s Multiple Comparisons test. (C) Representative 
immunoblots UBXD8, ATGL and CPT1a in scrambled or UBXD8 KD AML12 hepatocytes treated with the PPARa agonist 
WY14643 as indicated (two independent experiments performed in duplicate). (D) Quantification of immunoblots ATG7 and 
LC3 in scrambled or UBXD8 KD AML12 hepatocytes. Data are presented as mean + SEM; p < 0.05 compared to scrambled 
by unpaired student’s t-test from eight independent experiments performed in duplicate. 
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In mammalian liver, there are two major pathways for LD degradation controlled by PPARa: 
mitochondrial and peroxisomal (micro) catabolism or lysosomal (macro) lipid autophagy 
(lipophagy) (Schulze et al. 2017). Key lipophagy-related proteins were quantified in UBXD8 
KD cells to determine if UBXD8 influences a broad array of PPARa regulated pathways. 
Interestingly, both ATG7 and LC3 protein levels were not altered by UBXD8 loss-of-function 
(Fig 5.7D), despite being PPARa target genes. These results demonstrate that UBXD8’s effects 
to regulate ATGL proteins levels and TAG lipolysis selectively PPARa-CPT1a signalling and 
fatty acid oxidation but not PPARa-autophagy pathways.  
 
5.3.8 UBXD8 KD Downregulates Oxidation and Upregulates FA Synthesis 
Pathways 
The loss of function of UBXD8 resulted in changes in key proteins involved in lipolysis and 
FA oxidation (Fig 5.6-7). High throughput mass spectrometry was used to elucidate the broader 
patterns in the proteome of UBXD8 KD cells. Hepatocytes were treated with siRNA for 48 
hours before performing mass spectrometry to identify groups of proteins and general pathways 
that were affected by UBXD8 KD. In AML12 cells, 133 proteins were differentially expressed 
with UBXD8 siRNA treatment (Fig 5.8); 67 of which were downregulated (Table 5.3) and 66 
of which were upregulated (Table 5.4) compared to control. In particular, UBXD8 KD was 
associated with a reduction in mitochondrial and peroxisomal oxidation proteins, such as 
CPT2, ATP synthase, and the peroxisomal targeting receptor, PEX5. However, proteins such 
as ATGL, PPARa, CPT1a and G0S2 were not enriched sufficiently to be detected in all 
samples by the mass spectrometer. Further, UBXD8 KD enhanced the expression of key 
proteins involved in FA synthesis and LD generation. The protein most significantly 
upregulated was atlastin, an ER-embedded GTPase essential for ensuring structural integrity 
of ER tubules required for LD budding and expansion (Klemm et al. 2013). Similarly, proteins 
involved in generating very long unsaturated FAs such as FA desaturase and long-chain FA 
elongase were also increased with UBXD8 KD. Interestingly, two enzymes in the cholesterol 
biosynthesis pathway, squalene monooxygenase and sterol reductase, were significantly 
upregulated with UBXD8 KD, whereas sterol carrier protein, a cholesterol transport protein 
localized in peroxisomes and mitochondria, was downregulated. Collectively, these results 
suggest an overarching role for UBXD8 in lipid and cholesterol metabolism and provide further 
evidence that UBXD8 expression is associated with lipid catabolism rather than anabolism.  
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Figure 5.8 Differentially Expressed Proteins Associated with UBXD8 KD 
AML12 hepatocytes were treated with scrambled or UBXD8 siRNA for 48 hours and loaded onto a mass spectrometer for 
identification and quantification of differentially expressed proteins. Data is presented as log fold change of UBXD8 KD 
proteins compared to scrambled control from 5 independent experiments. 
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Table 5.3. List of downregulated proteins in AML12 hepatocytes with UBXD8 KD 
Name Symbol Uniprot ID LogP Log2FC 
FAS-associated factor 2 Faf2 Q3TDN2 2.50 -2.37 
Lysosomal thioesterase PPT2 Ppt2 E9Q0T0 1.64 -0.78 
dCTP pyrophosphatase 1 Dctpp1 Q9QY93 1.67 -0.76 
Son of sevenless homolog 1 Sos1 Q62245 1.36 -0.58 
Large subunit GTPase 1 homolog Lsg1 Q3UM18 1.40 -0.41 
Enhancer of rudimentary homolog Erh P84089 1.31 -0.38 
Interferon-induced, double-stranded RNA-activated protein kinase Eif2ak2 Q03963 2.12 -0.38 
Zinc finger protein 706 Znf706 Q9D115 1.67 -0.36 
Vacuolar protein sorting-associated protein 28 homolog Vps28 Q9D1C8 2.35 -0.31 
COX assembly mitochondrial protein 2 homolog Cmc2 Q8K199 1.68 -0.31 
Protein S100-A11 S100a11 P50543 1.35 -0.30 
Aftiphilin Aftph Q80WT5-2 1.77 -0.30 
Bromodomain-containing protein 7 Brd7 O88665 1.33 -0.28 
Non-specific serine/threonine protein kinase;Serine/threonine-
protein kinase PAK 1 Pak1 G5E884 1.35 -0.27 
PHD finger protein 3 Phf3 B2RQG2 2.04 -0.26 
ADP-ribose pyrophosphatase, mitochondrial Nudt9 Q8BVU5 1.73 -0.24 
Adipocyte plasma membrane-associated protein Apmap Q9D7N9 1.38 -0.24 
Non-specific lipid-transfer protein Scp2 P32020 1.33 -0.24 
Regulation of nuclear pre-mRNA domain-containing protein 1B Rprd1b A0A0R4J195 1.44 -0.23 
Tropomyosin 1, alpha, isoform CRA_k Tpm1 G5E8R2 1.59 -0.22 
RalBP1-associated Eps domain-containing protein 1 Reps1 D3Z2E3 1.40 -0.22 
Heterogeneous nuclear ribonucleoprotein U-like protein 2 Hnrnpul2 Q00PI9 1.94 -0.20 
Protein FAM195B Fam195b Q3UGS4 1.74 -0.20 
Prenylcysteine oxidase-like Pcyox1l Q8C7K6 1.50 -0.19 
LIM domain-containing protein 1 Limd1 Q9QXD8 1.34 -0.19 
Negative elongation factor A Nelfa Q8BG30 1.33 -0.19 
LIM domain and actin-binding protein 1 Lima1 Q9ERG0 1.39 -0.19 
SWI/SNF-related matrix-associated actin-dependent regulator of 
chromatin subfamily E member 1 Smarce1 O54941 1.45 -0.18 
Thioredoxin domain-containing protein 12 Txndc12 Q9CQU0 1.31 -0.18 
Carnitine O-palmitoyltransferase 2, mitochondrial Cpt2 P52825 1.40 -0.18 
RNA polymerase-associated protein LEO1 Leo1 Q5XJE5 2.11 -0.18 
EF-hand domain-containing protein D2 Efhd2 Q8C845 1.52 -0.17 
Trinucleotide repeat-containing gene 6B protein Tnrc6b Q8BKI2 1.46 -0.17 
Cadherin-6 Cdh6 P97326 1.34 -0.17 
Glutathione synthetase Gss P51855 1.30 -0.16 
Peroxisomal targeting signal 1 receptor Pex5 O09012-2 1.33 -0.16 
Oxidation resistance protein 1 Oxr1 E9Q0A7 1.93 -0.16 
Bromodomain-containing protein 1 Brd1 E9Q412 1.51 -0.15 
Leucine-rich repeat protein SHOC-2 Shoc2 O88520 1.50 -0.15 
Tyrosine-protein phosphatase non-receptor type 11 Ptpn11 P35235 1.68 -0.15 
Lamina-associated polypeptide 2, isoforms alpha/zeta Tmpo Q61033 2.85 -0.15 
Interferon regulatory factor 2-binding protein 2 Irf2bp2 E9Q1P8 1.46 -0.14 
Leucine-rich repeat-containing protein 47 Lrrc47 E9PV22 2.49 -0.14 
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Glutathione S-transferase P 1 Gstp1 P19157 1.91 -0.14 
Diphosphoinositol polyphosphate phosphohydrolase 2 Nudt4 Q8R2U6 1.34 -0.14 
28S ribosomal protein S11, mitochondrial Mrps11 Q3U8Y1 1.42 -0.14 
Membrane-associated progesterone receptor component 1 Pgrmc1 O55022 1.41 -0.13 
Probable RNA polymerase II nuclear localization protein Slc7a6os Q7TPE5 1.31 -0.12 
PDZ domain-containing protein 8 Pdzd8 B9EJ80 1.31 -0.12 
cAMP-dependent protein kinase type I-alpha regulatory subunit Prkar1a Q9DBC7 1.37 -0.12 
55 kDa erythrocyte membrane protein Mpp1 P70290 1.63 -0.12 
Heterogeneous nuclear ribonucleoprotein H2 Hnrnph2 P70333 1.54 -0.11 
Cleavage and polyadenylation specificity factor subunit 6 Cpsf6 H3BJ30 1.55 -0.11 
X-ray repair cross-complementing protein 5 Xrcc5 P27641 1.34 -0.11 
S-phase kinase-associated protein 1 Skp1 Q9WTX5 1.99 -0.10 
tRNA-splicing ligase RtcB homolog Rtcb Q99LF4 1.68 -0.10 
Transmembrane 9 superfamily member 3 Tm9sf3 Q9ET30 1.45 -0.10 
Protein disulfide-isomerase P4hb P09103 1.85 -0.09 
Protein ERGIC-53 Lman1 Q9D0F3 1.34 -0.09 
Nucleosome assembly protein 1-like 1 Nap1l1 Q3TF41 1.43 -0.09 
Plexin-B2 Plxnb2 B2RXS4 1.40 -0.08 
Serpin B6 Serpinb6 Q60854 1.53 -0.08 
Keratin, type I cytoskeletal 19 Krt19 CON__P19001 1.31 -0.08 
Ubiquitin carboxyl-terminal hydrolase 47 Usp47 A0A1L1SV73 1.61 -0.08 
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 Pin1 Q9QUR7 1.41 -0.07 
Microtubule-associated protein RP/EB family member 1 Mapre1 Q61166 1.41 -0.06 
ATP synthase subunit beta, mitochondrial Atp5b P56480 1.99 -0.05 
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Table 5.4. List of upregulated proteins in AML12 hepatocytes with UBXD8 KD 
Name Symbol Uniprot ID LogP Log2FC 
Vesicle transport protein SEC20 Bnip1 Q6QD59 1.31 0.57 
Fatty acid desaturase 3 Fads3 Q9JJE7 1.60 0.46 
Squalene monooxygenase Sqle P52019 1.96 0.46 
Growth hormone-inducible transmembrane protein Ghitm Q91VC9 2.13 0.45 
SAGA-associated factor 29 homolog Ccdc101 Q9DA08 2.35 0.44 
Delta(24)-sterol reductase Dhcr24 Q8VCH6 1.91 0.44 
Atlastin-2 Atl2 Q6PA06 2.69 0.37 
Ubiquitin-like protein 3 Ubl3 Q9Z2M6 2.17 0.35 
Elongation of very long chain fatty acids protein 1 Elovl1 Q9JLJ5 1.30 0.34 
Prostaglandin G/H synthase 2 Ptgs2 Q05769 1.41 0.34 
Protein transport protein Sec61 subunit alpha isoform 1 Sec61a1 P61620 1.98 0.31 
Septin-10 Sep10 A0A0R4J233 1.36 0.31 
CDGSH iron-sulfur domain-containing protein 2 Cisd2 D3Z3X4 1.45 0.30 
Midasin Mdn1 A2ANY6 1.47 0.30 
DnaJ homolog subfamily B member 12 Dnajb12 Q8C4C9 2.28 0.29 
Renin receptor Atp6ap2 Q9CYN9 1.77 0.28 
Integrator complex subunit 4 Ints4 Q8CIM8 1.89 0.27 
40S ribosomal protein S17 Rps17 P63276 1.71 0.26 
U3 small nucleolar RNA-associated protein 18 homolog Utp18 Q5SSI6 1.77 0.24 
U3 small nucleolar ribonucleoprotein protein IMP4 Imp4 Q8VHZ7 1.88 0.22 
Cell division cycle protein 23 homolog Cdc23 A0A0R4J1W7 1.48 0.22 
Cyclin-dependent kinase 2 Cdk2 P97377-2 1.89 0.22 
HEAT repeat-containing 1 Heatr1 G3X9B1 1.44 0.21 
Unconventional prefoldin RPB5 interactor Uri1 A0A0U1RPG9 1.32 0.21 
Ribonuclease H2 subunit A Rnaseh2a Q9CWY8 1.76 0.21 
Calcium-binding protein 39 Cab39 Q06138 1.42 0.21 
Apoptosis regulator BAX Bax A0A1B0GT81 1.35 0.21 
Surfeit locus protein 4 Surf4 Q64310 2.06 0.21 
Protein MAK16 homolog Mak16 Q8BGS0-2 1.34 0.20 
Exportin-1 Xpo1 Q6P5F9 2.26 0.20 
mRNA turnover protein 4 homolog Mrto4 Q9D0I8 1.94 0.20 
Ancient ubiquitous protein 1 Aup1 Q3U3K9 1.50 0.20 
40S ribosomal protein S3 Rps3 P62908 1.61 0.20 
AP-1 complex subunit gamma-1 Ap1g1 Q8CBB7 1.47 0.20 
Vacuolar protein sorting-associated protein 33B Vps33b P59016 1.32 0.20 
Keratin, type II cytoskeletal 7 Krt7 CON__Q9DCV7 1.45 0.19 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit 
A beta isoform Ppp2r1b Q3TTF6 1.55 0.19 
Hsp70-binding protein 1 Hspbp1 Q99P31 1.84 0.19 
40S ribosomal protein S28 Rps28 G3UYV7 1.55 0.18 
THO complex subunit 2 Thoc2 B1AZI6 1.73 0.18 
60S ribosome subunit biogenesis protein NIP7 homolog Nip7 Q9CXK8 1.76 0.17 
40S ribosomal protein S18 Gm10260 F6YVP7 1.53 0.17 
Melanoma-associated antigen G1 Ndnl2 Q9CPR8 1.43 0.16 
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Alpha-parvin Parva Q3UF75 1.95 0.16 
26S proteasome non-ATPase regulatory subunit 6 Psmd6 Q99JI4 1.97 0.15 
40S ribosomal protein S4, X isoform Rps4x P62702 2.52 0.15 
40S ribosomal protein S2 Rps2 P25444 1.44 0.15 
Exportin-2 Cse1l Q9ERK4 1.57 0.15 
60S ribosomal protein L12 Rpl12 P35979 2.12 0.14 
40S ribosomal protein S5 Rps5 Q91V55 1.59 0.13 
Importin subunit beta-1 Kpnb1 P70168 1.70 0.13 
mRNA cap guanine-N7 methyltransferase Rnmt Q9D0L8 1.67 0.13 
T-complex protein 1 subunit eta Cct7 P80313 1.85 0.12 
Retinoblastoma-binding protein 5 Rbbp5 A0A0R4J2B6 1.46 0.12 
Myb-binding protein 1A Mybbp1a Q7TPV4 1.42 0.12 
Phenylalanine--tRNA ligase alpha subunit Farsa Q8C0C7 1.87 0.12 
Nuclear protein localization protein 4 homolog Nploc4 P60670 1.74 0.12 
Serine hydroxymethyltransferase Shmt2 Q3TFD0 1.33 0.12 
Ribosome biogenesis regulatory protein homolog Rrs1 Q9CYH6 1.50 0.11 
Polypeptide N-acetylgalactosaminyltransferase 3 Galnt3 P70419 1.46 0.11 
MCG21756, isoform CRA_b Nup205 B9EJ54 1.43 0.10 
Prohibitin-2 Phb2 O35129 1.42 0.09 
Coatomer subunit beta Copb1 Q9JIF7 1.84 0.09 
T-complex protein 1 subunit delta Cct4 P80315 1.45 0.08 
SUMO-activating enzyme subunit 1 Sae1 Q9R1T2 1.43 0.06 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit 1 Rpn1 Q91YQ5 1.34 0.04 
 
5.3.9 UBXD8 Co-Localizes with Cholesterol Ester Pools Upon Lipid Treatment 
To corroborate the mass spectrometry data on the role of UBXD8 in sterol metabolism, 
cholesterol and cholesteryl ester levels were quantified in subcellular fractions of AML12 
hepatocytes. In these cells, the majority of the total cholesterol pool is composed of CE, 
regardless of lipid availability (Fig 5.9). CE accumulated in two pools located in fractions 5 
(~4-6) and 8 (~7-10) in cells cultured in basal media; the latter pool likely representing sterol 
biogenesis in the ER (Fig 5.9A; organelle markers presented in Fig 5.3B). With overnight 
oleate stimulation, CE levels increased in fractions 1-6, including the formation of two equal 
peaks in fractions 5 (~3-6) and 8 (~6-9) (Fig 5.9B). CE levels in Fractions 1-3 is representative 
of increased cholesterol storage in LDs (Fig 5.3B-C) while fractions 6-9 is enriched for the ER. 
It is unknown what organelle(s) are enriched in fractions 3-6; however, it is hypothesized to be 
a Golgi or Golgi-related fraction due to its relative density compared to LDs (more dense) and 
ER/mitochondria (less dense) (Krahmer et al. 2018). Interestingly, UBXD8 protein expression 
peaked precisely where CE levels peaked in both basal and lipid-treated cells, suggesting a 
close relationship between UBXD8 and cholesterol formation, storage or transport.  
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Figure 5.9 UBXD8 Intracellular Movement Across Cholesterol Pools 
Quantification of (A) total UBXD8 protein expression and cholesterol levels across 12-fractions obtained by fractionation of 
sucrose density gradient in AML12 hepatocytes in basal media and (B) after overnight incubation with 300 µM of oleate.  
 
5.3.10 UBXD8 is Not Related to Expression of Key Cholesterol-Related Proteins 
Cholesterol is synthesized de novo by a series of reactions in the mevalonate pathway which is 
primarily regulated by the ER-bound rate-limiting enzyme 3-hydroxy-3-methylglutaryl-CoA 
reductase (HMGCR) (Ness 2015). Free cholesterol is stored in plasma/organelle membranes 
or esterified to form CE which stored in LDs. Cholesterol is converted to CE by members of 
the ACAT family consisting of ACAT1 and ACAT2. While ACAT1 is expressed ubiquitously, 
ACAT2 is largely expressed in the liver and intestine and aids in lipoprotein secretion (Lee et 
al. 2000). UBXD8 KD did not alter the protein levels of HMGCR (p = 0.06) or ACAT2 (p = 
0.16) in AML12 hepatocytes (Fig 5.10), despite demonstrating a strong downward trend. These 
results indicate an insignificant role for UBXD8 in regulating cholesterol and CE synthesis. 
UBXD8 KO studies in mice have shown decreased lipoprotein transport (Imai et al. 2015), 
therefore the levels of the lipoprotein receptor LDLR were measured. In AML12 hepatocytes, 
LDLR protein expression was unchanged in the absence of UBXD8. Collectively, these results 
indicate that UBXD8 associates with pools of CE away from the ER but is not involved in 
lipoprotein endocytosis. Further, it does not strongly correlate with HMGCR and ACAT2 
protein expression, despite mass spectrometry data pointing towards a role in cholesterol 
metabolism. These results are inconsistent with published reports on UBXD8’s role in 
HMGCR degradation in Drosophila melanogaster and blunted VLDL secretion in UBXD8 
KO mice synthesis (Suzuki et al. 2012, Imai et al. 2015).  
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Figure 5.10 Cholesterol-Related Protein Expression with UBXD8 KD 
AML12 hepatocytes were seeded and treated with UBXD8 siRNA for 48 hours before protein visualization. Data are 
representative immunoblots and quantification for HMGCR, ACAT2 and LDLR with scrambled and UBXD8 siRNA (eight 
independent experiments in duplicates) and are presented as mean + SEM; *p < 0.05 compared to scrambled by unpaired 
student’s t-test. 
  
 167 
5.4 Discussion 
Metabolic disorders such as obesity, NAFL and IR are widespread in Western countries and 
are becoming increasingly prevalent in developing nations. An excessive amount of 
intracellular lipid, and subsequent LD biogenesis, is a hallmark feature of these disorders (Khan 
et al. 2015, Engin 2017). Thus, understanding the precise players involved in LD formation 
and utilization will provide important insights into the pathophysiology of LD dysregulation 
commonly observed in these populations. Although impairment of several neutral lipolytic LD 
proteins, such as ATGL, HSL, CGI58, G0S2 and PLIN proteins, are reported to cause or 
alleviate NAFL, they are often explored in isolation rather than as interacting and 
compensatory partners (Brown et al. 2010, Ong et al. 2011, McManaman et al. 2013, Sugaya 
and Satoh 2017). In the results described in this chapter, UBXD8, a protein known to inhibit 
ATGL activity at the LD, was further characterized under the lens of lipid storage, oxidation 
and molecular regulation to position it in the grand scheme of LD physiology. In particular, 
knockdown of UBXD8 in AML12 hepatocytes revealed an unexpected decrease in lipolysis, 
causing subsequent TAG accumulation and reduction in FA oxidation. These affects were 
associated with major changes in the protein expression of LD-associated metabolic players 
and regulators of mitochondrial fatty acid oxidation. 
 
5.4.1 UBD8 and TAG Homeostasis 
UBXD8 performs a significant role in controlling intracellular FA availability. In the absence 
of unsaturated FAs, UBXD8 promotes the proteolytic activation of SREBP-1 which in turn 
allows SREBP-1 to enter the nucleus and activate the transcription of FA synthesis genes (Lee 
et al. 2008). Consequently, ATGL remains bound to its lipolytic coactivator CGI58 at the LD 
and continues to hydrolyse TAG into DAGs and FAs (Olzmann et al. 2013). In the presence of 
FAs, UBXD8 is reported to polymerize and migrate to LDs to segregate ATGL from its 
coactivator and subsequently inhibit its activity in HEK293 and SV589 cells (Lee et al. 2010, 
Kim et al. 2013, Olzmann et al. 2013). It was therefore hypothesized that knockdown of 
UBXD8 will remove the anti-lipolytic signal and thereby increase ATGL activity. However, 
results described in this chapter demonstrate that KD of UBXD8 in AML12 hepatocytes 
significantly lowers ATGL protein expression, resulting in a 2-fold increase in TAG content 
and associated accumulation of cytosolic LDs. Interestingly, these observations were 
consistent with studies reporting decreased acetate incorporation into FAs in fibroblasts in the 
absence of UBXD8 (Lee et al. 2010) and macrovesicular steatosis in mice with liver-specific 
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UBXD8-KO (Imai et al. 2015). However, these reported observations were attributed to 
impaired TAG synthesis and secretion, rather than a reduced TAG lipolysis. In contrast, 
UBXD8 KD in AML12 cells was not associated with changes in protein expression of lipid 
synthesis enzymes, such as DGAT2 and ACC1, but may influence the transcription of the 
SREBP-1 target gene, FASN. Strikingly, overexpression of S-peptide tagged UBXD8 
generated the same lipid phenotype in HEK cells (Olzmann et al. 2013) as UBXD8 KD in 
AML12 cells. Specifically, UBXD8 overexpression led to a reduction in lipolysis that was 
strongly linked to decreased association of CGI58 with ATGL and greater LD and TAG levels. 
These results were amplified in the presence of oleate, whereby total protein levels of UBXD8 
were increased, likely due to polymerization, leading to migration to LDs to control ATGL-
mediated lipolysis. Despite the inhibition of ATGL by UBXD8, protein expression of ATGL 
was elevated in the presence of oleate (Lee et al. 2010). It has been demonstrated that oleate 
stimulation prevents proteasomal degradation of ATGL, regardless of its activity (Olzmann et 
al. 2013), presumably as a marker for LD generation or a secondary mechanism to limit 
uncontrolled lipid synthesis when required. An interesting development to this story was the 
novel finding that UBXD8 protein expression was regulated by insulin stimulation and that 
acute signalling caused its migration to LDs in hepatocytes, similar to that of oleate treatment. 
In previous studies, FOXO1 has been shown to directly stimulate ATGL transcription and 
promote TAG catabolism in adipose tissue, while insulin inhibits this pathway (Zhang et al. 
2016). It is therefore conceivable that insulin may stimulate the migration of an endogenous 
inhibitor of ATGL to further suppress its activity in the presence of lipids. The similarities and 
differences in lipid phenotypes arising from KD and overexpression experiments across 
various treatment conditions is likely explained by nuances in the protein expression of 
molecular interactors of ATGL. 
 
Emerging evidence indicates that different cell types have distinct molecular regulators of lipid 
metabolism, particularly around ATGL-mediated lipolysis. In adipocytes, the interaction 
between ATGL and its coactivator CGI58 is inhibited by Plin1 sequestration and stabilization 
of CGI58 in the fed state (Subramanian et al. 2004). In HEK cells, UBXD8 segregates ATGL 
from CGI58 to inhibit lipolytic activity. Although plausible, previous studies investigating 
UBXD8 have largely ignored the role that G0S2 plays in hepatic modulation of TAG 
catabolism, and thus its association with UBXD8 is completely unknown. The results described 
in this chapter demonstrated a concomitant decrease in G0S2 protein expression with UBXD8 
KD, despite the increase in TAG levels. This may be explained by the ability of ATGL to 
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stabilize and retard the proteasomal degradation of G0S2 post-transcriptionally, regardless of 
the presence of CGI58 or FA accumulation (Heckmann et al. 2016) (Fig 5.11). In other words, 
ATGL decreases the ubiquitination of G0S2 protein and thus the reduction in ATGL expression 
following UBXD8 KD consequently allows for the degradation of G0S2 protein, but not 
mRNA. Although it is apparent that G0S2 is still a binding partner and regulator of ATGL in 
hepatocytes, it is unclear how it functions alongside UBXD8. When looking through the lens 
of insulin signalling in hepatocytes, studies show that insulin inhibits FOXO1-mediated 
promotion of ATGL activity and suppression of G0S2 activity, thereby attenuating TAG 
lipolysis (Zhang et al. 2016). Similarly, UBXD8 protein levels were increased and UBXD8 
translocated to LDs upon insulin stimulation, presumably to inhibit ATGL activity. With two 
potent inhibitors of ATGL activity regulated by similar hormonal stimulation, it is likely that 
UBXD8 and G0S2 associate to regulate lipolysis via ATGL. 
 
Figure 5.11 Molecular Interactors of UBXD8 and Associated Lipid Phenotype  
ATGL is coactivated by CGI58 to promote lipolysis and inactivated by G0S2 to promote TAG storage. UBXD8 is known to 
dissociate ATGL from CGI58 to prevent lipolysis, whereas the role of G0S2 is unknown. It is proposed that UBXD8 promotes 
inhibition of lipolysis through the formation of a G0S2 binding complex with ATGL.   
 
5.4.2 UBXD8 and Oxidation 
In addition to its role as a TAG hydrolase, ATGL was reported to selectively partition FA 
products into b-oxidation pathways. In the liver, gain and loss of function studies on ATGL 
modulate production of both CO2 and acid soluble oxidative intermediates but do not alter the 
rate of VLDL synthesis or secretion (Reid et al. 2008, Ong et al. 2011, Wu et al. 2011). 
Although mechanisms that discern FA transport to mitochondria over lipoproteins are currently 
unknown, newly hydrolysed FAs can act as ligands for transcriptional regulation of oxidative 
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genes via PPARa activation, further promoting energy production (Ong et al. 2014). PPARa 
expression is elevated in tissues with high oxidative capacities, such as muscle and liver and 
its targets genes are involved in mitochondrial and peroxisomal oxidation, FA transport, and 
FA utilization for gluconeogenic pathways (Burri et al. 2010). In particular, expression levels 
of PPARa and downstream target genes such as CPT1a are attenuated in the absence of ATGL 
(Ong et al. 2011). This was consistent in AML12 hepatocytes in the absence of UBXD8, 
whereby a reduction in ATGL protein expression led to decreased PPARa and CPT1a protein 
levels. These results were associated with reduced rates of b-oxidation in UBXD8 KD cells 
and could only be partially rescued with PPARa agonism. Thus, UBXD8 expression modulates 
FA availability by regulating ATGL activity and these FAs control b-oxidation by acting as 1) 
ligands for PPARa activation and transcription of key oxidative genes such as CPT1a and as 
2) direct substrates for the citric acid cycle in b-oxidation (Chakravarthy et al. 2009).  
 
Apart from ATGL, little is known about the independent role that other lipolytic regulators 
play in modulating mitochondrial oxidation in hepatocytes. Due to their relationship with 
ATGL, expression levels of both regulators have been associated with changes in oxidation 
(Liu et al. 2009, Brown et al. 2010, Zhang et al. 2014). For example, ASO-mediated CGI58 
KD in mice lowered β-hydroxybutyrate levels, indicating less hepatic oxidation (Brown et al. 
2010). Interestingly, CGI58 plays an additional role in the selective autophagic degradation of 
mitochondria, otherwise known as mitophagy (Zhang et al. 2014). Specifically, CGI58 
overexpression promoted mitochondrial fission and translocation of key proteins involved in 
mitophagy to the mitochondria, suggesting an independent function in bioenergetics beyond 
ATGL regulation (Zhang et al. 2014). While few studies have reported mitophagy in models 
of hepatic TAG accumulation (Liu et al. 2009), the expression levels of CGI58 as well as other 
autophagy markers such as ATG7 and LC3 were not altered with UBXD8 KD. In contrast, 
G0S2 expression markedly decreased by 75% in UBXD8 KD cells in comparison to the almost 
50% reduction in ATGL levels, suggesting additional functions beyond ATGL inhibition. 
While overexpression of G0S2 caused decreased oxidation rates in primary mouse hepatocytes 
(Kim et al. 2013, Zhang et al. 2014), studies have reported utilization of both PPARa-
dependent and independent pathways (Zhang et al. 2014, El-Assaad et al. 2015). In particular, 
ablation of G0S2 in primary mouse hepatocytes led to increased expression of some PPARa 
target genes such as CPT1a, but caused no alterations in the expression of PPARa or other 
PPARa-sensitive genes like ACOT1 (Zhang et al. 2014, El-Assaad et al. 2015). These results 
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suggest an uncoupling of G0S2 from PPARa-regulated FA oxidation. Interestingly, G0S2 has 
been identified as a mitochondrial regulator of hypoxia, whereby it can directly bind to 
mitochondrial proteins such as BCL2 and F0/F1 ATPase and promote oxidative 
phosphorylation and ATP production (Welch et al. 2009, Kioka et al. 2014). Through the dual 
and antagonistic role of G0S2 in mediating oxidation, it is conceivable that G0S2 can regulate 
oxidation independently, and that the influence of UBXD8 on G0S2 protein expression acts as 
an additional regulator of oxidation (Fig 5.12). This model provides a third alternative to the 
role that UBXD8 plays in modulating FA oxidation in hepatocytes.  
 
Figure 5.12 Model of UBXD8 in FA Oxidation  
UBXD8 binds to ATGL and inhibits its ability to hydrolyse TAG. Released FAs can act as ligands for PPARa activation in 
the nucleus to promote the transcription of oxidative genes or as substrates for oxidation in the mitochondria. Binding of 
UBXD8 to ATGL may have an additional role of retarding its proteasomal degradation in hepatocytes. UBXD8 is proposed 
to bind to G0S2 to regulate inhibition of ATGL and directly modulate FA oxidation under particular conditions.   
 
In the fed state, insulin action may also add a secondary layer of regulation to FA oxidation in 
the liver. In AML12 hepatocytes, insulin stimulation elevates UBXD8 protein expression. 
Although its role in insulin-suppression of FA oxidation was not assessed, it is plausible that 
UBXD8 aids in the regulation of this pathway. For example, expression of UBXD8 and G0S2 
and hepatic stimulation with insulin have all been independently associated with the inhibition 
of lipolysis (Yang et al. 2010, Olzmann et al. 2013). Further, G0S2 mRNA was increased in a 
time-dependent manner when stimulated with insulin in hepatocytes (Zhang et al. 2016), which 
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is similar to UBXD8 patterns described in this chapter. Strikingly, overexpression of G0S2 at 
LDs decreased FA oxidation (Wang et al. 2013), but promotes oxidative phosphorylation in 
hypoxic environments, suggesting G0S2’s opposing roles in modulating oxidation (Welch et 
al. 2009, Kioka et al. 2014). Taken together, these results strongly point towards a working 
relationship between UBXD8 and G0S2 in basal, lipid and insulin-stimulated conditions. 
Collectively, insulin action on lipid metabolism may employ UBXD8 to regulate FA oxidation 
in hepatocytes using key molecular partners. Future experiments should focus on identifying 
the mechanism by which UBXD8 affects FA oxidation. Measuring oxidation rates of cells with 
UBXD8 KD in the presence and absence of FAs can help determine if UBXD8 directly inhibits 
FA oxidation at the mitochondria or indirectly via ATGL-mediated lipolysis. Validation of this 
proposed model needs to be confirmed in order to pinpoint the interactors that are key to 
UBXD8’s role in LD physiology.  
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Chapter 6 
General Discussion 
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6.1 Overview  
The increasing prevalence of NAFL(D) is an emerging health concern due to its strong 
association with metabolic diseases such as obesity, type 2 diabetes, metabolic syndrome and 
cardiovascular disease, all of which are clinical and economic burdens to health care systems 
(Younossi et al. 2016). NAFL(D) pathophysiology is localized intracellularly, where hepatic 
lipid deposition is characterised by cytosolic LD accumulation (Green and Hodson 2014). The 
molecular networks involved in regulating intracellular metabolism are connected to 
essentially every other process, such as cell cycle, detoxification, and redox balance, and as a 
result, perturbations in metabolic signalling have widespread consequences. One of the most 
pervasive impairments of NAFL(D) is the dysregulation of insulin action, which has profound 
effects on whole-body energy storage, distribution and utilisation (Rui 2014). Through its 
activation and secretion from the pancreas, insulin regulates protein abundance, activity, 
translocation and interactions at target tissues using post-translation modifications (PTMs) 
(Virkamaki et al. 1999, Luiken et al. 2002, Mounier and Posner 2006). In NAFL(D), 
diminished insulin sensitivity is known to be associated with an accumulation of intracellular 
lipids stored in LDs and hence exploring the relationship between the two can be elucidated 
using proteomic and PTM analysis (Zhang et al. 2013). While high-throughput studies 
investigating hepatic steatosis exist, few have explored this relationship at the LD level. In 
reality, LDs are metabolic hubs that connect cellular signalling with energy substrates via the 
dynamic network of PTM-sensitive proteins associated with the LD (Arrese et al. 2014, 
Krahmer et al. 2018). Explaining how the proteomic circuitry goes awry in close proximity to 
large pools of TAG and neutral lipid stores is important to extend the understanding of the 
pathogenesis of NAFL and IR. 
 
6.1.1 Cooperative Regulation of Insulin Signalling: A PTM Story 
There are currently more than 450 different types of PTMs that can occur in complex 
organisms, with ubiquitination and phosphorylation being two of the most common (UniProt 
Consortium 2017). PTMs are advantageous in initiating critical processes such as hormone 
signalling because they provide a relatively rapid and reversible manner of regulating pathways 
(seconds) over other types of molecular controls such as gene expression and protein 
translation (minutes to hours) (Venne et al. 2014). To date, protein phosphorylation is the most 
studied PTM in NAFL and IR due to the pivotal role that Akt/PKB phosphorylation plays in 
insulin signalling and energy metabolism. Once insulin binds to its receptor at the cell surface 
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and triggers a signalling cascade, Akt is phosphorylated at Thr308 by PDK1 and Ser473 by 
mTORC-2 for maximal activation (Risso et al. 2015). Accordingly, this stimulates the 
phosphorylation of intermediary signalling proteins such as FOXO1 and GSK3b as well as 
other downstream targets (Dong et al. 2008). However, in reality, there is considerable 
crosstalk between different types of PTMs in the regulation of metabolic flux. In fact, 37% of 
all modified proteins in any given cell are regulated by at least two different PTMs and are 
highly conserved across mouse and human models (Minguez et al. 2012). The complex 
interplay between phosphorylation and ubiquitination in insulin signalling is an added 
cooperative layer of regulation, and can occur at multiple levels (Venne et al. 2014). For 
example, phosphorylated Akt is tagged for degradation following Lys48 ubiquitination, which 
is a known signal for proteasomal targeting of proteins (Suizu et al. 2009, Bae et al. 2012). 
Another example is Lys63-linked ubiquitination of proteins. In particular, ubiquitination of 
Lys63 on Akt by the E3 ligase TRAF6, stimulates Akt phosphorylation and membrane 
recruitment leading to activation of downstream insulin signalling (Yang et al. 2009, Cheng et 
al. 2013). Further, a lack of Akt phosphorylation at Ser473 and Thr308 promotes its 
degradation by the ubiquitin-proteasome system (Wei et al. 2018). Thus, ubiquitination of Akt 
can regulate, and be regulated, by the phosphorylation of Akt, demonstrating a clear example 
of PTM coupling in insulin signalling. 
 
The complex interplay between ubiquitination and phosphorylation is, however, not exclusive 
to Akt. One of the main findings presented in Chapter 2 was that almost all enzymes responsible 
for glycolysis/gluconeogenesis and related pathways are ubiquitinated, thereby indicating the 
importance of ubiquitin in regulating this fundamental metabolic process. Strikingly, all 15 of 
these enzymes have been reported to be phosphorylated and even acetylated based on 
proteomic and in vitro validation studies (Lundby et al. 2012, Lundby et al. 2012, Wagner et 
al. 2012). For example, phosphofructokinase (PFKL), the rate-limiting bifunctional enzyme of 
glycolysis/gluconeogenesis, is phospho-activated in response to insulin or adrenergic 
stimulation and phosphorylates fructose-6-phosphate to generate fructose-1,6-bisphosphate 
(Ausina et al. 2018). Similar to Akt, unphosphorylated PFKL is sensed by an unknown E3 
ligase and is subsequently degraded by the ubiquitin proteasomal pathway (Swaney et al. 
2013). Interestingly, data presented in Chapter 2 indicate that PFKL is inappropriately 
ubiquitinated in response to insulin in the HFD-fed rats but not the chow-fed rats (Fig 6.1). It 
is possible that diminished insulin signalling in the obesity-induced IR animals cannot 
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stimulate phosphorylation of PFKL and is therefore degraded, consistent with recent data in 
cardiomyocytes obtained from HFD-fed animals (Bockus et al. 2017).  
 
 
Figure 6.1 Proposed Model of Ubiquitin Dysregulation of PFKL 
A conceptual model based on ubiquitomic data obtained from basal and insulin-stimulated chow and HF-fed rats. In chow-fed 
rats, insulin facilitates the phosphorylation of PFKL in order to stimulate glycolysis. Ubiquitin targets unphosphorylated PFKL 
for proteasomal degradation. In HF-fed animals, ubiquitin targets phosphorylated PFKL for unknown reasons and prevents 
propose glucose utilisation.   
 
Many proteins involved in insulin-stimulated lipid metabolism were both ubiquitinated at the 
whole liver level (see Chapter 2) and phosphorylated at the LD (see Chapter 3) in response to 
acute insulin treatment or diet in the liver, such as Plin2, ACBD5, ACSL4 and Decr1. Due to 
its more defined role in regulating LD biology, this section will focus on Plin2. Plin2 is a 
constitutive LD protein thought to promote LD expansion by stimulating lipid and sterol 
synthesis proteins such as MGAT, DGAT and ACAT1 while decreasing the expression of 
lipases such as HSL and ATGL at the LD in muscle and fibroblasts (McIntosh et al. 2012, 
MacPherson et al. 2013). In the absence of Plin2, a 60% reduction in TAG content was 
observed in MEF cells, whereas TAG, CE and PC levels increased in Plin2-overexpressing 
cells, consistent with LD composition (McIntosh et al. 2012, Tsai et al. 2017). Plin2’s role in 
promoting LD expansion is likely regulated by multiple independent yet related mechanisms.  
In particular, two of the three PLIN2 phosphosites detected in Chapter 3 were identified as 
‘insulin-resistant’ after systematic filtering. While PLIN2 was dephosphorylated on Ser254 
with insulin stimulation in both chow and HF-fed rats, Ser253 and Ser417 were 
dephosphorylated with insulin in the HFD fed group only. The functional consequence of Plin2 
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phosphorylation, or any other PTM, has largely been unexplored, despite the identification of 
numerous PTM sites (Hornbeck 2015). Emerging evidence indicates that pan-phosphorylation 
of Plin2 reduces its own expression and stimulates ATGL-mediated lipolysis in NIH3T3 cells 
(Kaushik and Cuervo 2016), suggesting a positive relationship between Plin2 phosphorylation 
and TAG hydrolysis. Therefore, it is conceivable that Ser254 phosphorylation of Plin2 
promotes lipolysis in the absence of insulin, when energy is poor. Although no specific 
phosphosites have been characterised yet, AMP-activated protein kinase (AMPK) is a known 
upstream kinase of Plin2 and is primarily activated by a nutrient deficit status, thereby 
promoting the release of FAs from TAG stores and shunting them towards mitochondrial 
oxidation for energy production (Long and Zierath 2006). Therefore, the dephosphorylation of 
Ser254 observed with insulin stimulation may act as a potential insulin-responsive regulatory 
mechanism to inhibit lipolysis in energy-rich conditions.  
 
The tight regulation of Plin2 phosphorylation is facilitated by chaperone-mediated autophagy, 
whereby Plin2 is transported by chaperone complexes and engulfed by lysosomes in AMPK-
active conditions (Nedelsky et al. 2008, Kaushik and Cuervo 2016). Interestingly, in results 
presented in Chapter 2 of this thesis, Plin2 was ubiquitinated in chow-fed rats under basal 
conditions (i.e. not ubiquitinated following insulin stimulation) which is identical to the Ser254 
phosphorylation pattern of Plin2 (Fig 6.2). Although chaperone-mediated autophagy and the 
ubiquitin-proteasome system are two uniquely discrete processes, they possess strikingly 
similar signalling cascades that often have parallel activation (Nedelsky et al. 2008). For 
example, the deletion of key autophagy genes such as Atg5 and 7 in mice lead to accumulation 
of ubiquitinated proteins despite normal proteasome function, suggesting that the lysosome 
feeds on non-ubiquitinated and ubiquitinated proteins (Komatsu et al. 2006). In other words, 
ubiquitination of Plin2 may occur prior to chaperone-mediated autophagy. This makes sense 
because the ubiquitin-proteasome system is traditionally thought to be the primary route for 
degradation of proteins with short half-lives under acute chronic starvation, such as Plin2 
(Ciechanover et al. 2000, Vabulas and Hartl 2005). In light of this, it is conceivable that it is 
ubiquitin that directly targets phosphorylated Plin2 for degradation in a similar manner to 
ubiquitin-targeting of phosphorylated Akt, as described above.  
 
Although Ser254 phosphorylation of Plin2 remains insulin-responsive with HFD-feeding, a 
number of other dysregulated PTMs on Plin2 occur in this HFD-induced IR condition. Namely, 
HFD-feeding increases the phosphorylation of Ser253 and Ser417 and this is associated with 
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increased protein abundance at the LD. If phosphorylation of Ser254 is hypothesized to signal 
its degradation, it is possible that phosphorylation of Ser253 and Ser417 may prevent its 
degradation, despite the likely continued ubiquitination of phosphorylated Ser254. 
Consequently, increased association of Plin2 to LDs prevents lipase-mediated TAG breakdown 
and thus promotes the development of steatotic liver in a HF environment. Inversely, Plin2-/- 
mice fed a western diet had a marked reduction in TAG and cholesterol levels in the liver and 
prevented the development of obesity and IR (Libby et al. 2016). Further, its deletion was 
associated with suppression of DNL and cholesterol synthesis gene and protein expression. 
Therefore, elevated Plin2 expression with HFD-feeding is consistent with the steatotic 
pathology observed. Furthermore, Plin2 remained ubiquitinated in the HF-fed insulin-
stimulated group, despite a complete lack of phosphorylation. This could present as an 
alternative mode of regulating Plin2 biology. Alternatively, ubiquitin may also be able to target 
Plin2 without phosphorylation, as occurs with the majority of proteins, and the conditions in 
which this is required could be dysregulated with impaired insulin action (Nguyen et al. 2013). 
As such, inappropriate degradation of Plin2 following insulin stimulation in a HF environment 
(i.e. IR) would be predicted to allow lipases access to their substrates leading to increased 
release FFAs from large TAG stores. Thus, it is conceivable that lipotoxic FFAs may overload 
the mitochondrial oxidation system, thereby causing oxidative stress and the production of 
reactive oxygen species that are commonly associated with NAFL pathology (Cichoz-Lach and 
Michalak 2014).  
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Figure 6.2 Proposed Model of PTM Dysregulation of Plin2  
A conceptual model based on ubiquitomic, proteomic and phosphoproteomic data obtained from basal and insulin-stimulated 
chow and HF-fed rats. In the basal energy-poor state, Plin2 is phosphorylated and ubiquitinated for degradation, thereby 
allowing lipase sequestration on LDs for FA release. In the fed state, insulin stimulation inhibits phosphorylation of Plin2. 
With HF-feeding, phosphorylation on alternative sites prevents its degradation and promotes hepatic steatosis. The potential 
role of persistent ubiquitination of Plin2 with insulin stimulation under HFD remains unclear.  
 
It is important to note that these results are derived from mass spectrometry data mining and 
thus targeted in vitro measures are required to substantiate these hypotheses. Instead, high-
throughput datasets such as those presented in this thesis act as launching pads in modelling 
data in novel and creative ways with a biologically sound foundation. Combining proteomic 
data with multiple PTM datasets, in combination with biochemical changes associated with 
lipid homeostasis, allows us to postulate complex mechanisms at a larger scale, and thus 
presents as a valuable resource in understanding diseases of impaired signalling. Future studies 
should focus on the validation of novel and known phosphosites identified in the LD, 
particularly those sites on regulators of lipolysis such as G0S2, Plin2, Plin5 and ATGL. 
 
 
 180 
6.1.2 Coordinated Interplay of the ‘Lipolysome’: An Interactor Story 
Apart from PTMs, differential regulation of protein activity can occur through a multitude of 
mechanisms, such as subcellular translocation and protein-protein interactions, each bringing 
a new layer of complexity. It is conceivable that proteins that have multiple types of regulation 
are critical nodes for controlling essential processes. This is evident by the relatively high 
conservation (>60% across >80 eukaryotes) of multiple types of PTMs found specifically on 
metabolic enzymes such as ATGL, suggesting the importance of efficiently utilising energy 
sources (Venne et al. 2014). A fitting example is the lipase primarily responsible for the first 
step of lipolysis, ATGL, and its long list of modifications and binding partners that modulate 
its lipolytic activity and thereby govern the storage of energy-dense substrates in hepatocytes 
until required (Yang et al. 2010, Granneman et al. 2011, Wang et al. 2011, MacPherson et al. 
2013, Olzmann et al. 2013, Grahn et al. 2014, Kim et al. 2016). Although ATGL-mediated 
hydrolysis of TAG occurs in nearly all tissues, the large network of regulators that control its 
activity, sometimes referred to as a ‘lipolysome’, is quite variable between cell types and is 
largely cell autonomous (Lass et al. 2011). Indeed, the majority of proteins that are considered 
lipolytic regulators have been characterized in adipocytes and myocytes, with limited 
knowledge existing in hepatocytes. For instance, Plin1 is a known PKA-activated transporter 
of HSL to LDs and facilitates TAG hydrolysis in adipocytes (Miyoshi et al. 2006). However, 
Plin1 is not expressed in hepatocytes and it is uncertain whether other perilipins, such as Plin2 
or Plin5 compensate for this, despite having vastly different associations and functions 
(Kimmel and Sztalryd 2014, Tsai et al. 2017, Wei et al. 2018). Therefore, identification of the 
hepatic lipolysome and characterisation of its regulation are crucial in elucidating lipolytic 
dysregulation in NAFL. 
 
Two of the most commonly discussed regulators of ATGL activity are its activator, CGI58 and 
inhibitor, G0S2. The two proteins bind to different domains on ATGL and are therefore not 
competitive, despite acting in opposition to each other (Lu et al. 2010). While CGI58 binds to 
the hydrophobic C-terminal domain used to target ATGL to LDs, G0S2 binds to its patatin-
like domain and blocks substrate accessibility, irrespective of CGI58 binding. (Lu et al. 2010). 
Additionally, PLIN5 decreases ATGL activity by competitively sequestering CGI58, thereby 
inhibiting ATGL-mediated lipolysis and protecting mitochondria from lipotoxic overload 
(Wang et al. 2015). More recently, UBXD8 was identified as another binding partner of ATGL, 
where it separates ATGL and CGI58 via its p97 segregase domain to inhibit lipolysis (Olzmann 
et al. 2013); In results described in Chapter 5, UBXD8 was identified as a novel regulator of 
 181 
FA oxidation, alongside its role in regulating ATGL activity. Interestingly, UBXD8 
knockdown in AML12 hepatocytes caused a marked reduction in G0S2, PPARa and CPT1a 
protein expression and an increase in Plin5 expression, thereby linking ATGL-mediated FA 
release with transcriptional regulation of FA oxidation. Together, these data illustrate a multi-
protein complex consisting of at least five independent LD-associated proteins that govern 
ATGL activity in hepatocytes.  
 
Traditionally, unrestrained lipolysis is associated with hepatic steatosis and IR solely from the 
standpoint of adipose tissue, where leaky LDs in adipocytes supply excess substrates to the 
liver for TAG synthesis (Schweiger et al. 2017). However, studies have reported the influence 
of insulin on ATGL mRNA or lipolysis in hepatocytes, suggesting insulin-stimulated 
regulation of FA release in the liver (Beynen et al. 1981, Zhang et al. 2016). The mechanism 
that ATGL uses in the tight regulation of protein-protein interactions lie in PTMs such as 
phosphorylation and ubiquitination. In Chapter 3, mass spectrometry data revealed very little 
change in ATGL protein abundance at LDs across all conditions, but a significant decrease in 
Ser422 phosphorylation with insulin stimulation. Further, the insulin-stimulated 
phosphorylation of ATGL was absent in HFD-fed animals, likely affecting lipolytic activity. It 
is conceivable that phosphorylation of ATGL at this phosphosite in response to insulin 
promotes the association of ATGL with G0S2, and diminished insulin signalling in IR is 
insufficient to appropriately suppress lipolysis.  Interestingly, ATGL was not identified in the 
rat liver ubiquitome, as described in Chapter 3 of this thesis. In other cell types, ATGL has 
been reported to have a short half-life and associates with proteins that have the ability to signal 
and degrade ATGL via the ubiquitin-proteasome system (Olzmann et al. 2013), however this 
was not observed in hepatocytes in this study. The coactivation of CGI58 and ATGL is unlikely 
to depend on phospho- or ubiquitin-regulation of CGI58 in hepatocytes, despite being a 
validated target of PKA phosphorylation in Plin1-expressing adipocytes (Sahu-Osen et al. 
2015). It is possible that the phospho-activated separation of CGI58 from Plin1 is not necessary 
in cells that lack Plin1 such as hepatocytes, especially because phosphorylation is not known 
to affect ATGL-mediated LD turnover. The role of PTMs in the association of UBXD8 with 
ATGL is a little more controversial, whereby mass spectrometry data identified decreased 
abundance of UBXD8 at the LD in healthy insulin stimulated animals, whereas 
immunofluorescence data suggested LD targeting with insulin stimulation. Considering the 
established role of UBXD8 in inhibiting ATGL-mediated lipolysis, it is likely that UBXD8 
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translocates to LDs with insulin stimulation to inhibit this process in the energy-rich fed state 
that insulin treatment mimics. Thus, while ATGL itself is mediated by a variety of regulators, 
each of those regulators is also independently regulated by other factors, thereby demonstrating 
the complexity of LD dynamics. 
 
Collectively, ATGL protein activity can be regulated by protein abundance, protein-protein 
interactions and PTMs in response to hormone stimulation and altered diet composition. In this 
thesis, several layers of regulation were measured through thoughtful modelling of this 
complexity. Furthermore, the ATGL binding protein UBXD8 was further characterized to shed 
light on the importance of ATGL translocation, degradation and interaction in facilitating 
lipolysis in hepatocytes. 
 
6.1.3 Modelling Metabolic Disease: Influence on Proteome 
The complex network of control measures for intracellular protein regulation requires 
considerable sensitivity to their microenvironment to distinguish subtle changes. Thus, 
representative models of metabolism and disease that generate these microenvironments are 
essential for obtaining accurate data. In the experiments described in this thesis, the HFD-fed 
rat was the primary model of fatty liver and IR. This is a well described model that exhibits 
classical aspects of short-term high-fat and high-sucrose feeding such as hepatic steatosis and 
IR but not oxidative stress or intralobular inflammation (Nakamura and Terauchi 2013). The 
liver ubiquitome and liver LD proteome and phosphoproteome were defined in this model as 
well as their response to acute insulin stimulation.  Although rodents are often preferred for 
diet studies of metabolism, obesity and NAFLD, selection of the most appropriate model often 
involves trading one advantage in favour for another. For instance, NAFLD is a spectrum 
disease encompassing NAFL, NASH, fibrosis, cirrhosis and HCC; however, C57BL/6 mice 
and Wistar rats fed a diet composed of 40%-70% fat for less than a year do not progress from 
NAFL to NASH (Ragab et al. 2015, Lau et al. 2017). Rather, a methionine and choline deficient 
diet causes oxidative stress and impairs lipid metabolism leading to NAFL/NASH, but these 
diets do not induce obesity or IR, which are often associated with NAFL(D) (Xu et al. 2010, 
Rinella et al. 2016). However, studies have shown that longer HFD-feeding (> 1 year) in 
C57BL/6 mice and even less time (> 6 months) in B6/129 mice can lead to an increased degree 
of livery injury, albeit not comparable to methionine and choline deficient diets (Asgharpour 
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et al. 2016). Thus, variability can result from rodent species, proportion and type of fat in the 
diet and duration of treatment.  
 
The specific constrains on steatotic pathology in the liver can have a significant impact on 
proteomic, phosphoproteomic and ubiquitomic data obtained. The HFD-fed rat is one of many 
models of fatty liver. Alcoholic fatty liver disease (AFLD) is a related liver pathology to NAFL 
with similar pathological spectra and associated comorbidities. AFLD has greater oxidative 
stress due to ethanol intake, greater inflammatory infiltration and thus greater progression to 
steatohepatitis compared to NAFL (Toshikuni et al. 2014). To date, the LD proteome of AFLD 
has not been reported. The whole liver proteome of a mouse model of AFLD was described by 
Carr et al. (2014), which identified Plin2 as the sole member of the ‘lipolysome’ to have altered 
protein abundance in AFLD liver. Similarly, the LD phosphoproteome of the AFLD has yet to 
be described; however, it is predicted that other PTMs linked to oxidative stress, specifically 
carbonylation, nitrosylation and ubiquitination leading to decreased anti-oxidant functions, are 
likely to be most abundant and biologically important in this setting (Newton et al. 2009). 
Another pathology that is characterised by hepatic lipid accumulation and IR is hepatitis C. 
The LD proteome of hepatitis C-infected Huh7 hepatocytes was enriched with proteins 
involved in RNA binding, cytoplasmic stress granule and vesicle pathways (Rosch et al. 2016). 
Strikingly, members of the ‘lipolysome’ including ATGL, CGI58 and PNPLA3 were depleted 
in infected cells, suggesting alternative mechanisms in the development of hepatic steatosis in 
the presence of hepatitis C compared to HFD-fed rodents. Collectively, variable models of fatty 
liver all accumulate LDs in hepatocytes regardless of general adiposity and that these LDs 
show changes in protein expression of lipolytic regulators as a pathogenic feature of the 
disease. Additionally, LD proteins are highly modified by PTMs beyond phosphorylation and 
ubiquitination in numerous models of fatty liver, suggesting their importance in dysregulated 
lipid flux. Further, AFLD and hepatitis C exhibit hepatic IR; however, the common features of 
the LD proteome and PTMs in response to acute insulin stimulation across these varied models 
of fatty liver remains to be determined. Moreover, no studies have assessed the proteomic and 
phosphoproteomic differences in the liver between IR and insulin sensitive NAFL(D) models. 
The pathophysiology of lipid accumulation and IR are often so intimately linked that results 
from such a study would help delineate the LD proteome in steatosis from IR.  
  
The validation of mass spectrometry data using in vitro systems also requires careful 
consideration of the metabolic sensitivity of specific cell lines. In liver research, the majority 
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of in vitro studies use HepG2 and Huh7 cells, two hepatic carcinoma cell lines, for non-
cancerous work (Hewitt et al. 2007, Reid et al. 2008, Kuo et al. 2012, Jin et al. 2018). Although 
these cell lines possess various features that can be useful, such as pronounced glucose uptake, 
they exhibit many markers of tumour metabolism that are likely to be predominant in the 
phenotype. To tackle this challenge, the metabolic phenotype of three normal human and 
mouse hepatic immortalised cell lines were measured against the gold-standard model of 
primary mouse hepatocytes and the commonly used model, HepG2 cells. Results described in 
Chapter 4 demonstrated remarkable baseline differences in FA, glucose and cholesterol 
intracellular utilization and variable sensitivity to hormonal or lipid treatment. AML12 cells, a 
mouse hepatocyte cell line, were chosen as the model to characterise UBXD8 function in 
Chapter 5 due to their consistent sensitivity to insulin treatment, and their ability to store and 
oxidize lipid and glucose appropriately (glucose data not shown in thesis). Although AML12 
cells were the best immortalised cell line to use for UBXD8 validation, it is important to note 
that there are a number of individualised factors that can influence or even improve 
experimental readouts for each cell line. This includes but is not limited to the confluence of 
cells when exposed to treatment, culture volume and media composition, incubation time and 
treatment toxicity, all of which can affect cell lines differently (Dong et al. 2008, Wright 
Muelas et al. 2018). For example, AML12, IHH and HepG2 cells were able to handle higher 
concentrations of unsaturated FAs compared to PH5CH8, which died if treated above a certain 
concentration. However, this was remedied when PH5CH8 cells were seeded at a higher 
confluence in order to 1) account for their lower growth rate and 2) reduce the ratio of FA 
availability per individual cell, thereby reducing the toxicity of the treatment to these cells. 
These nuances in physiological environments during treatment can feedback into the way that 
proteins of interest respond under particular conditions. Thus, thorough characterisation or 
investigation of available in vivo and in vitro models for a specific set of experiments is 
required before choosing one out of convenience or familiarity.  
  
6.1.4  Conclusion 
In conclusion, results presented in this thesis demonstrated for the first time that the ubiquitome 
and LD proteome and phosphoproteome are sensitive to insulin and diet and are perturbed in 
HFD-induced IR. In particular, multiple levels of molecular and PTM regulation work together 
to tightly modulate expression and activity of key lipases at the LD. Further, these regulatory 
processes were, in general, more dysregulated than total protein expression itself in the disease 
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state. Finally, UBXD8 has been characterized as a new member of the ‘lipolysome’ and an 
integral regulator of lipid metabolism by controlling lipase-mediated FA oxidation in 
hepatocytes. Collectively, this thesis describes the complexity of protein dysregulation in 
NAFL and IR and presents novel perspectives in the investigation of its pathogenesis.   
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